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ABSTRACT 
 
Though DNA nanostructures (DNs) have become interesting subjects of drug 
delivery, in vivo imaging and biosensor research, however, for real biological 
applications, they should be ‘long circulating’ in blood. One of the crucial requirements 
for DN stability is high salt concentration (like ~5–20 mM Mg2+) that is unavailable in a 
cell culture medium or in blood. Hence DNs denature promptly when injected into living 
systems. Another important factor is the presence of nucleases that cause fast degradation 
of unprotected DNs. The third factor is ‘opsonization’ which is the immune process by 
which phagocytes target foreign particles introduced into the bloodstream. The primary 
aim of this thesis is to design strategies that can improve the in vivo stability of DNs, thus 
improving their pharmacodynamics and biodistribution. 
Several strategies were investigated to address the three previously mentioned 
limitations. The first attempt was to study the effect length and conformation of 
polyethylene glycol (PEG) on DN stability. DNs were also coated with PEG-lipid and 
human serum albumin (HSA) and their stealth efficiencies were compared. The findings 
reveal that both PEGylation and albumin coating enhance low salt stability, increase 
resistance towards nuclease action and reduce uptake of DNs by macrophages. Any 
protective coating around a DN increases its hydrodynamic radius, which is a crucial 
parameter influencing their clearance. Keeping this in mind, intrinsically stable DNs that 
can survive low salt concentration without any polymer coating were built. Several DNA 
compaction agents and DNA binders were screened to stabilize DNs in low magnesium 
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conditions. Among them arginine, lysine, bis-lysine and hexamine cobalt showed the 
potential to enhance DN stability.  
This thesis also presents a sensitive assay, the Proximity Ligation Assay (PLA), 
for the estimation of DN stability with time. It requires very simple modifications on the 
DNs and it can yield precise results from a very small amount of sample. The 
applicability of PLA was successfully tested on several DNs ranging from a simple 
wireframe tetrahedron to a 3D origami and the protocol to collect in vivo samples, isolate 
the DNs and measure their stability was developed.   
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CHAPTER 1 
DRUG DELIVERY SYSTEMS AND DNA NANOSTRUCTURES  
1.1 Introduction to Drug Delivery Systems (DDS) 
1.1.1 DDS 
 The application of nanotechnology in medicine has opened up a new arena of research 
called ‘nanomedicine’ and in the recent years this field has given an emphasis on development of 
drug-loaded nanocarriers like the nanoparticles (NPs), liposomes and micelles. These nanocarriers, 
commonly termed as DDS, are being developed to combat serious threats like neurodegenerative 
disorders, cancer, etc.  In principle, DDS alter several of the pharmacological properties of the 
conventional ‘free’ drugs. They are designed to improve the pharmacokinetics and biodistribution 
of drug molecules associated to them. In addition, they often act as drug reservoirs enabling 
sustained release of the drugs in vivo.  
1.1.2 Advanced DDS 
The advanced DDS have two basic features: they can target drugs to specific sites inside 
the body and the release rates of the drug from the vehicle can be precisely controlled for prolonged 
time. There has been remarkable advancement in the research and marketing of advanced DDS in 
the past few decades. They improve drug delivery by allowing the following features: a) keeping 
drug levels in a therapeutically desirable range inside the body continuously, b) allowing usage of 
a decreased amount of drug in comparison to previous methods in use, c) reduce number of dosages 
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and allow less invasive dosing, d) reduction of harmful side effects by targeted to the desired sites, 
and e) making possible the administration of less stable (low in vivo half-lives) drugs.1 
The nanoparticulate systems used for drug delivery have diameters from 1 to 1000 nm and 
they are made up of a variety of materials like inorganic materials, polymers, and lipids. Hence 
they have varying physiochemical properties and are suited to different applications. 
 
Figure 1.1: Schematics of a targeted DDS.2 Two different strategies for cargo loading are shown. 
However, most of the DDS currently approved for parenteral administration can be 
classified into two groups: a) polymer based systems, and b) lipid based systems. The lipid based 
systems are the liposomes and different lipid-based formulations while the polymer based systems 
are mostly drug molecules conjugated to PEG. One well known DDS available in market is a 
PEGylated liposomal doxorubicin (Doxil / Caelyx). These polymer based colloidal systems have 
drawn much interest due to reasons like the flexibility in macromolecular synthetic methods, the 
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incredible diversity of polymers with respect to their nature, composition, properties and scopes 
(ease and diversity) of functionalization.3 
The mechanisms by which these DDS deliver the drugs are basically of three types: a) 
diffusion of drug molecules from the system, b) cleavage of drug from DDS or a chemical or 
enzymatic degradation of the delivery system, and c) activation of the system by solvent. A 
combined functioning of these three mechanisms is also possible. 
A. Polymer based DDS 
 The polymer based DDS can be classified into three major types: a) polymeric micelles, b) 
polymersomes, and c) NPs. Polymeric micelles are formed by self-assembly of amphiphilic block 
copolymers in aqueous solution.4 They are a combination of hydrophobic core and hydrophilic 
outer shell. Hydrophobic drugs are contained in the core that is stabilized by the hydrophilic shell.5 
Till date, micelles are the most advanced nanoparticulate systems for clinical trials.6 They have 
shown considerable efficacy to deliver DNA and hydrophobic drugs and they can be functionalized 
by a number of ligands.7 In the nanoparticle DDS the drug molecules are dissolved, dispersed or 
chemically conjugated to the constituent polymer chains.8 The method of preparation governs 
whether the NP will be a nanocapsule (vesicular systems) or a nanosphere (matrix-like system). 
Polymersomes are the biomimetic analogs of phospholipids and the membrane is the primary 
feature of these nanocarriers. They confer the advantage of encapsulation of both hydrophilic and 
hydrophobic molecules in their aqueous cavities and membranes respectively.9 
B. Lipid based DDS 
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Lipid bilayer vesicles were originally developed as a trial to mimic biological 
membranes.10 Encapsulating drugs inside a vesicle instead of attaching them to a polymer chain 
provides the advantage of higher drug-loading capacity. Their internal aqueous compartment can 
be loaded with hydrophilic payloads while the phospholipid bilayer membrane can carry the 
hydrophobic drugs. The application of liposomes to deliver anticancer drugs is now well-
established. In solid tumors the vasculature becomes leaky and the lymphatic drainage become 
defective, thus allowing the stealth liposomes to accumulate in them. The nanometer sized 
liposomes that contain doxorubicin in their aqueous compartment (Doxil, Caelyx and Myocet) are 
employed for Kaposi's sarcoma, ovarian cancer, and multiple myeloma.11-14  
 
Figure 1.2: Some common carriers used in nanomedicine. (These carriers have specially been 
tested for in vivo delivery of anti-thrombin agents.)15 
1.1.3 Enhanced Permeability and Retention (EPR) Effect and Targeting DDS 
Paul Enrich was awarded the Nobel Prize in medicine in 1908 as he put forward the concept 
of ‘magic bullet’, which is a drug that can reach and destroy the diseased cells selectively without 
causing any harm to the normal healthy cells.16 This concept led to the development of targeted 
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nanocarriers. The fundamental aim of drug delivery is to enhance the drug concentration in the 
diseased site with a simultaneous reduction in the systemic exposure.17 Several drug delivery 
methods have been formulated to achieve this aim, some of the most important being micelles, 
liposomes, antibody-directed enzyme-prodrug therapy18, photodynamic therapy19, affinity 
targeting20, and macromolecular drug carriers.21,22 In case of treating tumors, most of these DDS 
exploit the characteristic pathophysiology of the tumor vasculature. In 1920, it was found that 
unlike normal tissue, tumors have a high density of dilated and poorly differentiated blood vessels. 
These vessels have an unordered architecture and aberrant branching.23-26 This leads to hindered 
functions of the tumor vasculature like enhanced permeability than normal blood vessels and 
increased concentration of plasma proteins in tumor tissues in comparison to the normal ones.27-36 
In addition to this there is a lack of functional lymphatic vessels in the tumor resulting in a 
decreased rate of clearance. Maeda and colleagues named this as the enhanced permeability and 
retention (EPR) effect, 37-39 which is responsible for the enhanced passive accumulation of 
intravenously administered macromolecules in tumors. The EPR effect is the key behind the 
technique of passive tumor targeting. Understanding the concept of EPR makes it clear why the 
PEGylation strategy is so effective in treating certain tumors. Covalent conjugation of PEG chains 
to nanocarriers increases circulation times, thus increasing its opportunity to reach the desired site.  
However, there are instances where the vascular permeability is low like in pancreatic cancers. 
Also there is the phenomenon of accelerated blood clearance40 arising from the phenomenon that 
repeated administering of PEGylated liposomes lead to the production of anti-PEG 
immunoglobulin-M induced by the first injection. Hence the liposomes are cleared off from the 
circulation quickly. These two situations set the basis for development of targeted drug delivery 
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systems that can recognize certain cells or tissues. The ligand-conjugated liposomes developed in 
1980 provide the first examples of targeted DDS.41  
1.2 Properties of an Efficient DDS 
There are several factors that have to be considered for designing a DDS applicable to a 
particular disease, some of the very crucial ones being: a) stability b) solubility c) size (molecular 
weight) d) charge e) potency f) circulation time g) targeting ability h) loading mechanism i) 
protection of the drug molecule from premature metabolism, and j) drug release profile.   
Stability of the DDS is of obvious importance and both liposomes and polymer based systems 
have demonstrated sufficient in vivo stability for real life applications. Polymers like PEG have 
enough in vivo solubility to be used as efficient DDS. The solubility of liposomes can be modified 
by conjugating PEG chains of varying lengths on the surface.   
The size and surface charge of the nanocarriers govern the efficiency of drug delivery and 
determine the pathway of cellular uptake for liposomes42, polymeric NPs43,44, gold NPs45, and 
silica NPs46 by altering the particle adhesion and their interaction with cells47. He and co-workers 
found that murine macrophages engulf NPs with high surface charge and large particle size more 
efficiently.48 Their study also showed that slightly negatively charged NPs of size 150 nm show 
enhanced accumulation in tumor. In addition to accumulation profiles, particle size is a significant 
factor in determining the in vivo life time of the nanocarriers. It has been found that cell membranes 
have a higher concentration of negative charge, so positively charged peptides (the cell penetrating 
peptides (CPPs)) have been used for building targeted DDS. The CPPs are less than 30 amino acids 
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in length and have a net positive charge. Liposomes are often conjugated with CPPs, which assist 
in the transfer of cargos into the cells.49 
The amount of carriers to be used for the delivery of a certain amount of drug depends largely 
on the drug potency.11 Lesser the number of drug molecules that the DDS can carry, the higher the 
potency of the drug must be. In cases such as immunoconjugates and immonotoxins, the DDS can 
carry only a few number of molecules and the polymer conjugates can carry few tens of molecules, 
in these cases the drug molecules should have higher potencies for delivering therapeutically 
relevant amounts of drug.20  
Circulation time of a nanocarrier is simultaneously governed by several factors like its stability 
under physiological conditions, solubility, size etc. In order to increase circulation time, the carrier 
has to be prevented from opsonization. PEGylation of drug delivery vehicles has emerged as a 
successful strategy to render them long circulating.   
1.3 Polyethylene glycol (PEG) and Its Effect on In Vivo Lifetime of Nanocarriers 
In 1977 Abuchowski  and co-workers  demonstrated that bovine serum albumin (BSA) 
when covalently conjugated to methoxypolyethylene glycols of 1900 and 5000 Daltons (PEG1900, 
PEG5000) loses immunogenicity and its half-life is circulation is enhanced.50 During the very short 
period of 1990-91, there were several reports showing that PEG can be used to increase circulation 
times of liposomes.51-54 Different researchers have proposed different hypotheses to explain the 
effect of PEG in rendering nanocarriers long circulating. According to Ilium and co-workers 
surface hydrophobicity plays a major role in the phagocytosis of NPs by mononuclear phagocyte 
system (MPS) and they demonstrated that hydrophilic coatings with poloxamers reduced MPS 
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uptake of colloidal particles.55 The ether oxygen of (CH2—CH2—O)n units of PEG, being capable 
of hydrogen bonding with water, can also result in the formation of a highly hydrophilic surface 
in aqueous solution. There are hypotheses that this hydration forms of a polymer brush that extends 
outwards from the liposome surface, thus resulting in steric stabilization of the liposomes by 
bringing down attractive forces and enhancing repulsive forces at the liposome surface.56-59 Lasic 
and co-workers presented a more detailed explanation about the theory of steric stabilization.56,60,61 
 
Figure 1.3: Different types of PEGs. a) Linear, and b) branched. 
1.4 DNA Nanotechnology 
DNA, the carrier of our genetic information, is undoubtedly one of the most widely studied 
biopolymers. Owing to its highly predictable base pairing, chemical stability and biocompatibility, 
it has become an interesting candidate for building nanometer-sized 2D and 3D structures of 
varying shapes, sizes and complexities.62-65 DNA nanotechnology66 is primarily concerned with 
building up novel DNs with interesting properties and look for their realistic applications. DNs 
can be designed to have very sophisticated capabilities like mechanical67 and logic gating68, which 
is not possible with structures build from other known nanomaterials. The excellent strategy put 
forward by Paul K. Rothemund in 2006, known as the ‘DNA Origami’69 has made the formation 
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of complex 3D structures very convenient using a single stranded long scaffold and few hundreds 
of smaller single stranded DNA (staples). Moreover, the distance between two consecutive bases 
on the phosphate backbone of a single stranded DNA being 0.34 nm and due to the availability of 
a library of chemical modifications separately on each base, DNA allows precise modifications 
every 0.34 nm long its length. This makes DNs very suitable platforms for precise spatial 
arrangements of interesting molecules like aptamers70, antibodies71, fluorophores72, metal NPs and 
quantum dots73, etc. In addition to this, reconfigurable DNs can be built and their dynamics can be 
controlled by external stimuli like a single stranded DNA (strand displacement), small molecule 
and light. All these attributes make DNs promising candidates for applications in nanoplasmonics, 
biosensors and drug delivery. 
1.5 DNs in Nanomedicine 
Nanomedicine uses nanosized materials to build platforms for gene and drug delivery.74 
With respect to size, DNs are potential candidates as cellular transport occurs at nanometer length-
scale.75 The multivalence of DNA, the diverse nature of functionalizations available and the 
compatibility of biological systems have drawn considerable attention of the nanomedicine 
researchers and DNs have been used as drug delivery vehicles in a number of reports. Douglas and 
co-workers have built a nanorobot that can release Fab antibody fragments in the presence of target 
cells.76 A DNA tetrahedron was employed by Anderson and co-workers for in vivo delivery of 
small interfering RNA to target and suppress gene expression in a mouse model.77 The DNs have 
also demonstrated their potential to serve as platforms for synthetic vaccines. Fan, Huang and co-
workers assembled a multivalent DNA tetrahedron for noninvasive delivery of immunostimulatory 
CpG oligonucleotides.78 Yan, Chang and co-workers have employed a DNA tetrahedron for 
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coassembly of model antigens and CpG with precise control over the valency and spatial 
arrangement of each constituent.79  
DNs have also been employed to carry drug molecules in vivo either by intercalation into 
the carrier DNA helix or by attachment through chemical conjugation. Huang and co-workers 
demonstrated the application of aptamer-conjugated DNA icosahedral NPs as carriers of 
doxorubicin for cancer therapy.80 In 2012, Ding and co-workers constructed 2- and 3-D 
doxorubicin-loaded DNs, the loading being through intercalation, and their construct showed 
prominent cytotoxicity to regular human breast adenocarcinoma cancer cells (MCF 7) and also to 
doxorubicin-resistant cancer cells.81 In the same year, Högberg and co-workers developed DNA 
origami delivery systems for cancer therapy having tunable release properties.82 Their aim was the 
optimal delivery of anthracycline doxorubicin (Dox) to human breast cancer cells. With varying 
degrees of global twists, the amounts of DN relaxation also varied. They tuned the DN design to 
control the encapsulation efficiency and release rate of Dox, increase the cytotoxicity and decrease 
the intracellular elimination rate of Dox in comparison to the free drug molecule. 
1.6 Stability of DNs 
Formation of DNs require a high concentration (~5-20 mM) of divalent magnesium ions 
in the annealing buffer and this concentration increases with rise in packing density of the structure. 
In absence of sufficient Mg2+ concentration, the phosphate backbones of DNA strands being 
negatively charged repel each other and thus prevent formation of packed structures. Positively 
charged Mg2+ ions screen the negative charges on the phosphodiester backbone and allow two 
DNA strands to come closer and form DNs. For 3D DNs at least 16 mM Mg2+ is required. The 
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physiological concentration of Mg2+ is almost tenfold lower than that required for formation of 3D 
DNs and this is a major factor limiting stability of DNs in vivo.  
When administered in blood, DNs have to encounter nucleases that degrade them rapidly. 
Even in cell culture medium supplemented with fetal bovine serum, the life time of DNs is 
considerably reduced due to the presence of the nucleases. Protection from the nucleases is a 
crucial issue that needs to be addressed in order to use the DNs for in vivo applications. 
In addition to these two issues, there is another limitation posed on the in vivo fate of DNs 
by opsonization. As soon as NPs are introduces in circulation, a series pf chemical-physical 
interactions are established between their surfaces and the various components of the physiological 
medium like phospholipids, DNA, proteins etc. Hence, NPs lose their ‘synthetic identity’ in no 
time and a new interface termed as the ‘bio-nano interface’ is developed around it. This interface 
is actually responsible for the biological fate of injected NPs.75 DNs are also opsonized like other 
NPs and opsonins on their surface are promptly recognized and sequestered by macrophages. An 
efficient DDS based on DNs has to be retained in circulation for a minimum period of time to exert 
their effect. Exerting their effect might require pre-requisites like unloading of the drug from the 
vehicle through diffusion, hydrolysis of some covalent bond etc. If prior to this the delivery vehicle 
is removed by the excretory system, the drug will require a) a higher dosage, and / or b) very 
frequent dosages.  Hence, to improve in vivo lifetime of DNs, they have to be protected beforehand, 
so that they can avoid rapid opsonization followed by clearance from blood in the spleen and liver.  
Few reports have been published with investigations on the stability of DNs under 
physiological conditions. In 2014, Perrault and coworkers reported that while the denaturation of 
the DNs due to low salt conditions was dependent on design and time, the degradation by nucleases 
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is not time dependent.83 Very recently in 2017, Shih and coworkers reported an oligolysine coating 
that can be applied over the DNs via electrostatic adsorption and this coating can protect them 
from low salt denaturation and nuclease degradation for prolonged hours.84 However, the detailed 
study on how the PEG coating affects the stability of DNs and their uptake by macrophages still 
remains to be done. 
1.7 Overview of the projects in this thesis 
1.7.1 Effect of PEG Length and Conformation and PEG-lipid on Stability and Cellular 
Uptake of DNA Nanostructures  
The conventional method of forming PEG-coated DNs is to pre-PEGylate a certain number 
of staples before annealing, mix them with the non-PEGylated staples and m13 scaffold and then 
subject the mixture to the annealing program. But PEG chains often hinder base pair recognition 
and thus render the DN formation kinetically demanding leading to the formation of deformed 
structures. So we PEGylated pre-formed DNs decorated by strained alkyne moiety (DBCO) on the 
surface employing the copper-free click reaction. 
Then we studied the effect of three different linear PEGs of molecular weights 2 kD, 5 kD 
and 10 kD on the stability of two different DNs in the cell culture medium supplemented with 10% 
fetal bovine serum (FBS). We also investigated the effect of PEG branching on uptake of DNs by 
macrophages. In addition to PEG, we investigated the effect of PEG-lipid coating on the cellular 
uptake of DNs by macrophages. There has been reports that PEGylation alters the composition of 
the outer protein corona of a NP when it is introduced in blood.85,86 It is this protein corona that 
affects cellular uptake of NPs. It has also been reported that the clusterin protein plays an important 
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role in reducing the uptake of the NPs.87 In order to investigate this effect on DNs, we incubated 
PEGylated DNs with human serum and clusterin protein separately before studying cellular 
uptake. We found that increasing the PEG length (from 2–10 kD) led to enhancement of stability 
in low salt conditions and also enhanced resistance towards nucleases. The cellular uptake is also 
reduced as the PEG length increases. Branched PEG reduces the cellular uptake further in 
comparison to the linear polymers of same molecular weight. The PEG-lipid coating reduces the 
cellular uptake more efficiently than the only PEG polymer of equal molecular weight. Incubation 
with clusterin further reduces the DN uptake by macrophages; the branched PEGs being most 
efficient for allowing deposition of clusterin on the DN surface. 
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Figure 1.4: Effects on PEGylation and PEG-lipid conjugation on stability and cellular uptake of 
DNs. 
1.7.2 Enhancing Stability of DNA Nanostructures in Low Salt Conditions by Using Free 
Stabilizing Agents 
After screening several molecules (free, not covalently conjugated to the structures) that 
are DNA compaction agents or DNA binders or intercalators and studying their effect on stability 
of 3D DNs, we found that four of them, namely arginine, lysine, bis-lysine and hexamine cobalt, 
can provide stability to the DNs under low salt conditions. We studied the extent of stability 
enhancement by using transmission electron microscopy (counting intact DNA structures using 30 
nM gold NPs as internal standards), and time vs fluorescence assay. We also found that the 
stabilizing agents enhance the thermodynamic stability of the DNs as is reflected in their increase 
in melting points. 
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Figure 1.5: Enhancing stability of DNA nanostructures in low salt conditions by using free 
stabilizing agents. 
1.7.3 Building Albumin-coated DNA Nanostructures for In Vivo Applications 
Albumins are among the very common proteins found in serum. We hypothesized that if 
we can coat DNs with serum albumin then they would be able to maintain structural integrity in 
low salt conditions and also be able to avoid prompt degradation by nucleases. In addition, as their 
surfaces are coated by a protein familiar to the opsonins, the albumin-coated DNs will have delayed 
recognition by opsonins, leading to increase in their circulation times in blood. For coating DNs 
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we coated the DN surfaces with an albumin attracting molecule (figure 1.6) and then incubated 
them with normal HSA. 
 
Figure 1.6: Albumin attracting molecule (AAM). 
The albumin coated structures showed reduced uptake by murine macrophages and in 
addition to this they are found to be more resistant toward nuclease degradation (tested in the 
DMEM cell culture medium containing 10% FBS). 
 
Figure 1.7: Coating DNA nanostructures with serum albumin to enhance stability and reduce 
uptake by macrophages. 
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1.7.4 Proximity ligation assay (PLA) to estimate stability of DNA Nanostructures  
PLA is a well-known method for stability estimation of protein molecules. We applied that 
concept and studied the stability of a wireframe DNA tetrahedron (Td) reported by Tuberfield and 
co-workers. We developed a sensitive assay that can estimate the number of intact DNs even after 
administering them in blood. We subjected the Td under various conditions (buffer containing 16 
mM Mg2+, DMEM, DMEM containing 10% FBS and human serum and estimated the half-lives 
of the Td in these media. The results obtained from PLA showed matched with those obtained 
from electrophoretic gels. We also injected two different Tds, one having antennae pair with 
phosphodiester backbone and the other having antennae pair with phosphorothioate backbone,  in 
mice and estimated their half-lives applying the PLA.   
 
 
Figure 1.8: Proximity Ligation Assay on DNs. 
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CHAPTER 2 
EFFECT OF PEG LENGTH AND CONFORMATION AND PEG-LIPID COATING 
ON STABILITY AND CELLULAR UPTAKE OF DNA NANOSTRUCTURES 
2.1 Abstract 
DNA nanostructures (DNs) have become candidates of extreme interest in 
therapeutics and diagnostics during the last few decades, because of their ease of formation, 
precise control over shapes, sizes and sites of modification, and dynamic attributes 
responsive to simple stimuli. However enhancing the stability of DNs in low salt 
conditions, resisting nuclease degradation and reducing their opsonization while in 
circulation are crucial factors for making them suitable for in vivo applications. 
Polyethylene glycol (PEG) is widely being used as a biocompatible ‘stealth’ polymer that 
can render drug carriers like liposome long circulating. Here we studied the effect of PEG 
and PEG-lipid coating on the stability and macrophage uptake of DNs. We varied the 
length and branching of the PEG chains and studied their influence on cellular uptake. We 
found that increasing chain length provide higher stabilization towards low salt conditions 
and enhanced resistance to nuclease degradation. Branching has no observable effect on 
these two aspects, while higher branching showed higher efficiency towards reducing 
macrophage uptake of DNs in comparison to their linear isomers. We also tested the effect 
of plasma and clusterin incubation of the structures prior to incubation with the 
macrophages. Clusterin incubation highly reduces the uptake, the effect being most 
pronounced in case of the branched PEG-coated DNs. 
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2.2 Introduction 
In the past few decades a significant progress has been made in nanotechnology 
research, as a result of which diverse nanoscopic particles with different kinds of 
constitution and morphology have been developed for nanomedicinal applications like 
tissue regeneration, in vivo imaging and drug delivery.1 Paralleled with the flourishment of 
DNA nanotechnology, the pool of potential nanomedicine candidates have been largely 
enriched. This fascinating branch of nanotechnology can build biocompatible nanoscale 
objects with diverse structural and functional features and precisely defined modifications 
using DNA as the building material.2-7 These DNA nanostructures (DNs) can be engineered 
employing known biochemical methods and they can demonstrate controlled dynamics in 
response to stimuli like small DNA strand (fuels),8-10 pH,11,12 enzymatic reaction, and 
temperature. For these myriad abilities coupled with biodegradability and biocompatibility, 
DNs have also been employed for biomedical applications like biosensing, in vivo delivery 
of nucleic acids like siRNAs13, building synthetic vaccines14 and drug delivery.15-18  
 In the current stage of development, however, in vivo applications of DNs are 
limited by certain factors, among which three are the most important. The first one is 
requirement of high concentration of divalent cations like Mg2+ (~5–20 nM) for DN 
formation. These ions screen negative charges on phosphodiester backbone and allows 
DNA single strands to come closer during DN formation. But such a high concentration of 
divalent ions is not available in physiological conditions like cell culture medium and 
blood.19 Hence when incubated with cell culture medium or administered in circulation, 
the structures unfold and lose their structural integrity, a process the rapidity of which is 
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proportional to the packing density of the DN. The second important factor is degradation 
by the nucleases in both cell culture medium (supplemented with 10% FBS) and blood.20-
23 Thus, the protection of DNs from nuclease degradation before they can be employed for 
any tissue culture experiments or in vivo injections is a crucial requirement for successful 
nanomedicinal applications. The third element of concern is opsonization, an immune 
process by which a foreign particle entering bloodstream is identified to macrophages of 
the mononuclear phagocytic system (MPS). Various components of the complement 
system like C3, C4 and C5, immunoglobulins, laminin, C-reactive protein, type I collagen, 
fibronectin and several other proteins are known as opsonins.24 Macrophages do not 
possess the capability to recognize NPs directly, but they can identify the opsonin tags 
attached to their surfaces.25 The opsonins promptly bind to injected nanoparticles (NPs), 
leading to their recognition by macrophages which eliminate the particle from circulation 
within seconds of intravenous administration.26 This phenomenon leads to severe reduction 
of circulation lifetime of NPs. When a NP is injected into a physiological fluid like blood, 
the proteins from the medium quickly adsorb on the NP surface and form a protein corona 
around the NP.27 There has been several reports that claim this protein shell is actually 
responsible for the biological fate of NPs.28-30  
Among the several strategies devised to camouflage NPs from macrophages until 
they are done performing their desired roles in vivo, the most common is grafting of ‘stealth 
polymer’ polyethylene glycol (PEG) to NP surfaces.31 Reports are abundant where PEG 
and its various derivative have been employed to make polymeric NPs and liposomes ‘long 
circulating’ in the circulation. The exact and complete mechanism of opsonization and its 
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reduction by grafted PEG chains have not been yet revealed. Initially it was thought that 
PEG chains sterically hinder the attachment of opsonins on NP surface by creating a 
surface-random cloud, and thus hampers the formation of the protein corona around NPs. 
This reduces aggregation and receptor-mediated recognition of NPs eventually improving 
their pharmacokinetics (PK).32-36  
A recent report have shown that surface PEGs lead to an alternation in the 
composition of the protein corona formed as soon as NPs enter the bloodstream and this is 
actually responsible for the reduced uptake of PEGylated NPs by the MPS. This group has 
also found an increased abundance of the clusterin protein in the protein corona around 
PEGylated NPs, from which they investigated the role of clusterin in reducing phagocytosis 
of injected NPs.37 Another paper in 2013 reported that the conformation of surface PEGs 
influence the formation of protein corona around single-walled carbon nanotubes 
(SWCNTs).30 
There has been attempts to render DNs long circulating by encapsulating them in 
liposomes or forming an oligolysine-PEG coating around them.38,39 Both of these strategies 
have become successful to enhance the low salt stability of DNs and also to provide 
protection against nucleases. But these strategies require synthesis of specific polymers to 
coat DNs. Moreover encapsulation of DNs within a liposome raises the obvious question 
that why we cannot use a liposome directly instead of forming it around a DN. However, 
a detailed study on how PEGylation affects the stability of DNs in physiological conditions 
and their uptake by the MPS, was missing till date. We have attempted to pursue that 
investigation. We studied the effect of both PEG lengths and conformations (linear or 
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branched) on their circulation lifetime. In addition to simple PEGs, we also conjugated a 
PEG-lipid to DN surface and studied its efficacy. In addition, we have also studied how 
incubation with plasma and clusterin protein separately affects internalization of different 
PEGylated DNs.  
We designed two DNs: a tetrahedron (Td) and an 8x8 layered structure (DNO), and 
covalently attached PEG chains of varying lengths and conformation on their surface. 
Higher PEG chain lengths provide enhanced protection to the DNs against degradation in 
physiological conditions. Branching of PEG chain does not provide any additional stability 
in comparison to the linear isomers. However, they show higher efficiency in reducing 
macrophage uptake of DNs than the corresponding linear chains. We conjugated a 2 kD 
PEG-lipid on DN surfaces and that reduced the uptake with greater efficiency than the 
corresponding linear and even the 4 arm PEG isomer. Incubation of bare DNs with plasma 
increased their cellular uptake, while incubation with clusterin reduced the same. Branched 
PEGs, especially those having higher molecular weights, have pronounced effect on 
reduction of cellular uptake when the DNs were pre-incubated with clusterin. 
2.3 Results and Discussion 
2.3.1 Building PEG-conjugated DNs 
In order to compare results and establish the generality of our findings, we 
conducted studies using two DNs: a DNA tetrahedron (Td) and an 8x8 DNA origami 
(DNO) designed in the square lattice motif of caDNAno. Td being a comparatively 
hollower structure more resembling a wireframe DN than a densely packed DNA origami, 
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the divalent cation requirement should be lesser while the scope for nuclease action should 
be higher. Exactly the reverse is expected to be true for densely packed DNO. 
 
Figure 2.1: a) Td b) DNO. 
The common method to form simple DNs with PEG coating is to select a certain 
number of staples, conjugate PEG to them, and then mix them with the other normal staples 
prior to annealing. But from our experiments, we found that the PEG chains probably 
hamper the base pair recognition during the process of annealing, an effect which becomes 
increasingly pronounced in larger and tightly packed DNs like DNA origami resulting in 
highly compromised yields. So we chose to PEGylate pre-formed DNs.  
The schematic representation of Td shows that each structure is comprised of four 
symmetric units capable of inter-unit assembly through sticky end hybridization. Three 
strands on each of the constituent units were modified with a single stranded handle. Hence, 
a complete Td had 12 DNA handles and each handle was hybridized with a complimentary 
strand containing a reactive alkyne group (DBCO) to which PEG-azide can be conjugated 
via copper-free click reaction. Similarly, in case of DNO, 24 surface staples were selected 
and their amine versions (single strand with a terminal amine) were conjugated to DBCO. 
Thus we obtained DNO decorated with 24 reactive DBCOs on the surface. This DNO was 
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reacted with different PEGs having terminal azides to yield pegylated DNOs as required 
for further experiments. Formation of the pegylated structures (both Td and DNO) was 
confirmed by agarose gel electrophoresis. 
2.3.2 Stability in Physiological Conditions 
DMEM supplemented with 10% fetal bovine serum is a very common medium used 
for in vitro cell culture. This medium provides an excellent environment to study the 
stability of DNs in physiological conditions. Mg2+ content of DMEM is ~0.8 mM and it 
contains more than 256U/L of DNase I activity.22 Hence, when incubated with DMEM + 
10% FBS, DNs experience loss in structural integrity both due to low salt concentration as 
well as nuclease mediated degradation. We studied stability of bare and PEG-coated DNs 
in this medium. We incubated each structure separately and monitored their stability via 
gel electrophoresis. DNO being a densely packed structure had considerably lower half-
life in the medium (~39 minutes) than Td (~5 h). On studying PEG-coated DNs we found 
that increase in the length of linear PEG chains positively contribute towards enhancing 
DN stability. The half-life of Td was almost doubled by 10 kD linear PEG coating while 
the effect is almost 2.5 fold for DNO. However, branched PEGs or DSPE-PEG did not 
provide any higher stability to the tested structures over their linear isomers. 
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Figure 2.2: Stability of Td in DMEM supplemented with 10% FBS. a) Plotting 
concentration of Td and different PEG coated Tds with time b) comparison of half-lives of 
bare Td and different PEG-coated Tds. 
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Figure 2.3: Stability of DNO in DMEM supplemented with 10% FBS. a) Plotting 
concentration of DNO and different PEG coated DNOs with time b) comparison of half-
lives of DNO and different PEG-coated DNOs. 
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2.3.3 Confocal Microscopy 
A probability of the DNs being attached to the cell surface without being 
internalized and thus giving false positive was very feasible. We used confocal microscopy 
to visualize the internalization of bare and coated DNs. The Alexa fluor 488 labeled DNs 
show green fluorescence when excited at 488 nm. To show co-localization we stained the 
cell membranes with CellTracker CM-Dil dye (553/570 nm). In addition to imaging cells 
directly after incubation, we also studied batches treated with DNase after incubation, such 
that any DNA or DN sticking to the surface was degraded by the nuclease. The images for 
DNase treated RAW cells after incubation with Td, Td–5L and Td–2 –lip are shown below. 
DNs coated with DSPE-PEG might have higher tendencies to stay stuck to the 
phospholipid bilayer instead of entering the cytoplasm. Also, the protein corona formed on 
the DNs after incubation with plasma and clusterin might cause them to be attached to the 
cell surface. We investigated all the situations and confirmed the internalization of 
structures in all cases. The confocal and z-stacked images with orthogonal sectioning are 
provided in the supplemental information. 
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Figure 2.4: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled Td followed by DNase treatment. The cell membranes were stained with 
CellTracker CM-Dil dye. a) Bright field image b) green fluorescence from internalized Td 
c) overlay of bright field and green fluorescence d) red fluorescence from CellTracker CM-
Dil dye e) overlay of green and red fluorescence f) overlay of bright field, green and red 
fluorescence. 
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Figure 2.5: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled Td followed by DNase treatment. The crosshairs indicate orthogonal 
sectioning. The bottom and right panels show the sectioned planes and confirm that 
fluorescent particles (green) are located inside the cells and not merely attached to the cell 
membrane. 
 
Figure 2.6: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled Td–5L followed by DNase treatment. The cell membranes were stained with 
CellTracker CM-Dil dye. a) Bright field image b) green fluorescence from internalized Td–
5L c) overlay of bright field and green fluorescence d) red fluorescence from CellTracker 
CM-Dil dye e) overlay of green and red fluorescence f) overlay of bright field, green and 
red fluorescence. 
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Figure 2.7: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor488 labeled Td and then treated with DNase.  
 
Figure 2.8: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled Td–5L followed by DNase treatment. The cell membranes were stained with 
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CellTracker CM-Dil dye. A) Bright field image b) green fluorescence from internalized 
Td–2-lip c) overlay of bright field and green fluorescence d) red fluorescence from 
CellTracker CM-Dil dye e) overlay of green and red fluorescence f) overlay of bright field, 
green and red fluorescence. 
 
Figure 2.9: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor488 labeled Td and then treated with DNase.  
2.3.4 Uptake of DNs by Macrophages 
2.3.4.1 Cellular uptake without plasma or clusterin incubation 
Stealth polymers like PEG enhance the circulation lifetime of nanocarriers by 
ambushing them from the MPS, thus avoiding their clearance by the immune system. 
Macrophages play an active role in clearing foreign particles from the blood. Thus, if DNs 
are to serve as successful drug delivery vehicles, they have to be protected from recognition 
by the macrophages. To investigate how recognition by macrophages in altered by PEG 
37 
 
coating on DNs, we studied their internalization into a murine macrophage cell line, 
RAW264.7. 
The S4 strand of Td labeled with Alexa fluor 488 was used as a control. The other 
controls were both bare Td and DNO, each labeled with 12 dye molecules. In order to 
mitigate the probability of fluorescence contribution from DNs sticking to cell surfaces, 
after incubation with dye-labeled DNA, bare Td and bare DNO, we treated the cells with 
DNase and measured their fluorescence. They acted as another set of controls. Comparing 
the fluorescence, it was found that there was almost no difference between the DNase 
treated and untreated controls. This confirmed that all the results obtained are from actually 
internalized structures and not mere DNs sticking to the cell surface. However, the data 
presented here are all from DNase treated cells. 
 
Figure 2.10: Comparing fluorescence intensity of DNase treated and untreated controls. 
When the cellular uptake of DNs coated with linear PEGs was studied, we found 
that the uptake is inversely related to the length of PEG chains, which is in agreement with 
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our prediction. Looking carefully at the values, we can see that a 2L coting does not reduce 
the uptake of DNO to an extent similar to Td. This might be because the amount of 
coverage conferred to DNO by 2L is insignificant as it has a much higher size than Td. But 
the effect of 5L coating on DNO was much pronounced. Again, we note that the extent of 
decrease from 5L to 10L is higher in case of DNO than Td. This probably implies that a 
shift from 5L to 10L coating in Td does not improve the amount of coverage much. 12 5L 
PEG might be able to provide a decent ambush around the smaller Td structures. But, the 
same shift decently enhances the coverage of larger DNO that is reflected in the higher 
reduction of macrophage uptake. 
 
Figure 2.11: Comparing fluorescence intensities from internalized linear PEG coated DNs. 
After studying the effect of linear PEGs, we directed our attention to investigate the 
effect of PEG conformation on cellular uptake. Both Td and DNO were coated with a 4 
arm 2 kD PEG (2-4 arm), a 4 arm 10 kD PEG (10-4 arm) and an 8 arm 10 kD PEG. The 
data shows considerable decrease in uptake of DNO when an 8 arm 10 kD PEG is used 
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instead of the linear isomer. However the decrease is not that prominent for Td probably 
because 12 10 kD linear PEG chains were enough to give the structure a sufficient 
coverage.  
 
 
Figure 2.12: Effect of PEG branching on cellular uptake of DNs. a) Td b) DNO. 
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2.3.4.2 Effects of plasma and clusterin Incubation 
In 2016, Wurm and coworkers analyzed the protein corona formed over 
nanoparticles when they are subjected to plasma and found that PEG coating does not 
inhibit the formation corona, but they change its composition relative to the uncoated 
particles.37 The corona with altered composition is responsible for determining their extent 
of uptake by the macrophages. They also found a higher percentage of clusterin protein in 
the PEG coated NPs. As the cellular internalization of NPs depends on the material of the 
core, we decided to study how plasma and clusterin incubation of bare and PEG-coated 
DNs influence their internalization by macrophages. We found that incubation with mouse 
plasma had almost no effect on the uptake of bare Td but the same was increased in case 
of bare DNO. On the other hand, clusterin incubation marked decreased the uptake of both 
the structures.  
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Figure 2.13: Effect of plasma and clusterin incubation on cellular uptake of bare DNs. a) 
Td b) DNO. 
After studying the bare structures we looked at the effect of plasma and clusterin 
incubation on PEG coated DNs. Figure 2.14 shows the effect of linear PEG chains on 
cellular uptake of plasma and clusterin incubated structures. From the plots we can find 
two noteworthy trends. First, plasma incubation of bare structures had almost no influence 
on the uptake, but the same reduced the uptake of coated DNs to various extents. And 
second, clusterin incubation always brought about reduction in internalization.  
a)  
 
b)  
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Figure 2.14: Effect of plasma and clusterin incubation on cellular uptake of linear PEG 
coated DNs. a) Td b) DNO. 
Branching of the PEG chains showed a dramatic effect on the internalization of 
DNs when they are incubated with clusterin. And this effect was pronounced in case of 
higher chain lengths (i.e., higher in 10 kD branched PEG than 2 kD branched PEG). This 
is probably due to the fact that branching provides a higher coverage and this attracts more 
clusterin to deposit around the structure, thus reducing engulfment by macrophages. 
a)  
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b)  
 
Figure 2.15: Effect of plasma and clusterin incubation on cellular uptake of branched PEG 
coated DNs. a) Td b) DNO. 
2.3.5.3 Effect of PEG-lipid coating 
The cell membrane being a phospholipid bilayer, might not recognize another lipid-
coated article as a candidate for prompt internalization – this was the rationale behind 
choosing the DSPE-PEG (2 kD) coating. Without any plasma or clustering incubation, the 
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DSPE-PEG coating indeed reduced the uptake of DNs, ~35% for Td and ~40% in case of 
DNC. But clusterin incubation did not reflect any consistent trend as was observed in case 
of the PEG coatings. This is probably due to the fact clusterin deposition is no more the 
key component in the protein corona formed over DSPE-PEG coating, and hence its 
deposition did reflect any significant reduction in the internalization of DNs by 
macrophages. However, this issue requires a separate investigation where the protein 
corona around a PEG-lipid coated DN would be analyzed meticulously and a detailed 
profile of the corona constituents would be built. 
a)  
 
b)  
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Figure 2.16: Effect of PEG-lipid coating on cellular uptake of DNs. a) Td b) DNO. 
2.4 Conclusion 
We reported the effect PEG coating on the stability and macrophage internalization 
by macrophages. In this study, the aspects of PEG length and conformation have been 
studied and increased chain length has demonstrated increased resistance towards low salt 
denaturation and nuclease attack. Also, higher chain lengths reduce the cellular uptake of 
the DNs more in comparison to the shorter ones. But from careful analysis of the results, it 
is clear that without considering length or extent of branching as isolated parameters, the 
ideal parameter for consideration would be ‘surface coverage’ of the DN under study. PEG 
branching has shown its effect on reducing cellular uptake of structures, but the amount of 
reduction differs in case of Td and DNO. This observation, again, points to the issue of 
surface coverage. Higher coverage makes the DNs more efficient in avoiding recognition 
by the MPS. This might be due to the fact that higher coverage allows enhanced deposition 
of clusterin, incubation with which prior to cellular internalization has demonstrated 
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prominent effects. The findings definitely open up a new direction of investigation where 
covalent conjugation of clusterin to DNs could be employed to reduce the cellular uptake. 
Another interesting observation is the results from DSPE-PEG coating, which indicates, 
not clusterin but some other blood component is also playing a crucial role in reducing 
clearance of DNs in circulation.  
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CHAPTER 3 
ENHANCING LOW SALT STABILITY OF DNA NANOSTRUCTURES USING  
FREE STABILIZING AGENTS 
3.1 Abstract 
 Stability of the DNs is a crucial factor determining their suitability for in vivo 
applications. The formation of DNs require a very high concentration of divalent 
magnesium and this concentration is not available in physiological fluids like blood. Hence 
when injected in a living system, the DNs rapidly unfold and thus their lifetime becomes 
extremely reduced. In this project we screened several DNA compaction agents, 
intercalators and groove binders and only four of them, arginine, lysine, bis-lysine and 
hexamine cobalt, were able to enhance the stability of DNs in low salt condition. Bis-lysine 
was found to be the most stabilizing. The enhancement of stability was studied by counting 
the number of intact structures via transmission electron microscopy using 30 nm gold NPs 
as internal standards. In addition to studying the effect of single agents, we also studied the 
efficacy of their combinations. Hexamine cobalt in combination with bis-lysine 
demonstrated the highest efficacy. Through melting point studies we also confirmed that 
the stabilizing agents enhance the thermodynamic stability of the DNs which is reflected 
by the increase in their melting points when formed in presence of the four stabilizing 
agents.  
3.2 Introduction  
Because of its versatility and functionality, DNA has contributed largely to bridge 
the gap between material science and biology. DNA nanotechnology, a burgeoning field 
51 
 
of research for the past few decades, have used DNA as a structural nanoscale material and 
has provided an easy and convenient method to produce nanoscale 2D and 3D structures 
of diverse shapes, sizes and complexities1-4 that would not be possible with any other 
known nanomaterial. The DNA origami method5 has become a very popular choice to build 
3D DNs owing to its convenience and robustness. The intrinsic biocompatibility and 
nanosize of the DNs has made them obvious choices for various biological applications. In 
addition to this, as the DNs allow very precise organization of functional molecules like 
fluorophores6, quantum dots7, aptamers8, antibodies9, etc. on them with excellent control 
over number, position and architecture, and the dynamics of reconfigurable and dynamic 
DNs can be controlled by stimuli like a single stranded DNA (fuel), small molecules, or 
light, they have become candidates of interest in the fields of biomimicking, 
nanoelectronics, biosensors and nanomedicine.10-13  
The multivalence of DNA, the diverse nature of functionalizations available and 
the compatibility of biological systems have drawn considerable attention of the 
nanomedicine researchers and the DNs have been used as drug delivery vehicles in a 
number of reports. Douglas and co-workers build a nanorobot that can release Fab antibody 
fragments in the presence of target cells.14 A DNA tetrahedron was employed by Anderson 
and co-workers for in vivo delivery of small interfering RNA in order to target and suppress 
gene expression in a mouse model.15 The DNs have also demonstrated their potential to 
serve as platforms for synthetic vaccines. Fan, Huang and co-workers assembled a 
multivalent DNA tetrahedron for noninvasive delivery of immunostimulatory CpG 
oligonucleotides.16 Yan, Chang and co-workers have employed a DNA tetrahedron for 
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coassembly of model antigens and CpG with precise control over the valency and spatial 
arrangement of each constituent.17  
DNs have also been employed to carry drug molecules in vivo either by 
intercalation into the carrier DNA helix or by attachment through chemical conjugation. 
Huang and co-workers demonstrated the application of aptamer-conjugated DNA 
icosahedral NPs as carriers of doxorubicin for cancer therapy.18 In 2012, Ding and co-
workers constructed 2- and 3-D doxorubicin-loaded DNs, the loading being through 
intercalation, and they demonstrated that their construct showed prominent cytotoxicity to 
regular human breast adenocarcinoma cancer cells (MCF 7) and also to doxorubicin-
resistant cancer cells.19 In the same year Högberg and co-workers developed DNA origami 
delivery systems for cancer therapy that have tunable release properties.20 Their aim was 
the optimal delivery of anthracycline doxorubicin (Dox) to human breast cancer cells. As 
they designed different DNs having varying degrees of global twists, hence the amounts of 
relaxation of the structures also varied. They tuned the DN design to control the 
encapsulation efficiency and release rate of Dox and also increase the cytotoxicity and 
decrease the intracellular elimination rate of Dox in comparison to the free drug molecule. 
However, all the DNs used as the delivery vehicles are very simple structures, either 
2D or wireframe or single layer DNA origamis. There are several concerns while using 
these structures like drug potencies and leakage. Simple wireframe structures offer limited 
number of valencies, so when the drug needs to be chemically conjugated, the amount of 
carrier to be administered will be quite high. And, as the drug delivery vehicles reported 
do not provide encapsulation of the drug molecules, they might leak while being circulated 
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and exert non-specific effects. The application of densely packed 3D origamis are limited 
by the shorter in vivo lifetimes. In vivo stability of a DN is a function of several factors, the 
important ones being low salt denaturation, nuclease degradation and opsonization.  
The basic principles underlying the attempts to address these issues could be 
summarized as: a) increase low salt stability by replacing divalent magnesium with other 
positively charged species that are either available in the blood, or that can adhere to the 
DNs even after administering, b) coat DNs with protective layers that can minimize their 
exposure to nucleases, and c) avoid immune recognition. Several attempts have been 
reported to increase the lifetime of DNs in circulation.  Being inspired by the natural 
particle systems like viruses, Shih and co-workers demonstrated membrane encapsulation 
of DNs in order to achieve enhanced circulation times.21 They encapsulated DNs with 
PEGylated lipids and achieved a twofold lower immune activation and 17 fold higher 
pharmacokinetic bioavailability. In 2014, Perrault and co-workers addressed the instability 
of DNs in tissue culture, which is basically a combination of low salt and nuclease 
degradation effects.22 They systematically studied the sensitivity of DNA nanostructures 
to cation depletion and effect of nucleases in cell culture medium. Shih and co-workers 
further reported a oligolysine-based coating that can protect nanostructures from low-salt 
denaturation and nuclease degradation.23 
In this project we have focused on enhancing the stability of DNs in low magnesium 
buffers. The strategies reported till date that aim at enhancing the DN lifetime in low salt 
conditions require coating by some special polymers or lipids, either covalently conjugated 
or electrostatically anchored to the DN surface. These modifications increase the net 
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hydrodynamic radius of the structures, alter their shapes and surface properties and thus 
might alter their excretory and cellular uptake profiles.24 It has been reported that 
nanomaterials of same geometric shape but different dimensions have varying rates of 
uptake by cells. For spherical gold NPs, silica NPs, single-walled carbon nanotubes and 
quantum dots, a 50 nm diameter is of optimal value that can maximize the rate of cellular 
uptake and intracellular concentration in certain mammalian cells.25-27 Not only the shape 
and size but also the composition of the nanomaterial is a significant factor that influences 
the uptake of nanomaterials. It has been found that both 50 nm carbon nanotube and gold 
NPs have endocytosis rates of 10−3 min−1 and 10−6 min−1, respectively. The observed 
difference of 1000-fold might arise from the difference of the intrinsic properties of carbon 
and gold. 
Our aim was to use free stabilizing agents that could be added to the mixture of 
DNA strands prior to annealing of a particular structure. To look for the potential 
stabilizing agents we turned our attention towards the natural DNA compaction agents. 
There are certain molecules like polyamines that can bring about DNA compaction by 
binding electrostatically to the DNA double helix. Borrowing this concept, we tried to 
combat the low salt instability of DNs by forming them in the presence of simple amino 
acids like arginine and lysine, their low molecular weight polymers, and spremine. In 
addition we also used some intercalators and groove binders to test if they can contribute 
towards the stability enhancement of DNs under low magnesium conditions.  
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3.3 Results and Discussion 
3.3.1 Designing the DNs  
We chose three different structures (DN1, DN2 and DN3) for this project. DN1 is 
a hollow cage closed on all sides, DN2 is a densely packed 8x8 structure, and DN3 is a 
hollow cage open on two ends. DN1 and DN2 are designed in the square lattice motif while 
DN3 is designed in the honey-comb motif of the caDNAno software. The rationale for 
choosing these three structures lies in the difference of their packing densities. The stability 
dependence on divalent magnesium (and also on the stabilizing agents) should be a 
function of the packing density as more densely packed structures would require higher 
concentration of cations to screen the negative charge on the phosphodiester backbone of 
the DNA strands. 
 
Figure 3.1: DNA nanostructures studied. a) DN1 b) DN2 c) DN3. 
3.3.2 Screening of Stabilizing Agents 
 We screened ten different materials that can act as potential stabilizing agents (table 
3.1). Different concentrations of aqueous solutions of these agents were added to the 
annealing mixture of DN1 (5 nM m13, 10X staples) making the final stabilizing agent 
56 
 
concentrations 1 uM, 10 uM, 50 uM, 100 uM, 500 uM, 1 mM and 1.5 mM. The resulting 
structures were imaged using TEM. From the results a table (3.2) was built showing the 
maximum amount of stabilizing agent that allowed the formation of complete DNs. 
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Table 3.1 List of potential stabilizing agents screened. 
 
Nature of 
Interaction 
 
Potential Stabilizing Agents 
 
 
 
 
 
 
 
 
 
Electrostatic 
Interaction 
 
  
  
 
 
 
 
 
Groove Binder 
 
Arginine Lysine Hexamine Cobalt  
Glyoxyl-derived lysine dimer trifluoroacetate salt  
Spermine 
Netropsin 
Hoechst Dye 
58 
 
 
 
Intercalators 
 
 
 
Dual interaction 
 
(Groove binding 
+ intercalation) 
 
 
 
 
 
  
YOYO  Thiaozle Orange 
DAPI 
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Table 3.2 Maximum concentration of each stabilizing agents that allow the formation of 
DN1. 
Stabilizing agent Maximum 
concentration of 
stabilizing agent that 
allowed formation of 
DN1 (mM) 
Arginine / Lysine 1.0  
Lysine 1.0  
Bis-lysine 0.7  
Spermine 0.1 
Thiazole Orange 0.01 
Hoechst Dye 0.01  
Netropsin 0.01 
DAPI 0.01 
Hexamine Cobalt 0.01 
YOYO 0.001 
 
DN1 was annealed with the highest tolerable concentration of the free stabilizing 
agents in 1X 3D buffer containing 16 mM Mg2+. Then we exchanged the annealing buffer 
with 1X physiological buffer and imaged the structures every 20 minutes. The images 
showed that out of the ten potential stabilizing agents only five are able to confer stability 
to the structures in low salt conditions. They are arginine, lysine, bis-lysine, hexamine 
cobalt and thiazole orange. Unlike the first four promising stabilizing agents, thiazole 
orange is not innocuous, so we discontinued using thiazole orange for further studies. 
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From the nature of the molecules that conferred enhanced stability to the DN in low 
salt conditions, it is prominent that four bind to the DNA electrostatically, while only 
thiazole orange is an intercalator. Probably, the ionic stabilizing agents are least demanding 
in terms of structural integrity than the other class of molecules studied. The other 
intercalator studied was YOYO that is a much larger molecule that thiazole orange. It is 
probable that it caused much higher deformation of the double helices than thiazole orange, 
and hence DN1 could be formed only in the presence of 1 M YOYO, the least in the 
series. 
3.3.3 Estimation of Stability Enhancement 
The most commonly known method for estimating the stability of DNs is studying 
their mobility on electrophoretic gels. This method is not very sensitive and does not yield 
very accurate conclusions mainly because of three reasons. While studying stability in low 
salt conditions it might happen that some structures are partially deformed or unfolded but 
still they might have the same mobility on an electrophoretic gel. The second point is 
running through an agarose gel under a certain voltage is quite a harsh treatment that might 
itself bring about degradation of some structures. And the last, during the running time the 
structures might get degraded. Keeping these in mind we employed a different strategy to 
estimate the stability enhancement.  After forming the DNs with and without the potential 
stabilizing agents, we subjected them to low magnesium buffer and then made TEM 
samples at different time points. While preparing TEM samples, 30 nm gold nanoparticles 
(AuNPs) were used as internal standards. We counted only the intact structures from TEM 
images and plotted the number of DNs per 100 AuNPs. While counting the intact images 
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from TEM images we can have a better idea about the intactness of the structures and 
exclude any deformed and/or degraded structures. This might be a better strategy to 
approach towards accurateness. 
From the counting results we obtained the half-lives of each DN following the 
procedure explained in supplementary information S3.7. Figure 3.2 shows the half-lives of 
DN1 formed with maximum concentration of the stabilizing agents as mentioned in table 
3.2. On comparing the values with the half-life of normal DN1, we see that bis-lysine 
provided the highest stabilization in absence of high magnesium in the buffer. With bis-
lysine, the half-life of DN1 was increased almost three fold than the bare DN1. This 
increase is significant when looked at perspective of in vivo delivery as we need the carriers 
to be stable in circulation not for ever but for a therapeutically relevant length of time. The 
stabilizations conferred by arginine and lysine were almost same, lysine being slightly 
higher in efficiency.  
 
Figure 3.2: Comparison of half-lives of DN1 formed with and without free stabilizing 
agents. 
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Figure 3.3 depicts the half-lives of all three DNs formed with and without 
stabilizing agents. Bis-lysine always provided the highest stabilization irrespective of the 
structure studied. It is to be noted that the half-life of DN3 is the highest among the three 
structures followed by DN1 and then DN2. This could probably be explained by looking 
at their designs. DN3 was designed in the honeycomb motif of the caDNAno while the 
other two were designed using the square lattice motif. The former motif being more porous 
than the later, leads to less denser packing of the DNs. Hence the requirement of stabilizing 
cations was lesser for DN3 than the other two. While designing DN1, a cavity was 
intentionally left inside the structure. Conceptually, it can be said that if the cavity of DN1 
is filled with densely packed DNA layers, we arrive at DN2. From this it is pretty obvious 
that DN1 had the highest packing density among the three DNs and this was reflected in 
the half-lives of the normal structures and the stabilized ones as well.  
 
Figure 3.3: Comparison of half-lives of all three DNs formed with and without free 
stabilizing agents. 
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Being encouraged by the higher efficiency of lysine dimer in stabilizing structures 
we studied pentamer, decamer and higher polymers of lysine. But their presence in the 
annealing solution in concentrations as low as 100 nM did not allow the formation of well-
defined structures. Those who are formed were either deformed, or incomplete or the yields 
were highly compromised. High degree of aggregation was observed in most of the cases.  
3.3.4 Combination of Stabilizing Agents 
 After testing the stabilizing agents separately, we attempted to study the effect of 
their combination. The rationale behind this was that the different stabilizing agents might 
bind to different domains of a DNs thus providing additive stability to the structures, the 
following combinations were studied: a) arginine + lysine b) arginine + bis-lysine c) 
arginine + hexamine cobalt, d) lysine + hexamine cobalt, and e) bis-lysine + hexamine 
cobalt. Concentration titrations were also performed in a way similar to the single 
stabilizing agents and DN1 was used as the test structure. The results obtained are 
summarized in table 3.3. 
  
64 
 
Table 3.3 Concentration titration of combination of stabilizing agents 
 
Combination 
Maximum 
concentrations of 
combination of 
stabilizing agents 
that allowed 
formation of DN1 
(mM) 
Arginine + Lysine 0.5 + 0.6 
Arginine + Bis-lysine 0.5 + 0.4 
Arginine + Hexamine 
cobalt 
0.5 + 0.0075 
Lysine + Hexamine cobalt 0.5 + 0.0075 
Bis-lysine + Hexamine 
cobalt 
0.3 + 0.0075 
 
Figures 3.4, 3.5 and 3.6 show the comparison of half-lives of DN1, DN2 and DN3 
respectively formed with the single and selected combination of stabilizing agents.  
 
Figure 3.4: Comparison of half-lives of DN1 formed with single and combined stabilizing 
agents. 
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Figure 3.5: Comparison of half-lives of DN2 formed with single and combined stabilizing 
agents. 
 
Figure 3.6: Comparison of half-lives of DN3 formed with single and combined stabilizing 
agents. 
In all three cases, hexamine cobalt when combined with arginine, lysine and bis-
lysine conferred the highest stabilization. But a combination of arginine and lysine (data 
not shown) did not enhance stability over any one of the amino acids. This might be an 
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indication that hexamine binds to different domains of the DNs than arginine and lysine 
and thus when used in combination the stabilization from each agent was added. However, 
this aspect requires further study to be confirmed and put in further applications.  
3.3.5 Melting Temperature of DNs 
All the stabilizing agents used in this study bind to the DNs electrostatically and 
have demonstrated stability enhancement effects in low salt conditions. In order to find out 
whether this enhancement is thermodynamic in nature we studied the melting temperatures 
of each DN formed with each stabilizing agent (or their chosen combination) following the 
procedure described in the supplementary information.  
 
Figure 3.7: Melting temperatures of three DNs when formed with different stabilizing 
agents and their combinations.  
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Figure 3.7 compares the melting temperatures of the three DNs formed will all the 
stabilizing agents (single and combinations). It is evident that the stabilizing agents confer 
thermodynamic stabilization to the DNs that is reflected in their higher melting 
temperatures in comparison to the normal DNs. It is to be noted that the agent providing 
highest stability singularly (bis-lysine) makes the DN the most stable thermodynamically 
and similar is the effect of the most stabilizing combination (i.e., bis-lysine + hexamine 
cobalt). 
3.4 Conclusion 
From the screening of the potential stabilizing agents, we found that the molecules 
that bind electrostatically with the DNA double helix are the least demanding in terms of 
forming DNs and they confer the maximum stabilization. This can be explained primary 
by two rationale. First, probably they bring about the least deformation among the batch of 
stabilizing agents screened in this study. The other molecules bring about deformation of 
the DNA double helix to an extent such that formation of well-defined DNs are not 
possible. So when they are present in higher concentration in the annealing buffer, the DNs 
are not formed or form in deformed manner. The second reason behind the efficiency of 
the stabilizing agents in the dissociation kinetics of the molecules with DNA. The more 
they are retained inside the structure, the more they are able to screen the negative charge 
of the phosphodiester backbone and maintain the dense packing of the DNs.  
We have presented the results from the bis-lysine in this paper. But we have also 
studied pentamers and decamers of both arginine and lysine and they generally do not allow 
the formation of structures even at a concentration as low as 1.0 uM. This strengthens the 
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probability that if the stabilizing agents present in the annealing buffer deform the shaped 
of the DNA double helix beyond a certain extent, the DNs would not form.  
In this study we have tested a certain number of potential stabilizing agents in a 
particular range of concentration and some limited number of their combinations. This 
study shows the promise that smart DNs that are intrinsically stable under low salt 
conditions can be made by forming them with simple stabilizing agents. A wide range of 
DNA compacting and complexing agents in different concentrations and combinations can 
be studied in order to search for better and more effective stabilizing agents. They can 
eliminate the need of any special polymer coating on the DNs to make them stable under 
physiological conditions, thus alleviating the scope of an increased hydrodynamic radius 
and unknown immune activations while in circulation. 
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CHAPTER 4 
BUILDING SERUM ALBUMIN-COATED DNA NANOSTRUCTURES  
FOR IN VIVO APPLICATIONS 
4.1 Abstract 
Stabilization of DNA nanostructures (DNs) in physiological conditions is a 
threshold that must be crossed if DNA nanotechnology has to make successful 
contributions in the field of therapeutics and diagnostics. The factors limiting the in vivo 
stability of DNs are low salt conditions, degradation from nucleases and opsonization. 
Opsonization is the immune process that renders a foreign particle recognizable to the 
macrophages of the mononuclear phagocyte system (MPS) and bring about rapid clearance 
of the injected particles. Albumin proteins are one of the most abundant proteins in blood 
and if we can coat the DNs with serum albumin before injection, they might void 
recognition by the macrophages. We tested this hypothesis by ornamenting two DNs with 
a albumin attracting molecule reported earlier and incubated them with human serum 
albumin (HSA). On studying the cellular uptake of HSA coated DNs, it was found that they 
showed a lower uptake than the uncoated structures. We also studied if this coating can 
render the DNs more stable in a cell culture medium that provides both the physiological 
conditions of low salt and presence of nucleases. The time vs stability results demonstrated 
that HSA coating was able to enhance the lifetimes of DNs.  
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4.2 Introduction 
From being simply a structural arena of research exploring the 3D design space of 
nanoscale objects and building nanostructures of increasingly diverse shapes, sizes and 
dynamics,1-4 DNA nanotechnology has shown tremendous potential in biomedical 
applications like biosensing,5,6 building synthetic vaccines7,8,  nucleic acid delivery9 and 
drug delivery10,11 in the past few decades.  However for delivering cargo in a living system 
the DNA nanostructures (DNs) have to be stable in physiological conditions. Lower half-
life of a drug requires high-frequency dosing in order to provide a sustained dosing effect. 
So half-life extension strategies have to be implemented on the DNs for improving their 
circulatory abilities for successful biomedicinal applications.  
There has been continuing attempts to comprehend the instability of DNs in 
physiological conditions and to come up with strategies overcoming the limitations. In 
2014, Perrault and coworkers reported that while the denaturation of the DNs due to low 
salt conditions was dependent on design and time, the degradation by nucleases is not 
dependent on time.12 Being inspired by virus capsules, the same group came up with a 
strategy to encapsulate DNA nanostructures into liposome and achieved higher lifetimes 
in circulation.13 In 2017, Shih and coworkers reported an oligolysine coating that can be 
applied over the DNs via electrostatic adsorption and this coating can protect them from 
low salt denaturation and nuclease degradation for prolonged hours.14 However, 
researchers have now directed their attention towards using proteins that are abundant in 
blood for coating DNs to make them stable in vivo. The most abundant protein in human 
blood is the 66 kDa human serum albumin that comprises 50–60% of the total serum 
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proteins.15  The half-life of HSA in circulation is around 19 days16 that makes it a promising 
candidate to be explored for half-life enhancement strategies. The high binding capacity, 
high bioavailability and low cost has made HSA a candidate of interest in drug delivery. 
In addition to all these advantages, it has also been found that HSA accumulates in solid 
tumors and is retailed due to EPR effect.17 FDA has already given approval to drugs 
encapsulated in albumin NPs that can be used for cancer treatment. Abraxane, currently 
available in the market, is being used to treat lung, breast and pancreatic cancers.18 This 
drug is actually an albumin paclitaxel NPs.  
Not many reports are available in the literature that have studied the applicability 
of HSA in nucleic acid delivery and therapeutics. In 2003, Manoharan and coworkers 
explored this strategy and conjugated ibuprofen to an antisense oligonucleotide, the oligo 
being itself bound to HSA with micromolar affinity.19 Recently in 2017, Lacroix and 
coworkers applied the strategy of HSA conjugation to improve the pharmacokinetics and 
biodistribution of DNs.15 They conjugated dendritic alkyl chains to a very simple DN and 
showed that it can bind to HSA with a Kd of ~5 nM. They also showed that HSA 
conjugation enhances the lifetime of the DN in cell culture medium supplemented with 
10% FBS.  
In our work we employed the albumin-binding molecule tags reported by Huang 
and coworkers in 2012.20 They have attached albumin binding molecule tags to compstatin, 
a 13-residue cyclic peptide that interacts with the complement component C3 and also with 
its activation fragment C3b and thus inhibits complement activation.21,22 In this project, we 
used the molecule tag used by Huang and coworkers and attached it with a single stranded 
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DNA which , in turn, was attached to DNA handles protruded out from two DNs. The azide 
version of the albumin binding molecule tag that we used is shown in figure 4.1.  
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Figure 4.1: Albumin attracting molecule (SP141C). 
In comparison to the work done by Lacroix and coworkers, we dealt more complex 
DNs that are more demanding with respect to salt concentration and are expected to unfold 
quite rapidly when injected. Our results confirm successful attachment of HSA to the two 
DNs we used and conjugation to the albumin considerably enhanced their half-lives in a 
cell culture medium supplemented with 10% FBS. Our findings also show that HSA coated 
DNs showed reduced uptakes by murine macrophages in comparison to the non-coated 
structures.  
4.3 Results and Discussion 
4.3.1 Building the DNs 
In order to compare results and establish the generality of our findings, we 
conducted studies using two DNs: a DNA tetrahedron (Td) and an 8x8 DNA origami 
(DNO) designed in the square lattice motif of caDNAno. The tetrahedron (Td) we used 
(with some modifications) have been employed by Chang, Yang and coworkers in 2012 
for building up a DNA platform for synthetic vaccines.8 The schematic representation (S 
4.3.2.1) shows that each Td is comprised of four symmetric units capable of inter-unit 
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assembly through sticky end hybridization. Three strands on each of the constituent units 
were modified with a single stranded handle. Hence, a complete Td had 12 DNA handles 
and each handle was hybridized to S5-AAM to which HSA can be attached. Similarly, in 
case of DNO 24 surface staples were selected and their ends protruding outside were 
extended leading to 24 handles that can be hybridized to S5-AAM. (Structural details for 
both Td and DNO are provided in S4.3).  
Td being a comparatively hollower structure more resembling a wireframe DN than 
a densely packed DNA origami, the divalent cation requirement should be lesser while the 
scope for nuclease action should be higher. Exactly the reverse is expected to be true for 
densely packed DNO that was designed in the square lattice motif of caDNAno. It requires 
high magnesium concentration in medium for being stable. Employing both of them for 
the experiments, we can get a better idea regarding the efficiency of our HSA-coating 
strategy to enhance the stability of DNA nanostructures in physiological conditions.  
 
 
Figure 4.2: a) Td b) DNO. 
76 
 
4.3.2 Synthesis of Albumin Attracting Molecule (AAM) 
Figure 4.3: Scheme showing the synthesis of AAM (SP141C). 
The molecule was synthesized by Dr. Stevan Pecic from the Stojanvic group at 
Columbia University. In order to prepare the albumin-attracting molecule SP141C, we 
employed synthetic approach that involves 5 synthetic transformations altogether (Scheme 
1). According to previously published procedure, we first synthesized the intermediate 4,4-
diphenylcyclohexanol, SP52D by a hydrogenation and reduction with sodium borohydride 
of commercially available starting material 4,4-diphenyl-2-cyclohexen-1-one in one pot. 
This reaction provided the intermediate molecule SP52D in 84% yield.23 We then coupled 
commercially available ethyl 6-hydroxyhexanoate with 2-cyanoethyl N,N-diisopropyl-
chlorophosphoramidite, which furnished phosphoramidite SP113C. In the next step, we 
coupled SP113C with the intermediate molecule SP52D, followed by oxidation with tert-
butyl hydroperoxide in order to obtain the phosphodiester. Subsequently, the cyanoethyl 
protecting group was removed using ammonia in methanol and the ethyl ester cleaved with 
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lithium hydroxide to the get the free acid SP117C. This carboxylic acid was then converted 
to the acid chloride SP127C by refluxing with thionyl chloride, and finally coupled to the 
amino terminus of the commercially available azido-(PEG)8-amine in order to get the final 
product SP141C. 
4.3.3 Conjugation of Serum Albumin to DNA 
AAM was synthesized with an azide terminal so that it can be conjugated to a DNA 
strand containing a strained alkyne (DBCO) via copper uncatalyzed click reaction. We 
conjugated the amine functionality of a DNA strand (S5) with DBCO-NHS ester 
(supplementary information 4.5) and obtained the DNA-DBCO. This strand was reacted 
with different equivalents of AAM at room temperature for 6 h and mass spectrometry of 
the click-conjugated product was recorded. It was found that a S5-DBCO: AAM ratio of 
1:2.5 yielded a S5-AAM product (S 4.6). The S5-AAM thus obtained was reacted with 
increasing equivalents of HSA and a characterization gel showed a 1:5 ratio of S5-AAM: 
HSA led to decent conversion to S5-HSA (S4.7). 
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Figure 4.4: HSA binding of S5-AAM. 
4.3.4 Coating DNA nanostructures with serum albumin  
Both Td and DNO were mixed with 5 fold equivalents of S5-AAM when S5 
hybridized with the handles on Td and DNO. When incubated with 5 equivalents of HSA 
for 4 h, the DNs got coated with HSA was demonstrated by agarose gel characterizations. 
For confirming that the DNs were bound to HAS we added excess of anti-HAS antibody 
to an aliquot from each of the HSA coated DNs. A prominent gel shift showed that the DNs 
were indeed coated with albumin. A mixture of DNs decorated with AAM and anti-HSA 
antibody was used as control that showed same mobility as the corresponding DNs on 
agarose gel. 
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Figure 4.5: HSA coating of a) Td b) DNO.  
4.3.5 Stability of Albumin-coated Structures in Physiological Conditions 
The DNA nanostructures require high magnesium concentration (~5–20 mM) to 
preserve their structural integrity. But this amount of magnesium is not available in the 
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physiological fluids or cell culture medium. Hence the structures degrade when incubated 
with cells or injected in a living body. In addition to the low salt denaturation, nucleases 
are abundantly present in blood as well as in the commonly used cell culture medium that 
is supplemented with 10% fetal bovine serum (FBS). We studied the stability of HSA 
coated DNs in DMEM + 10% FBS and our findings showed almost 2 fold increase in half-
life of Td and ~2.5 fold increase in case of DNO. 
 
Figure 4.6: Time vs stability of a) bare Td b) HAS-coated Td.  
 
Figure 4.7: Half-lives of coated and uncoated DNs.  
81 
 
4.3.6 Confocal Microscopy 
Before carrying out the flow cytometry studies to investigate the cellular uptake of 
albumin coated DNs, it was essential to be assured that the structures do not stick to the 
cell surface and thus do not contribute towards the fluorescence signal in cytometry leading 
to false positive results. So we incubated the structures with the RAW cells and recorded 
confocal microscopy images to confirm the cellular internalization of structures. We 
incubated dye-labeled S4, Td and DNO, and albumin coated Td and DNO with the RAW 
cells and imaged the living live. For all of them the internalization by the RAW cells was 
confirmed from the orthogonal section of the confocal microscopy images. In addition, we 
treated a batch of cells after incubation with the strands and the structures with DNase so 
that any strand or structure attached to the cell surface is degraded. The orthogonal sections 
of the confocal imaged recorded after DNase treatment also confirmed the presence of 
fluorescent particles inside the cells. Confocal microscopy images of Td, DNase treated 
Td, HSA coated Td, DNase treated HSA-coated Td are shown below.  
82 
 
 
Figure 4.8: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled Td. The cell membranes were stained with CellTracker CM-Dil dye. a) Bright field 
image b) green fluorescence from internalized Td c) overlay of bright field and green 
fluorescence d) red fluorescence from CellTracker CM-Dil dye e) overlay of green and red 
fluorescence f) overlay of bright field, green and red fluorescence. 
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Figure 4.9: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled Td. The crosshairs indicate orthogonal sectioning. The bottom and right 
panels show the sectioned planes and confirm that fluorescent particles (green) are located 
inside the cells and not merely attached to the cell membrane. 
 
Figure 4.10: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled Td and then treated with DNase. The cell membranes were stained with 
CellTracker CM-Dil dye. a) Bright field image b) green fluorescence from internalized Td 
c) overlay of bright field and green fluorescence d) red fluorescence from CellTracker CM-
Dil dye e) overlay of green and red fluorescence f) overlay of bright field, green and red 
fluorescence. 
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Figure 4.11: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled Td and then treated with DNase.  
 
Figure 4.12: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled HSA-coated Td. The cell membranes were stained with CellTracker CM-Dil dye. 
a) Bright field image b) green fluorescence from internalized Td c) overlay of bright field 
and green fluorescence d) red fluorescence from CellTracker CM-Dil dye e) overlay of 
green and red fluorescence f) overlay of bright field, green and red fluorescence. 
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Figure 4.13: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled HSA coated Td.  
 
Figure 4.14: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled HSA-coated Td followed by DNase treatment. The cell membranes were stained 
with CellTracker CM-Dil dye. a) Bright field image b) green fluorescence from 
internalized Td c) overlay of bright field and green fluorescence d) red fluorescence from 
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CellTracker CM-Dil dye e) overlay of green and red fluorescence f) overlay of bright field, 
green and red fluorescence. 
 
Figure 4.15: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled HSA coated Td followed by DNase treatment. 
4.3.6 Cellular Uptake of Albumin-coated DNs 
Albumin being a ubiquitously occurring member in the blood, the albumin-coated 
structures would not be identified by the macrophages as potential candidates of 
phagocytosis. We used murine macrophage (RAW) cells to study how the albumin-coating 
influences uptake of DNs. The bare and HAS coated structures were incubated with the 
RAW cells in DMEM + 10% FBS medium  at 37C and in 5% carbon dioxide for 1 h. The 
dye labeled DNA was also incubated as a control. The membrane of the dead cells have 
higher permeability towards foreign particles and hence they can contribute largely to the 
fluorescence signals, thus leading to erroneous conclusions. Before subjecting to flow 
cytometry analysis, the cells were suspended in a propidium iodide solution in order to 
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detect and exclude the dead cells from analysis. As controls, we also treated separate 
batches of cells (pre-incubated with controls and structures) with DNase for ten minutes 
before flow cytometry analysis.  
Comparing the fluorescence, it was found that there was almost no difference 
between the DNase treated and untreated controls. This confirmed that all the results 
obtained are from actually internalized structures and not mere DNs sticking to the cell 
surface. 
 
Figure 4.16: Comparing fluorescence intensity of DNase treated and untreated controls. 
On comparing the RFI values of bare and coated Tds we see that the albumin 
coating had reduced the internalization by almost 50% while the same is around 40% in 
case of DNO. 
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Figure 4.17: Cellular uptake of bare and albumin coated DNs. 
4.4 Conclusion 
We reported a successful synthesis of an albumin attracting molecule and coated 
two DNA nanostructures with that AAM. Those DNs when incubated with HSA developed 
an albumin coating around them. The coating was able to stabilize the DNs under 
physiological conditions and reduced their uptake by macrophages when incubated with 
murine RAW cells. The decrease in cellular uptake was lower in case of the larger DNO 
structure in comparison to Td. This might be due to the insufficient surface coverage of 
DNO by albumin molecules. Further studies can be done by varying the number and 
position of albumin attachment on larger DNs and this study would be able to reveal the 
optimal surface coverage that leads to minimum internalization of the coated DNs.  
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CHAPTER 5 
PROXIMITY LIGATION ASSAY TO ESTIMATE THE STABILITY  
OF DNA NANOSTRUCTURES 
5.1 Abstract 
DNA nanotechnology has emerged as a promising tool that can build 2D and 3D 
DNA nanostructures (DNs) with desired shape, size and complexity. The diverse scopes of 
modification of these structures along with their biocompatibility render them potential 
candidates for in vivo applications like biosensing and drug delivery. But for successful in 
vivo applications, DNs must be stable in circulation for at least a therapeutically relevant 
period of time. Currently, the most common method to estimate the time vs stability of 
DNs is to compare the electrophoretic gel mobility of the intact DNs and injected DNs. 
This method is not very sensitive and in many cases it is not able to differentiate between 
intact and partially degraded structures. We have developed a proximity based sensitive 
assay to estimate the time vs stability of DNs in realistic situations like cell culture medium 
and blood circulation. The concept of the assay, named the proximity ligation assay (PLA), 
is adopted from protein research and applied to the DNs. Two single stranded antennae on 
a wireframe DNA tetrahedron (Td), which, due to their proximity, were ligated during the 
PLA and the new sequence was amplified using PCR. The read out, when compared to a 
calibration curve, was able to estimate the number of intact Td present in the analyte after 
a certain time. In case of a degraded Td that is missing one or both of the antennae, or if 
they are far away from each other (due to partial degradation of the structure) ligation 
would not occur, thus differentiating between an intact and degraded structure with 
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excellent sensitivity. The PLA also works with antennae having phosphorothioate 
backbone (which is required to avoid nuclease degradation occurring in vivo.) We 
subjected the DNs to various degrading conditions (like low magnesium salt buffer, cell 
culture medium and human serum) and confirmed the validity of the newly developed 
assay results by comparison with electrophoretic gel results. We also injected the Td in 
mice models and established that the PLA can estimate the stay-time of the structures in 
circulation. In order to establish the generality of the assay we performed it on a larger 
tetrahedron and a DNA origami and confirmed its functionality.  
5.2 Introduction 
Over the past few decades DNA nanotechnology has become a promising area of 
research that exploits programmed self-assembly of single stranded DNA to build complex 
3D structures with a variety of shapes and sizes in nanoscale, with high degree of 
responsiveness and controllable dynamic properties.1-3 These DNs can be modified in 
diverse ways leading to site-specific functionalizations and owing to non-immunogenic 
and biodegradable nature, they are potential candidates for diagnostics and therapeutics. A 
nanorobot that can release Fab antibody fragments in the presence of target cells was built 
by Douglas and co-workers in 2012.4 Anderson and co-workers employed a tetrahedron 
for in vivo delivery of small interfering RNA to target and suppress gene expression in a 
mouse model.5 Fan, Huang and co-workers assembled a multivalent DNA tetrahedron for 
noninvasive delivery of immunostimulatory CpG oligonucleotides6 and thus demonstrated 
that DNs can also serve as platforms for synthetic vaccines. Yan, Chang and co-workers 
have employed a DNA tetrahedron for coassembly of model antigens and CpG with precise 
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control over the valency and spatial arrangement of each constituent.7 DNs have also been 
employed to carry drug molecules in vivo either by intercalation into the carrier DNA helix 
or by attachment through chemical conjugation. Huang and co-workers demonstrated the 
application of aptamer-conjugated DNA icosahedral NPs as carriers of doxorubicin for 
cancer therapy.8 In 2012, Ding and co-workers constructed 2- and 3-D doxorubicin-loaded 
(through intercalation) DNs and showed that their construct demonstrated prominent 
cytotoxicity to regular human breast adenocarcinoma cancer cells (MCF 7) and also to 
doxorubicin-resistant cancer cells.9 In the same year Högberg and co-workers developed 
DNA origami delivery systems for cancer therapy that have tunable release properties.10  
In spite of these outstanding reports, there are several concerns regarding 
biomedical application of DNs, the major ones are about their stability of DNs in low salt 
conditions, vulnerability towards nucleases and opsonization when injected leading to 
rapid removal from the body.11 Salt concentrations (~5–20 mM Mg2+) required for the 
stability of DNs is not present in normal physiological fluids. Divalent ions screen the 
negative charges on the phosphate backbones and assist the folding of DNs with varying 
density of packing. In absence of required amount of salt the DNs denature, their lifetime 
being dependent on several factors like the density of packing, shape and size of the 
structures, etc. In addition to denaturation, nuclease activity and opsonization also limit the 
circulation time of DNs in blood.  
To estimate the stability of DNs in physiological conditions, we need to administer 
them in a living animal, draw blood after regular intervals and subject the samples to an 
assay for obtaining a read-out. But after injection, DNs get highly diluted, and also develop 
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a corona of plasma proteins around them. Thus the structures exist in diverse states ranging 
from single intact entities to aggregates and deformed structures. This demands a very 
sensitive and accurate system of detection that can differentiate between the intact 
structures and everything else. The most common current method for stability detection is 
isolating structures from blood and running two dimensional electrophoretic gels, the band 
intensities being indicative of the stability of the injected DNs. This methods includes a 
high degree of approximation and lacks sensitivity and specificity. Electrophoresis could 
not be carried out with very low concentration of DNs, thus having a sensitivity limitation. 
In addition, the structures might be partially degraded and still show the same mobility as 
the intact structures. The intact structures might also aggregate with the mediation of 
plasma proteins and thus are collected in the gel wells, instead of running into the gel. The 
assay to be developed should be specific enough to differentiate based on the single criteria 
of the intactness of the DNs. Another issue is the time required to isolate the DNs from 
blood, as this lag period can lead to significant degradation. In 2013 Krishnan and 
coworkers demonstrated a method to estimate the in vivo stability of DNs.12 Their protocol 
involves incorporation of an I-switch into the DN and can be used only under special 
conditions. So we need to develop a smart solution-based assay that can be executed 
quickly, must yield easily detectable signals, have low background noise, and must be able 
differentiate between intact and denatured DNs even from a very low concentration of the 
structures.  
For development of the assay we direct our attention towards the arena of protein 
research. In 2002 Frederickson et al. proposed a method named Proximity Ligation for in 
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vitro detection and quantification of very small amounts of a specific protein.13 In terms of 
sensitivity, this method was far superior to existing methods like gel electrophoresis, mass 
spectrometry, and antibody-based ELISA. The researchers exploited the spatial proximity 
of two oligonucleotide extensions from two DNA aptamers that bind to the homodimer of 
the analyte protein. Once aptamer pair bind to the protein, the ends of the oligonucleotide 
extensions come into close vicinity and then they can be fixed by being hybridized to a 
connecter oligonucleotide. The free ends of the extensions are then ligated together by T4 
DNA ligase and the resulting sequence can act as PCR template, thus leading to 
amplification and quantification with remarkable sensitivity. It was able to detect 24,000 
molecules (4 x 10-20 moles) of the platelet-derived growth factor B-chain (PDGF-BB) 
protein, almost 103 fold lesser than that a standard sandwich ELISA assay can detect for 
the same target.  
We translated this assay to DNs to estimate their stability under various conditions 
both in vitro and in vivo. We hypothesized that we can extend two constituent strands of a 
DN and the extensions can act as the antennae that can be connected by the ‘connector’ 
strand, ligated and the resulting sequence can be used as the template for PCR 
amplification. For testing our hypothesis, we modified the wireframe DNA tetrahedron 
(Td) synthesized by Tuberfield and coworkers in 200414  first with a single pair of antennae 
(single-pair experiment) and incubated them in different media like low magnesium buffer 
(containing 1.2 mM Mg2+), cell culture medium (with and without FBS) and human serum. 
To study the dependence of sensitivity on the number of antennae we tested both single 
and double pairs of antennae (double-pair experiment). As the blood contains a number of 
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nucleases, there is always a chance that the nucleic acid antennae are chopped off by these 
enzymes. So we tested if the assay can be carried out with antennae having 
phosphorothioate backbone and the results turned out to be positive. After this, we injected 
two Tds with phosphodiester backbone (TdP) and phosphorothioate backbone (TdS) into 
mouse model to demonstrate the successful application of this assay. Finally we tested if 
this assay can be applied to estimate the stability of a more complex structure. When 
applied to a higher molecular weight Td (TD) made up of four symmetric units used by 
Yan, Chang and co-workers7 and a DNA origami (DNC), appreciable sensitivity of the 
assay was demonstrated.  
 
Figure 5.1: Proximity Ligation Assay design on a DNA tetrahedron.  
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5.3 Results and Discussion 
The structural designs and characterization was performed by Saswata Banerjee in 
the Yan Lab, ASU. All the RT PCR experiments were done by Dr. Nenad Milosavic from 
the Stojanovic research group at Columbia University in New York. 
5.3.1 PLA on Antennae with Phosphodiester Backbone  
           For the first trial we modified a very simple tetrahedron Td14 comprising of four 
single stranded DNA with two antennae that are extensions of two constituent strands. The 
antennae pair had normal phosphodiester backbones (hence denoted as TdP2). After 
annealing the tetrahedron following a standard protocol, we ligated the antennae pair using 
T4 ligase. The resulting structure was subjected to PCR amplification following the 
protocol described in S5.6. A mixture of the free antennae, TdP with single antenna (TdP1) 
and a Td without any antenna were used as controls. When compared to the mixture of free 
antennae, PLA on TdP2 yielded ~2x103 fold greater sensitivity, while compared to a 
mixture of TdP1 and the other antenna free in solution, PLA was ~5x103 fold more 
sensitive in detecting TdP2.  
 
Figure 5.2: PLA on TdP2. 
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                  After achieving positive results from the first trial, we wanted to estimate the 
effect of number of antennae on the sensitivity of PLA. On practical grounds, multiple pairs 
of antennae at different points on the structure can provide information about its overall 
integrity with time. We incorporated another antennae-pair (having same sequence as A1 
and A2) into Td by extending the remaining two constituent single strands (resulting 
structure being denoted as TdP4). When compared with structures (TdP3) having three 
antennae (A1, A2, A1 or A1, A2, A2), the TdP4 showed ~3 times higher sensitivity.  
 
Figure 5.3: PLA on TdP4. 
 The obvious next attempt was to test the generality of the designed assay by 
employing larger and more complex structures. With this goal in mind, we used the 
tetrahedron (TD) used by Chang, Yan and coworkers in 20127 and also designed a DNA 
origami cage (DNC) based on the square lattice motif of the caDNAno. The rationale 
behind designing this cuboid structure with a cavity inside, is to test whether PLA can work 
on a potential drug delivery vehicle. DNC can carry certain cargo in its cavity and the 
cavity being walled on all sides, chance of leakage is also reduced.  
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Figure 5.4: a) TD b) DNC. 
                 TD was comprised of four symmetric units, each of which is made up of ten 
single stranded DNA – one central strand hybridized to three sets of three single strands. 
We selected two strands from two of these three sets and attached the antenna sequences 
(A1 and A2) to each of them. Thus each constituent unit of TD has three antennae pairs 
and the complete structure consisted of 12 antennae pairs. When subjected to PLA, the TD 
showed ~3x103 fold higher sensitivity over the TD with no antennae. This increase is 
probably due to the higher number of antennae present on the structure. We placed a single 
pair of antenna at a distance of ~5 nm on its surface. When subjected to PLA, DNC with 
an antennae pair showed ~2.6x105 times more sensitivity over the control having no 
antenna. 
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Figure 5.5: PLA on TDP24. 
 
Figure 5.6: PLA on DNC with a various inter-antennae distances.  
5.3.2. PLA on antennae with Phosphorothioate Backbone  
           In realistic situations, when we inject the structures into blood stream, we need to 
consider the chance of degradation of antennae by nucleases abundant in blood. A common 
method to turn nucleic acids nuclease-resistant is backbone modification. So we replaced 
the backbone of the antenna pair on TdP2 with phosphorothioate backbone and constructed 
TdS2. PLA on this structure led to compromised sensitivity but it was ~2–3 fold higher 
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sensitivity over the free mixture of antennae. However, the sensitivity was higher when 
compared to the zero antenna and single antenna TDS controls. The backbone of DNC (5 
nm) on phosphorothioation resulted in much higher sensitivities both over the free antennae 
and DNCS0 and DNCS1 controls. 
 
Figure 5.7: Comparison of PLA results obtained from a) TdS2 and b) DNCS2. 
5.3.3 Time vs Stability Studies In Vitro 
           We wanted to test if the PLA can be applied to realistic situations where the existing 
conditions are detrimental to the structural integrity of the DNs. For formation of DNs, the 
individual DNA strands have to come closer and form a somewhat dense packing 
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(depending on the structure design). But the phosphodiester backbones being negatively 
charged repel the single strands approaching towards each other. So, conventionally high 
concentrations of magnesium (~5–20 nM) are used to screen the negative charges on DNA 
backbone. This concentration of magnesium is not available in physiological conditions or 
tissue culture medium. Hence, when DNs are incubated with cells for any experimental 
purposes or injected in blood, they degrade rapidly. Another factor aggravating their 
denaturation is the presence of nucleases in the serum. Combined, they lead to fast 
degradation of DNs in physiological conditions. We decided to subject one of the DNs we 
used previously under these conditions and estimate their stability with time using both 
PLA and conventional gel electrophoretic techniques and compare the results from both. 
We chose the TdP2 for this purpose. The rationale behind choosing this particular structure 
is that among the three structures studied, this one being the simplest wireframe structure 
does not involve any dense packing of DNA and hence is the least demanding in terms of 
salt concentration in the medium to maintain structural integrity. This would allow us to 
study the time vs stability for a considerable length of time involving several data points. 
We subjected TdP2 to four different conditions – a) buffer containing 0.8 mM Mg2+, b) 
DMEM medium, c) DMEM with 10% FBS, and d) human serum, and tested the time vs 
stability using PLA. It was found that in all the media the TdP2 showed exponential 
degradation. The results obtained from PLA closely matched with the ones obtained via 
gel electrophoresis.  
a)  
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b)  
 
Figure 5.8: PLA results from in vitro TdP2 samples. a) Particles/uL plotted with time b) 
comparison of half-lives. 
5.3.4 Time vs Stability Studies In Vivo 
Finally, we attempted to test whether PLA can estimate the stability of DNA 
nanostructures from in vivo samples. So both TdP2 and TdS2 were injected into rats and 
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the time vs stability curves were constructed following similar PLA protocols as was done 
in in vitro experiments. It is found that the PLA results obtained from the in vivo samples 
are in good agreement with the ones obtained from in vitro experiments.  
 
Figure 5.9: Time vs stability curve for TdP2 from in vivo sample. 
 
 
Figure 5.10: Time vs stability curve for TdS2 from in vivo sample. 
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5.4 Conclusion 
Herein we reported a simple proximity based assay that can estimate the stability 
of DNA nanostructures with high sensitivity. However, three aspects still need further 
investigation. The first is the dependence of PLA sensitivity on antenna sequence. By 
optimizing the GC content of the antennae better results could be obtained. The second 
point of interest should be using higher number of antenna. We used a single pair of antenna 
in most of our studies. By incorporating more number of similar and dissimilar pairs of 
antenna estimates about DN stability on local and global scales can be obtained. The next 
step of this research is to plant multiple pairs on 3D origamis and use smarter combinations 
of antennae where one central antenna can act as the pair-member for several surrounding 
antennae. Then by judicious use of different connecting strands and PCR primers, we can 
determine which antenna is present and which one is missing with time when DNs are 
subjected to degrading conditions. Comparison of results from our in vivo experiments 
show that phosphorothioate backbone perform better. From our in vitro experiments we 
found when the backbone was shifter from phosphodiester to phosphorothioate, there was 
a reduction in sensitivity. This aspect needs further investigations so that the PLA 
sensitivity can be improved with phosphorothioate antennae. 
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CHAPTER 6 
SUMMARY AND FUTURE DIRECTIONS 
6.1 Summary 
This thesis has mainly focused on enhancing the stability of 3D DNs under in vivo 
conditions. Three primary factors limiting the in vivo lifetime of the DNs are – a) low salt 
stability b) nuclease degradation, and c) opsonization. Coating the DNs with PEG have 
shown positive effects in terms of enhancing the DN lifetime in vivo. It can maintain the 
integrity of the DNs under low salt conditions for a higher length of time, prevent nuclease 
degradation to some extent and reduce the uptake of DNs by macrophages, thus increasing 
the circulation times. The various conformations and lengths of PEGs influence the uptake 
profiles of DNs and there are scopes of tuning these features (length, type and extent of 
branching, etc.) in order to achieve DNs with desirable in vivo lifetimes. The term 
‘desirable’ is crucial as we don’t want to have nanocarriers circulating forever in the living 
system and the ideal circulation time of a nanomedicine is also dependent on the type of 
disease and drug we want to cure. 
Human serum albumin has demonstrated its potential to confer stability to in vivo 
drug carriers. We have synthesized an albumin attracting molecule and coated DNs with 
albumin with the mediation of that molecule. The protein coated structure had higher 
stability in physiological conditions and it can avoid recognition by the macrophages more 
than the uncoated structures.  
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We have screened and selected some stabling agents which when added to the 
annealing solution of DNs enhance their thermodynamic stability and help them to survive 
under low magnesium conditions for prolonged periods. In our study, we combined some 
of these stabilizing agents and achieved even higher DN lifetimes for certain combinations. 
This is a significant towards building inherently stable DNs that would no longer require 
any coating or stealth sheath in order to become long circulating in the living system. 
We have also demonstrated that the proximity ligation assay, an assay well known 
to the protein researches, can also be applied to estimate the time vs stability of DNs with 
high sensitivity. The advantages of this assay lies in its very simple modification, extreme 
sensitivity and the very less amount of sample required for the investigations. 
6.2 Future Directions 
6.2.1 Further studies on PEG coated DNs 
PEGs have been used for few decades to produce long-circulating liposomes and 
currently there are drugs available in the market that employ this strategy. Reports are 
abundant that study biodistribution and pharmacokinetics of PEGylated nanoparticles in 
vivo. However, most of the NPs studied to reveal the effect of PEGs are polystyrene NPs 
and metal NPs. As the in vivo behavior and fate of NPs is highly dependent on the material 
of the core, the results obtained so far would definitely vary when PEGylated DNs will be 
injected in blood. More detailed investigation is required to study the effect of grafting 
densities of PEGs on DN surface, lengths and conformations of PEGs and PEG derivatives 
on the biological stability of these new class of potential DDS. The grafting density has to 
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be optimized based on the dimension of the drug delivery vehicle and the length of time 
the vehicle is required to be stable in circulation.  
Another important phenomenon to be studied is the drug release profile of the 
protected DNs. A dense bush of stealth polymer around a delivery vehicle can obviously 
reduce the leakage of drug molecules, but on the other hand it can also hamper the release 
of the same when required. This would require prolonged circulation times so that the 
desired concentration of the drug is attained.  
Several DNs have been designed whose dynamics can be controlled by stimuli like 
small molecules, pH, temperature and a small external nucleic acid. But till date it has 
never been studied how is the dynamics influenced when the structure is coated for 
rendering it long circulating. Generally, controlled dynamics require recognition of stimuli 
quickly, and the component processes occur in a narrow timescale to render the overall 
process of structural reconfiguration effective and highly responsive. But, surface coating 
of polymers might hamper the recognition thus making the process sluggish.  
6.2.2 New class of stealth polymers 
The wide usage of PEG was possible primarily because of its biocompatibility and 
non-immunogenicity. But reports have started appearing where researchers have found 
repeated dosages of PEGylated nanomedicines lead to the production of anti-PEG IgM. So, 
search for a new polymer that can be used as a coating material is evident now. 
Polyphosphates have started emerging as a new class of biodegradable polymers that are 
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completely non-immunogenic. DNs are to be coated with these new materials and their 
stability, and cellular uptake profiles should be studied.  
6.2.3 Self-coating structures 
 From the first project, we found that clusterin has crucial roles in reducing uptake 
of NPs by MPS. Hence, if we can precoat structures with clusterin, they would have very 
high chance to become long circulating. In another project we synthesized the albumin 
attracting molecule tag that helped the DNs to develop ann albumin coating around them. 
From this, we can envision to build structures that could be injected with the affinity tags 
on their surface, and as soon as they are injected, they would themselves bind to the 
stabilizing components from blood, preferably clusterin.  
6.2.4 Improvement of the PLA Assay 
The assay that we developed in this thesis for estimation of DN stability is an initial 
attempt towards more detailed and serious investigation into the issue. Unlike metal 
nanoparticles, the stability of DNs very much depends on their individual structure like 
size, shape, global and local morphologies density of packing. So any assay that works for 
one structure might not be applicable to another one. But PLA seems to be quite general 
and robust regarding structure with an appreciable degree of sensitivity over the free 
antennae and zero-antenna DN controls. But there remains a vast domain that can and must 
be explored to improve the overall efficiency and applicability of PLA on DNs.  
The effect of multiple pairs of antennae on large structures demands a more 
meticulous investigation. And depending on the similarity or dissimilarity of the antennae 
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sequences, we can gain insights into the global and local stabilities of structures. We can 
build a structure where n pairs of antennae can be attached and then can construct a 
calibration curve with known amounts of the structure itself starting from 1 pair to n pairs. 
When the DN with n pairs of antennae is injected and stability of the in vivo samples tested, 
we can determine the percentage of degradation of each structure from the previously 
constructed calibration curve. This would lead us estimating the global stability of a DN 
(as antennae sequences being the same, we cannot differentiate between two pairs and their 
corresponding locations). But in another strategy, n pair of antennae having dissimilar 
sequences can be planted on a DN surface. Hence the connector strand and the primers for 
PCR amplification would be different. After collecting in vivo samples at a particular time 
point, we can separately carry out PCR reactions on sample aliquots using the 
corresponding primers. Comparing these results, we can determine which 
antenna/antennae are missing and thus obtain insights on structural integrity at a local level. 
Even, we can try to correlate the results with degradation patterns and eventually find out 
areas on a structure that are more liable to in vivo degradation.  
We can make this PLA even smarter by removing the concept of individual 
antennae pairs. For example, on a cuboid DN, we can have one antenna on a particular face 
acting as the central antenna and plant one antenna on each of the remaining five faces. 
Now, by judicious use of connector strands, we can ligate the central antenna with each of 
the other five antennae in separate sample aliquots and carry out the PLA assay. The results 
would enable us finding out the missing antennae as a result of structural degradation. In 
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addition to the number of antenna pair, we can play with the distance between the members 
of each pair and also with their sequence.    
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APPENDIX A 
SUPPLEMENTAL NFORMATION FOR CHAPTER 2 
EFFECT OF PEG LENGTH AND CONFORMATION AND PEG-LIPID COATING  
ON STABILITY AND CELLULAR UPTAKE OF DNA NANOSTRUCTURES 
  
125 
 
S2.1 PEG-azides and Lipid-PEG-azide and their abbreviations 
 Chemical Molecular 
Weight 
Abbreviation Structure 
1. Linear 
PEG-
azide 
2 kD 2L 
(CH2CHO)43
N3
CH3O  
2. Linear 
PEG-
azide 
5 kD 5L 
(CH2CHO)111
N3
CH3O  
3. Linear 
PEG-
azide 
10 kD 10L 
(CH2CHO)225
N3
CH3O  
4. Branched 
PEG-
azide 
having 4 
arms 
 
2 kD 2 – 4 arm 
 
5. Branched 
PEG-
azide 
having 4 
arms 
 
10 kD 10 – 4 arm 
 
6. Branched 
PEG-
azide 
having 8 
arms 
 
10 kD 10 – 8 arm 
 
7. DSPE-
PEG 
azide* 
 
2 kD 2 - Lip 
 
 Table S2.1: PEG-azides and Lipid-PEG-azide and their abbreviations. 
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*1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[azido(polyethylene glycol)-2000] 
(ammonium salt) 
S2.2 Materials and Instruments 
All DNA strands were purchased from Integrated DNA technologies. The strands 
for DNO were bought in 96 well plates and used without any further purification. Rest of 
the strands were purified using 10% denaturing polyacrylamide gels prior to annealing 
structures. DBCO-NHS ester was bought from Click Chemistry Tools. Anhydrous DMSO 
was purchased from Life Technologies. All the linear and branched PEG-azides were 
bought from Creative PEGWorks. DSPE-PEG (2000) Azide was bought from Avanti Polar 
Lipids. Propidium iodide and CellTracker CM-Dil dye were bought from ThermoFisher 
Scientific. RAW264.7 cells used in the cellular uptake study were bought from ATCC. 
FBS that was used to supplement DMEM cell culture medium was purchased from Gibco 
Life Technologies. Mouse serum was purchased from Sigma Aldrich. DNase I, Bovine 
Pancreas was purchased from Gold Biotechnology. Recombinant Human Clusterin alpha 
chain protein was purchased from Abcam. All the other chemicals that are not mentioned 
here were bought from Sigma-Aldrich. 
Live cell confocal microscopy was done using the Confocal laser scanning 
microscope Leica TCS SP8. Flow cytometry studies were conducted using the S1000EXi 
flow cytometer coupled with the CellCapTure software from Stratedigm. The cytometry 
data were analyzed using the Flowjo v10 software from Flowjo, LLC and plotted using the 
Prism 5 software from Graphpad. For the time vs stability experiments, the band intensities 
of gels were measured using the ImageJ software. 
127 
 
S2.3 Details of Td and DNO Structures 
S.2.3.1 Td 
S2.3.1.1 Strands for Td 
Strand 1: AGG CAC CAT CGT AGG TTT C TTG CCA GGC ACC ATC GTA GGT 
TTCT TGC CAG GCA CCA TCG TAG GTT T CTT GCC 
Strand 2: CAG AGG CGC TGC AAG CCT ACG ATG GAC ACG GTA ACG ACT 
Strand 3: AGC AAC CTG CCT GTT AGC GCC TCT GTT TTT TCG ATC ACG TAG 
CAC AGC AT 
Strand 4: /5Alex488N/TTA CCG TGT GGT TGC TAG TCG TT 
The complementary of the single stranded handle (labeled in red) with strand 3 was named 
strand 5 and it had an amine modification at the 5’ end.  
Strand 5: /5AmMC12/AT GCT GTG CTA CGT GAT CGA 
The Alexa fluor 488 dye was attached to strand 4 for flow cytometry studies. For all other 
experiments the unlabeled strand was used. 
S2.3.1.2 Schematic for Td 
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Figure S2.1: Schematic showing one unit of Td. 4 similar units assemble together through 
sticky end hybridization to build up the complete Td.  
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S.2.3.2 DNO 
S2.3.2.1 Schematic for DNO 
 
Figure S2.2: caDNAno image of DNO. a) DNO b) caDNAno image showing the 
arrangement of double helices constituting DNO. 
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Figure S2.3: caDNAno design of DNO. 
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S2.3.2.2 Sequences for DNO 
Start End Sequence 
16[111] 15[111] CATATGTATTTTAACC 
20[111] 11[111] TAAAAATTAGCGCCAT 
13[16] 1[23] AGAGATAGTAGAGCTTATCAAGTT 
38[39] 40[24] GACCGTGTTGTTTAGTAAAGCCAACGCTCAAC 
50[63] 61[79] GAGCGTCTGCAAGGCCGGAAACTCAGAGCCGC 
11[16] 3[23] ATTTTGACGCGCGTAAGAGAAAGG 
58[63] 52[48] TGCCTAACGCAAAGACGAGGGAGGCATAAAAA 
44[103] 53[103] AGCATCGGAAAATACGAACCCATGACCCTCAT 
50[79] 35[79] ATTTTCTGGCTTGCAGGCTACAGAGCTCATTA 
59[8] 58[8] TTACCAGCTAGAAAAT 
29[16] 17[23] TTACAAAAACCTCAAACCGCCTGC 
60[87] 49[87] CCTTGATACACCAGAAGTAAATGACAACAGTT 
3[88] 13[95] GGGTGGTTCACCGCCTGATTGACC 
29[8] 28[8] ATACCAAGTCGCCTGA 
35[64] 51[63] AAGAACTGGGCTTTGAGGACTTCCTTTACAGA 
60[79] 43[79] TTCACAAAGCCTGTAGTTCGTCACTGAGGAAG 
60[71] 61[55] CAAATAAATCCTCGGTAAATATTGTACCATTA 
28[71] 36[64] GAGCTTCAGTCAGGATTAATCATT 
62[111] 49[111] CAGAGCCGAGAAAGGA 
51[8] 52[8] AAATAAGAAACACCCT 
20[39] 25[39] ATCTTTAGAAGTATTACAAAATTATGGAAGGG 
48[103] 61[111] GAATAATAGTGAGAATCCACCCTCAGAGCCGCCGCCAGCA 
132 
 
15[80] 0[72] AAATTTTTAGTGTTGTTCCAGTTT 
2[71] 11[71] CAGCAAGCAGGCGGTTGACGACGACAGCTTTC 
53[8] 54[8] CAGAGGGTAAGCCCTT 
46[63] 63[63] ATATACACACGCTAACGCTCCAAAAGCGTTTG 
50[111] 45[111] GTTTTGTCATCGTCAC 
32[23] 32[8] ACCTTGCTTCTGTAAA 
33[40] 16[48] ATAGCGATAGCTTTACGAGAATGATAATGGAACAAATATT 
7[48] 6[56] CTGTCCATAGCTCGAAGCGGGAGC 
32[79] 17[79] ACCAAAATGAGGGGGTAATGCTTTAGCAAACA 
56[39] 57[23] CCCAAAAGAACTGGCATGATTAAGAAACGTAG 
22[23] 10[16] CGAACGTTACATTTGATGCAACAG 
42[47] 26[48] TAAAGTACACCTAAATTTAATTACCAACTAAA 
51[80] 34[80] CATTCCACTAGCAACGGGAGTTAAACAGGTAG 
19[80] 1[87] GACAGTCATCTGCCAGAAACGGCGGGCCCTGATTGATGGT 
3[24] 17[31] AAGGGAAGCCCCGATTAACCCTTCCAATATTTAACAGTGC 
55[24] 58[24] AACAAAGTAATAGCTAAAAATACAATTTTGTC 
42[39] 55[39] CGACAAAATTAGGCAGGAAATAGCTACCAGAA 
30[111] 17[111] AATCGTCAAAAACTAG 
41[64] 56[64] AGCGATTACAGAACCGTCAGTACCGGATTAGG 
36[103] 42[96] AAATTGGGCTTGCCCTTAAAACGA 
5[8] 6[8] CTTAATGCTACGCCAG 
19[56] 30[56] TTCAAAAGAGGCTATCCAAAAATCCAGAAAAC 
43[8] 42[8] ACAACATGCCAGACGA 
15[8] 14[8] GCGAACTGCTATTAGT 
133 
 
62[23] 48[8] CAGAATCAGCGCGTTTGAGGTTTTGAAGCCTT 
30[103] 35[103] TAAATATTAAAGCGGAACGGAACAGGGAAGAA 
16[79] 2[72] CCAAAAACTTCGCATTGTAGCCAGAATCCTGTGAGAGTTG 
22[103] 24[96] GCAAAGAATAGCATTAACATTTCG 
38[71] 40[56] ACAAGAACCATAAGGGCGGAACGAGGCGCAGA 
2[63] 31[63] 
GGTCCACGACCCGTCGAACATTAATTGCCTGATGTATAAGAA 
AAGAAG 
18[47] 12[40] AAATCTAAAAGCGTAATTACATTG 
23[80] 6[80] ATTCTACTGCAGGTCGGTAACGCCAAAGTGTA 
27[32] 37[39] GAATATACATGCAAATATCTTCTG 
36[23] 28[16] AAGACAAACTTTTTAATAACGGAT 
36[31] 44[24] CCAATCGCATGCAGAACCTAATTT 
21[48] 4[40] AAACACGGGCTGGCGAAAGATCGCCAAAGGGCGCTGGCAA 
52[31] 60[24] ACGGGAGACAAAAGGGAAAGGTGA 
50[55] 32[48] TTCCAGAGTCTTACCATCATCGAGTAAGAACGACAGTACA 
31[8] 30[8] AATTAATTAAACATCA 
1[88] 15[95] GGTTCCGATAGGGTTGGTTAAATC 
55[8] 40[16] AGTAAGCAGATAGCCGAGTAGGGC 
51[32] 59[39] ACGTCAAATATTCATTCGACATTC 
35[48] 18[48] AACTATATCAGACCGGCCATAAATAGGATGAA 
36[87] 29[87] GGTTTAATTACCAGTCTATCGCGTTATTATAG 
50[47] 35[47] CCTAATTTGGTATTAAAAAAATAAGGTTATAT 
59[40] 53[47] AACCGATTACCACGGATAACCCAC 
5[96] 9[103] TAACTCACCAACTGTTCCCAGTCA 
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41[16] 26[16] AACGCCAAAGGCGTTATATTTTAGTAAAACAG 
22[79] 7[79] ATAAAGCCTAAGTTGGACTCTAGACATGGTCA 
36[79] 21[79] TTCAACTTTAGAGAGTGTAGCTCAATGACCCT 
61[8] 60[8] ATTTGGGACGTCACCG 
18[39] 28[32] AGCATCACCAGTTGAAACATCGGG 
23[8] 5[23] 
GAGTAACATTATCATTTGATTAGTGAACTCAAAGGAACG 
GGCCGCTAC 
28[79] 10[72] TTTAATTCAGGCCGGATGCAATGCCGGCACCGGCGGGCCT 
5[24] 12[24] AGGGCGCGGTCACGCTGCTCAATCACCAGTCA 
8[55] 5[55] CACGCAAAAAGGGGGATAAACAGGACGAGCAC 
18[79] 4[72] TTTGAGAGGTGGGAACTTTGAGGGTGCGTATTTGCCAGCT 
24[47] 23[55] TCATATTCCCACCAGAAGGAGCGG 
57[40] 55[47] GGTGGCAAACGGAATAGGAAACCG 
53[88] 60[88] GAGCCACCTACCGTAATGAATTTAACGATTGG 
6[111] 8[96] ACACAACATACGAGCCGAAATTGTCCAAGCTT 
46[87] 32[80] ACAACCATATCAGCTTCGATAAAA 
15[96] 17[103] AGCTCATTCCCCGGTTGTAATCGT 
27[56] 34[56] TCCAACAGAAGCGAACGCGATTTTAGATTTAG 
3[40] 3[63] AGGAGCGGGCGCTCGCGCGGGGAG 
53[80] 43[87] CACCCTCAAAAGAATATTTCCATT 
20[71] 25[71] CTGAGTAAAAAACATTACATGTTTTTTCATTC 
7[24] 9[31] AGTGAGGCTTTTAGACACTATCGG 
47[32] 61[39] GGCTTATCACCTCCCGACAATTTTCCGTAATCTCACCAGT 
30[95] 47[103] CATTGAATAAGGAATTCCAGACGAGCTTTCGAGGTGAATT 
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49[24] 63[39] ACCCAGCTACTTGCGGTCATCGGCATTTTCGG 
54[95] 58[88] CAGGAGGTTGCCCCCTAGTGTACT 
0[39] 13[39] TCCAACGTTCGAGGTGGGCACAGATGACCTGA 
55[56] 57[71] GGTTTTGCCCAATAATAGATGAGTAACAGTGC 
33[8] 34[8] TTAATTAACAAAATCA 
0[111] 1[103] AAAGAATAGCCCGAGAAATCGGCA 
7[80] 21[95] 
TAGCTGTTTCCTGTGTGGAAGCATAGGGTTTTGGGAAG 
GGTTTGCGGG 
44[111] 35[111] CGAAAGACAAATCTAC 
27[16] 12[16] AGGTTTAAACAACTAATCAGTTGGCACGACCA 
41[72] 39[79] TACCAAGCTACTTAGCAACCGAAC 
6[79] 8[64] AAGCCTTAGAATCAGATTCGTAATGGATCCCC 
45[56] 51[71] CCGTTCGGTCGCTGAGTATGGGATACTACAAC 
51[48] 34[48] TAGCAGCCTGAACAAGACCAAGTAGAAAGATT 
37[64] 53[63] ACGTAACACACTCATCTTTGAATAAGTTAAGC 
14[95] 31[95] CGCGTCTGGATGAACGGATAATCAAATGTTTA 
58[87] 52[80] GGTAATAAGCAGTCTCCACTGAGT 
27[48] 12[48] AAGCAAACTAAGGTTAAGGAAAGAGCCTCAGG 
34[95] 49[95] ACATTATTAGGCCGCTCAATGACATCAGCGGA 
36[47] 21[47] AAATGCTGAGTAACAGTACCATATGACTTTAC 
54[23] 43[23] TCTTACCGAATTGAGCAATTCTGTTTCAGCTA 
9[56] 20[56] TGTGCTGCTTACGCCATTGTACCATGTGTAGG 
51[96] 59[103] CTCATAGTCAGGTCAGCCGTTCCA 
39[48] 22[48] CGTTATACAATTATCAGTACGGTGAATATTCG 
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13[64] 19[71] GATTCTCCATCTACAAGGTGAGAA 
33[32] 50[32] TTGAAAACAGCCGTTTCAAGAACGGCCAGTTA 
60[111] 51[111] GGTTGAGGTAGCGTAA 
36[63] 43[71] GTGAATTAAAGAAAGACTTTTTCA 
22[39] 24[32] TATTAAATCAAAGAAACTGATTAT 
42[79] 23[79] 
CACTAAAAAAGCTGCTTAATCTTGCATATAACTGTTTAGC 
TGGCATCA 
35[32] 52[32] TTAGGTTGTATCCCATCGCGCCTGCGCATTAG 
14[103] 18[96] AAATAATTGTAATGGGTTAATGCC 
12[95] 29[95] ACCGTGCAAATCACCAGGAGAGGGTCAGAAGC 
8[95] 26[88] GCATGCCTAATAGTAGTTAGCAAACCCAATTCTGCTGAAT 
10[31] 28[24] CCAGCCATGGATTTAGGAGCACTACGTCAGATAGAAACAA 
24[95] 42[88] CAAATGGTTTTGAAAGTGACCTTCAAGTACAAAAGAGGCA 
15[48] 0[40] GTAAACGTATTAAAGAACGTGGAC 
24[71] 41[63] TATATTTTCATTTGGGCGGTCAATCGGATATTGTACCCCC 
29[32] 34[32] AGGCGAATGAGAAGAG 
37[88] 44[88] GAATAAGGCTTGAGATAAACGGGTAACGAGGG 
2[39] 11[39] AAGGGAGCAAAGCGAAGCAGATTCGTCTGAAA 
53[48] 36[48] AAGAATTGAGAGAATACAATAGATCCTTATGT 
4[39] 9[39] GTGTAGCGTACTATGGTATTACCGCCTTGCTG 
39[104] 39[111] TGAACGGT 
63[40] 49[47] TCATAGCCTAGCAGCAATCCTGAA 
54[47] 39[47] GAAACAATAGGCATTTACCAGTATATCATATG 
48[95] 63[111] ATTTTTTCCGGAACCAGAGCCACCACCGGAAC 
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19[24] 30[24] CAAATCAACTTGCTGATCGCGCAGAAGAAGAT 
1[40] 15[63] CCGTAAAGCACTAGTTTGCCCCAGAGTCCACTTAATATTT 
13[48] 2[40] GAGTAACACTGAATCGGAACCCTA 
51[24] 62[24] TTTGTTTACAAAATAACAGCAAAAAGTAGCGA 
56[63] 54[48] ATTAGCGGCAATAATACATATAAAAAGAGCAA 
20[47] 6[40] TCTAAAATTGGATTATCAGAACAATTGCTTTGAGGCCGAT 
59[72] 54[72] TGGAAAGCGTTTTAACAGAACCGCGCCACCCT 
0[71] 14[64] GGAACAAGCAGGCGAACTTTCATC 
31[64] 46[64] TTTTGCCAAGCGAGAGACTAATGCCATAACCG 
20[95] 35[95] CCTCATATTTGCTCCTACTTCAAAAGGACGTT 
39[96] 55[95] AGGACAGACGAAATCCGCGACCTGTCGAGAGG 
19[96] 27[103] TCAATATGCCCGAAAGTTTGATAA 
41[96] 56[96] CGGAGATTACCGTACTGTTGATATAAGTATTA 
22[47] 7[47] ACAACTCGGTAATATCTTAACCGTAAAAGAGT 
33[24] 47[31] TAGAATCCAGTGAATAATATAGAA 
51[88] 62[88] AGACAGCCAGACGTTACCACCACCAGAACCGC 
16[31] 32[32] CAGCAGAACAATTTCATTTGAATTTATATGTG 
25[24] 37[31] CTGAATAATTTGCACGTTAATTTC 
45[16] 30[16] TCTTTCCTGAATTTATTTTTCCCTGATGAAAC 
19[8] 20[8] ATATCTGGTAGATTAG 
36[111] 27[111] CGAGTAGTGAGGTCAT 
35[24] 46[24] CCTCCGGCTCAATAGTTATCATTCTTATTTTC 
47[64] 62[56] TTAATTGTAAAAAAAGTTTGCTAAACCCGTCACCAATGAA 
5[72] 11[95] TCGTGGGGTGCCTAATGAGTGAGCGTCGGGAAGCCGGAAA 
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21[96] 38[96] AGAAGCCTAGCTTAATTGCGAACGAGGCTGGC 
16[47] 30[32] TAACCGAACGAACCACCACGCTGACTGAGCAA 
11[80] 3[87] CTTCTGGTACCTGTCGGGGCGCCA 
58[23] 44[16] ACAATCAAGCCAAAGAATTAACTGAACGATTTACGAGCAT 
56[95] 54[80] AGAGGCTGAGACTCCTACAGTTAATTAGTACC 
34[47] 19[47] AAGACGCTTATTCATTTACCTTTTAGGAATTG 
63[64] 49[79] CCATCTTTTCATAATCGAGCCACCACAACTTT 
33[56] 47[63] CACATTCAGCTTTTGCAGGAGCCT 
58[103] 57[111] GATACAGGGCCTATTTCGGAACCT 
62[87] 48[80] CACCCTCAAAAATCACACGTTGAA 
49[8] 50[8] TTAGTTGCATTATTTA 
38[87] 20[80] ATCAAGAGCATTCAGTATAATGCTACCTTTAAATTTTAAA 
33[80] 16[80] AACGCCAACCCCCTCAAATAGTAAGAAAAGCC 
61[40] 43[47] AGCACCATACGGAAATAATGAAAACAGGGAAGTTTATCAA 
14[111] 1[111] GCCATCAAAAATCCCT 
14[23] 0[8] TTGAATGGATAGCCCTGAAAAACCGTCTATCA 
31[16] 16[8] ACATTTAAGATAAAACAGAGGTGA 
5[56] 12[56] GTATAACGGAATCGGCACTCCAGCCAGTATCG 
53[32] 57[39] CAGAGAGAATAAGTTTTACATAAA 
52[71] 58[64] CAGTACAACCACCCTCGGGGTCAG 
18[87] 14[80] TAGCTATTAGAGAATCGCCTTCCT 
52[63] 59[71] GAGAATAAGAAATTAAAGCCAGAA 
   
63[8] 62[8] AGACTGTAAGTTTGCC 
56[111] 55[111] AAACATGAAAGTATAG 
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37[8] 38[8] TTCAAATAAATAAGAA 
48[111] 47[111] GGAATTGCTCTTAAAC 
57[8] 56[8] ATGTTAGCACTCCTTA 
10[111] 5[111] AGGCTGCGATTAATTG 
25[8] 24[8] TGTTTGGAATCAATAT 
32[111] 31[111] TCATAACCAGCGTCCA 
11[8] 10[8] ATACCTACGAAAAACG 
47[8] 46[8] ATAGCAAGAATCATTA 
1[8] 2[8] TCACCCAAGACGGGGA 
52[111] 43[111] CCAATAGGTAATGCCA 
4[71] 23[71] GCATTAATTGCTTTCCCTTCGCTAAAGGCGATTCAGAGCATGAAAAGG 
2[111] 20[96] ACAGCTGATTGCCCTTTTTCTTTTGCATCGTACCAGGCAATTTAGAAC 
57[72] 41[87] CCGTATAACAAGAGAAAGGCGGATAAGTGCCGCTCCATGTGCGAAACA 
42[111] 23[111] CACCAACCGACGAGAAAGGCGCATAGTAGATTCATTAGATACATCCAA 
39[80] 10[80] TGACCAACCAATAACCAGTTGATTATTAAGCAGTAATACTCGATCGGT 
48[79] 29[79] AATCTCCAATCGGTTTCGCCCACGAGATACATAAAGATTCACCCTGAC 
31[96] 50[96] GACTGGATCTCGTTTAACGAGGCATGCGCCGATTTGCGGGGTCTTTCC 
21[8] 7[23] TAGATAATATTAATTTGAGTAGAAAATAACATAAGTGTTTTTATAATC 
41[8] 25[23] TATTTAACTTAATTGAGAATCATAATTACTAGGGCAATTCTTATACTT 
60[23] 47[23] ATTATCACATTAGAGCACAGCCATTATTTTGCATCGTAGGCAAATCAG 
1[24] 14[40] TTTTGGGGCAAAGGGCAAAACATCGCCATTAAAAATAATTGAATACGT 
The green strands are modified with a handle at their five prime end for hybridization 
with a strand containing alexafluor488 dye at its 5’ end. The modified sequences are: 
Start End Sequence 
63[8] 62[8] AAT GGC ACA CCA ACG ATC AGC 
AAAGACTGTAAGTTTGCC 
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56[111] 55[111] AAT GGC ACA CCA ACG ATC AGC 
AAAAACATGAAAGTATAG 
37[8] 38[8] AAT GGC ACA CCA ACG ATC AGC 
AATTCAAATAAATAAGAA 
48[111] 47[111] AAT GGC ACA CCA ACG ATC AGC 
AAGGAATTGCTCTTAAAC 
57[8] 56[8] AAT GGC ACA CCA ACG ATC AGC 
AAATGTTAGCACTCCTTA 
10[111] 5[111] AAT GGC ACA CCA ACG ATC AGC 
AAAGGCTGCGATTAATTG 
25[8] 24[8] AAT GGC ACA CCA ACG ATC AGC 
AATGTTTGGAATCAATAT 
32[111] 31[111] AAT GGC ACA CCA ACG ATC AGC 
AATCATAACCAGCGTCCA 
11[8] 10[8] AAT GGC ACA CCA ACG ATC AGC 
AAATACCTACGAAAAACG 
47[8] 46[8] AAT GGC ACA CCA ACG ATC AGC 
AAATAGCAAGAATCATTA 
1[8] 2[8] AAT GGC ACA CCA ACG ATC AGC 
AATCACCCAAGACGGGGA 
52[111] 43[111] AAT GGC ACA CCA ACG ATC AGC 
AACCAATAGGTAATGCCA 
The pink strands are modified with a handle at their five prime end for further attachment 
of PEGs and DSPE-PEG. The modified sequences are: 
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Start End Sequence 
4[71] 23[71] TCG ATC ACG TAG CAC AGC 
ATGCATTAATTGCTTTCCCTTCGCTAAAGGCGATTCAGAGCATGAAAAGG 
2[111] 20[96] TCG ATC ACG TAG CAC AGC 
ATACAGCTGATTGCCCTTTTTCTTTTGCATCGTACCAGGCAATTTAGAAC 
57[72] 41[87] TCG ATC ACG TAG CAC AGC 
ATCCGTATAACAAGAGAAAGGCGGATAAGTGCCGCTCCATGTGCGAAACA 
42[111] 23[111] TCG ATC ACG TAG CAC AGC 
ATCACCAACCGACGAGAAAGGCGCATAGTAGATTCATTAGATACATCCAA 
39[80] 10[80] TCG ATC ACG TAG CAC AGC 
ATTGACCAACCAATAACCAGTTGATTATTAAGCAGTAATACTCGATCGGT 
48[79] 29[79] TCG ATC ACG TAG CAC AGC 
ATAATCTCCAATCGGTTTCGCCCACGAGATACATAAAGATTCACCCTGAC 
31[96] 50[96] TCG ATC ACG TAG CAC AGC 
ATGACTGGATCTCGTTTAACGAGGCATGCGCCGATTTGCGGGGTCTTTCC 
21[8] 7[23] TCG ATC ACG TAG CAC AGC 
ATTAGATAATATTAATTTGAGTAGAAAATAACATAAGTGTTTTTATAATC 
41[8] 25[23] TCG ATC ACG TAG CAC AGC 
ATTATTTAACTTAATTGAGAATCATAATTACTAGGGCAATTCTTATACTT 
60[23] 47[23] TCG ATC ACG TAG CAC AGC 
ATATTATCACATTAGAGCACAGCCATTATTTTGCATCGTAGGCAAATCAG 
1[24] 14[40] TCG ATC ACG TAG CAC AGC 
ATTTTTGGGGCAAAGGGCAAAACATCGCCATTAAAAATAATTGAATACGT 
55[48] 25[47] TCG ATC ACG TAG CAC AGC 
ATAGGAAACGAAATTCTTTCGAGCCACATGGTTTGAAATACCTTAGAACC 
59[104] 40[104] TCG ATC ACG TAG CAC AGC 
ATGTAAGCGTCTTTTGATTTTCAGGGGGTGTATCTGTATCATAATTGTGT 
46[111] 19[111] TCG ATC ACG TAG CAC AGC 
ATCCGATAGTTAGTAAGAACGAACTATTGCATCAAGAGGAAGATATTCAA 
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26[111] 7[111] TCG ATC ACG TAG CAC AGC 
ATTGGCTTAGTTATTTCACAGGCAAGCGACGTTGGGCCAGTGTATCCGCT 
18[111] 4[96] TCG ATC ACG TAG CAC AGC 
ATCTGATAAAATAGGTCAAGATGGGCCACCAGTGCACTGCCCGCTTTCCA 
17[8] 4[8] TCG ATC ACG TAG CAC AGC 
ATTATTAACATATCAAACTGGCCAACGTAATAAAAACGTGGCCCACCACA 
62[55] 46[40] TCG ATC ACG TAG CAC AGC 
ATACCATCGACCCTTATTCGAGGCGTTTTAGCGACGGTATTCAACAAGCA 
45[8] 26[8] TCG ATC ACG TAG CAC AGC 
ATATCGGCTGGTAGAAACGAGACTACGAACGCGAAGATTTTCAAATAAAG 
8[63] 37[63] TCG ATC ACG TAG CAC AGC 
ATGGGTACCGGCGCGAGCTAAAGCTATCTGGAAGTAAATATGCCAAATCA 
24[31] 53[31] TCG ATC ACG TAG CAC AGC 
ATCAGATGATAAAAAGCCGATAAATACATGTAATGGTAAAGTGCTAATAT 
15[64] 34[64] TCG ATC ACG TAG CAC AGC 
ATTGTTAAAAAGGAAGATGAGTCTGGAAACAGTTAGGTCTTTATCAGTTG 
6[39] 22[24] TCG ATC ACG TAG CAC AGC 
ATTAAAGGGACACCGAGTTGTAGCAATACTTCTTTTGCGGAACCTTTGCC 
32[47] 14[48] TCG ATC ACG TAG CAC AGC 
ATTAAATCAAACCTTTTTTCAATTACGAGCCAGCAGCAATCAATGTGAGC 
S2.4 Annealing the DNs 
S.2.4.1 Td 
 Strand 5 was reacted with DBCO-NHS ester separately and converted to DNA-
DBCO. The five strands (1:2:3:4:5) were mixed in the molar ratio of 1:3:3:3:3 in 1X TAE 
buffer (containing 12.5 mM Mg2+) and was subjected to a 12 hour thermal annealing 
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program starting from 80C and ending at 4C with a regular decrease in the temperature 
by 1C. The structure was characterized and purified using 1% agarose gel electrophoresis.  
S.2.4.2 DNO 
DNO was annealed in 5 nM concentration by mixing 5 nM m13 scaffold and 10X 
staples in 1X 3D buffer. The annealing program used heated the mixture of strands to 95C 
and cooled them to 4C over a period of 37 hours. 
S2.5 Conjugation of DBCO to S5-amine 
100 mM stock solution of DBCO-NHS ester was prepared in anhydrous DMSO. 
20 uL of DBSO-NHS stock was diluted using the same solvent and reacted with 100 uM 
aqueous solution of S5-amine in 50 mM phosphate buffer (pH = 8.5). The volume ratio of 
S5-amine: DBSO-NHS (diluted with anhydrous DMSO): phosphate buffer was 1:8:3. The 
reaction mixture was stirred at room temperature for 30 minutes and then lyophilized 
overnight. The lyophilized powder was dissolved in water and purified using HPLC to 
obtain pure S5-DBCO. 
S2.6 Conjugation of different PEGs and DSPE-PEG with S5 – DBCO 
The linear and branched PEGs being water soluble, their stock solutions were made 
in water. Only the stock solution of DSPE–PEG was made in chloroform.  1, 2.5, 5 and 10 
equivalents of different PEG azides and DSPE–PEG were reacted with 100 uM S5-DBCO 
in 50 mM phosphate buffer (pH = 7.0) at room temperature for 4 hours. All the reaction 
mixtures were separately run on 10% denaturing polyacrylamide gels using 1X TBE as the 
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running buffer for 1 hour at 45C under 45 mA/gel. In each gel, S5-DBCO (named as ‘No 
PEG) was used as a control. In case of branched PEG conjugation, the conjugation product 
of the corresponding linear isomer with S5-DBCO was used as an additional control. 
 
Figure S2.4: Conjugation of 2 kD linear and branched PEGs with S5. 
 
Figure S2.5: Conjugation of 5 kD linear PEG with S5. 
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Figure S2.6: Conjugation of 10 kD linear and branched PEGs with S5. 
S2.8 Conjugation of Different PEGs and DEPE-PEG to Td and DNO 
We used 250 nM Td and 10 nM DNO to run the agarose gels. The Td samples were run on 
a 1.5 % gel for 45 minutes while the DNO samples were run on a 1% gel for an hour under 
100V. Both the gels were run in 1X TAE/Mg2+ buffer at 4C and stained with SYBR green 
to visualize the bands.  
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Figure S2.7: Conjugation of different PEGs and DSPE-PEG to a) Td b) DNO. 
S2.9 Time vs stability studies 
For the time vs stability studies the Td and DNO samples were concentrated 20 fold 
and then diluted to DMEM + 10% FBS medium, the final concentrations being 1 uM and 
10 nM for Td and DNO respectively. The Td samples were studied for 48 hours while the 
DNO samples were studied for 5 hours. 30 uL aliquots were taken out from each sample 
at different time points and were run on three separate gels (triplicate). The Td samples 
were run on 1.5 % agarose gel and the DNO samples on 1% agarose gel, both in 1X 3D 
buffer, at 4C. After the completion of run, the gels were stained with SYBR green for 
band visualization.  
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Figure S2.8: Agarose gels showing time vs stability of a) bare Td, b) Td coated with 10 
kD linear PEG. 
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Figure S2.9: Time vs stability plots for a) bare Td, b) 2L coated Td, c) 5L coated Td, and 
d) 10L coated Td.  
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Figure S2.10: Time vs stability plots for a) bare DNO, b) 2L coated DNO, c) 5L coated 
DNO, and d) 10L coated DNO.  
S2.10 Cell Culture 
The RAW cells were cultured in DMEM medium supplemented with 10% FBS 
under conditions of 37C and 5% CO2. The cells were seeded in 12 well plates at a density 
of 20,000 cells/well and cultured for 24 h.  
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S2.11 Flow Cytometry 
S.2.11.1 Incubation with DNs 
Before incubation the existing medium was replaced with fresh medium. The cells 
in each well were incubated with 10 uL of each sample (S5-dye or DN), the concentration 
of the sample was such adjusted that the concentration of Alexa fluor 488 was always 120 
nM. Td was annealed in 250 nM concentration and as each Td contained 12 fluorophore, 
hence the concentration of the fluorophore became 3 uM. The sample was diluted 25 fold 
and 10 uL of the diluted sample was added to each well when required. DNO was annealed 
in 5 nM and then concentrated to 10 nM. As each structure contained 12 fluorophores, 
hence concentration of fluorophore became 120 nM.  
An issue that we had to face during incubation of the cells with DNs was the 
instability of the structures in cell culture medium. Our previous experiments showed that 
Td had a half-life of about 5 h in DMEM + 10% FBS medium whereas the same was only 
~ 39 minutes for DNO. So, if we incubate the cells with only one aliquot of the structure, 
there was obvious chances of the macrophages internalizing free dye labeled DNA that 
resulted from the degradation of DNs. Hence, we replaced the medium every 30 minutes 
for Td incubation and added fresh aliquot of Td (10 nM, 10 uL) and for incubation with 
DNO the process was repeated every 10 minutes. This minimized the chance of dye labeled 
DNA internalization. 
S.2.9.2 Dead cell staining 
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Propidium iodide stock was prepared by dissolving solid propidium iodide in 
deionized water and the stock concentration was 1 mg/mL. While staining the cells, the 
stock was diluted to 3 uM by using 1X PBS buffer. 1 mL of the 3 uM dye was added to 
each well.  
S.2.9.3 DNase treatment 
DNase powder was dissolved at a concentration of 1 mg/mL in 50% Glycerol with 
20 mM Tris-HCl, pH 7.5, and 1 mM MgCl2. After the cells have been incubated with the 
DN, we replaced the medium and added 10 uL of the DNase stock per mL of the medium, 
incubated at 37C for 10 minutes and again changed the medium with 1X PBS in case of 
confocal microscopy or with 3 uM propidium iodide solution (in 1X PBS) in case of flow 
cytometry studies.  
S.2.9.4 Analysis of FACS data 
The RFI value from RAW cells incubated 10 uL of the blank was collected each 
time the experiment was done and this value was subtracted from the RFI values of 
samples. 40,000 events were collected for each sample and each sample was studied in 
triplicates. A separate sample was prepared for dead cells and they were incubated with 
propidium iodide (PI) for 15 minutes prior to the flow cytometry experiment. RFI value 
from this control sample show that most of the dead cells has an RFI (form PI) higher than 
102. This value for PI RFI was used as a gating. All the samples were incubated with PI 
solution prior to flow analysis and the gating was applied so that while analysis we could 
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collect the RFI values only from living cells. This minimized the chance of false positives 
as dead cells have a much higher permeability in comparison to the living ones. 
S2.12 Confocal Microscopy 
The confocal microscopy was performed on living cells in 1X PBS buffer. Cells 
were seeded at 3000 cells/well and grown for 24 h in a special 8 well transparent bottomed 
in DMEM + 10% FBS medium. Then each well was incubated with 2 uL of the sample 
(dye labeled DNA or structure, their concentrations modified in a way that alexa fluor 488 
concentration in each sample was always 120 nM). Incubation procedure similar to the one 
followed during flow cytometry studies was followed. After incubation for 1h, the cells 
were washed once with 1X PBS and 1 uM solution of the CellTracker CM-Dil dye in 1X 
PBS was added. The cells were incubated at 37C for 5 minutes and then at 4C for 15 
more minutes. The medium was again replaced with fresh 1X PBS. In addition to imaging 
cells directly after incubation, we also studied batches treated with DNase after incubation, 
such that any DNA or DN sticking to the surface was degraded by the nuclease. 
Conditions similar to cell growth were maintained during imaging. We used a 40X 
immersion objective and a white light laser for imaging.  
153 
 
 
Figure S2.11: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled S5. The cell membranes were stained with CellTracker CM-Dil dye. a) Bright field 
image b) green fluorescence from internalized S5 c) overlay of bright field and green 
fluorescence d) red fluorescence from CellTracker CM-Dil dye e) overlay of green and red 
fluorescence f) overlay of bright field, green and red fluorescence. 
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Figure S2.12: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor488 labeled S5. The crosshairs indicate orthogonal sectioning. The bottom and right 
panels show the sectioned planes and confirm that fluorescent particles (green) are located 
inside the cells and not merely attached to the cell membrane. 
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Figure S2.13: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled S5 followed by DNase treatment. The cell membranes were stained with 
CellTracker CM-Dil dye. a) Bright field image b) green fluorescence from internalized S5 
c) overlay of bright field and green fluorescence d) red fluorescence from CellTracker CM-
Dil dye e) overlay of green and red fluorescence f) overlay of bright field, green and red 
fluorescence. 
 
Figure S2.14: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled S5 and then treated with DNase.  
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Figure S2.15: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled Td. The cell membranes were stained with CellTracker CM-Dil dye. A) Bright 
field image b) green fluorescence from internalized Td c) overlay of bright field and green 
fluorescence d) red fluorescence from CellTracker CM-Dil dye e) overlay of green and red 
fluorescence f) overlay of bright field, green and red fluorescence. 
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Figure S2.16: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor488 labeled Td.  
 
 
Figure S2.17: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled Td–5L. The cell membranes were stained with CellTracker CM-Dil dye. a) Bright 
field image b) green fluorescence from internalized Td–5L c) overlay of bright field and 
green fluorescence d) red fluorescence from CellTracker CM-Dil dye e) overlay of green 
and red fluorescence f) overlay of bright field, green and red fluorescence. 
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Figure S2.18: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor488 labeled Td-5L.  
 
Figure 2.19: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled Td-2-lip. The cell membranes were stained with CellTracker CM-Dil dye. A) 
Bright field image b) green fluorescence from internalized Td-2-lip c) overlay of bright 
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field and green fluorescence d) red fluorescence from CellTracker CM-Dil dye e) overlay 
of green and red fluorescence f) overlay of bright field, green and red fluorescence. 
 
Figure S2.20: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled Td-2-lip.  
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Figure S2.21: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled Td that were pre-incubated with mouse plasma followed by DNase treatment. The 
cell membranes were stained with CellTracker CM-Dil dye. a) Bright field image b) green 
fluorescence from internalized Td c) overlay of bright field and green fluorescence d) red 
fluorescence from CellTracker CM-Dil dye e) overlay of green and red fluorescence f) 
overlay of bright field, green and red fluorescence. 
 
Figure S2.22: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled Td that were pre-incubated with mouse plasma. The incubated cells were 
treated with DNase.  
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Figure S2.23: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled Td that were pre-incubated with clusterin. The incubated cells were treated with 
DNase. The cell membranes were stained with CellTracker CM-Dil dye. a) Bright field 
image b) green fluorescence from internalized Td c) overlay of bright field and green 
fluorescence d) red fluorescence from CellTracker CM-Dil dye e) overlay of green and red 
fluorescence f) overlay of bright field, green and red fluorescence. 
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Figure S2.24: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled Td that were pre-incubated with clusterin. The incubated cells were 
treated with DNase.  
 
Figure S2.25: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled DNO. The cell membranes were stained with CellTracker CM-Dil dye. A) Bright 
163 
 
field image b) green fluorescence from internalized DNO c) overlay of bright field and 
green fluorescence d) red fluorescence from CellTracker CM-Dil dye e) overlay of green 
and red fluorescence f) overlay of bright field, green and red fluorescence. 
 
Figure S2.26: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled DNO.  
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Figure S2.27: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled DNO and then treated with DNase. The cell membranes were stained with 
CellTracker CM-Dil dye. a) Bright field image b) green fluorescence from internalized 
DNO c) overlay of bright field and green fluorescence d) red fluorescence from 
CellTracker CM-Dil dye e) overlay of green and red fluorescence f) overlay of bright field, 
green and red fluorescence. 
 
Figure S2.28: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor488 labeled DNO and then treated with DNase.  
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Figure S2.29: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled DNO–5L. The cell membranes were stained with CellTracker CM-Dil dye. a) 
Bright field image b) green fluorescence from internalized DNO–5L c) overlay of bright 
field and green fluorescence d) red fluorescence from CellTracker CM-Dil dye e) overlay 
of green and red fluorescence f) overlay of bright field, green and red fluorescence. 
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Figure S2.30: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor488 labeled DNO-5L and then treated with DNase.  
 
Figure S2.31: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled DNO–5L and then treated with DNase. The cell membranes were stained with 
CellTracker CM-Dil dye. a) Bright field image b) green fluorescence from internalized 
DNO–5L c) overlay of bright field and green fluorescence d) red fluorescence from 
CellTracker CM-Dil dye e) overlay of green and red fluorescence f) overlay of bright field, 
green and red fluorescence. 
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Figure S2.32: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor488 labeled DNO–5L and then treated with DNase.  
 
Confocal microscopy images of RAW cells incubated with Alexa fluor 488 labeled DNO 
that were pre-incubated with mouse plasma. The incubated cells were treated with DNase. 
The cell membranes were stained with CellTracker CM-Dil dye. a) Bright field image b) 
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green fluorescence from internalized DNO c) overlay of bright field and green fluorescence 
d) red fluorescence from CellTracker CM-Dil dye e) overlay of green and red fluorescence 
f) overlay of bright field, green and red fluorescence. 
 
Figure S2.33: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor488 labeled DNO that were pre-incubated with mouse plasma. The incubated cells 
were treated with DNase.  
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Figure S2.34: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled DNO that were pre-incubated with clusterin. The incubated cells were treated with 
DNase.  The cell membranes were stained with CellTracker CM-Dil dye. a) Bright field 
image b) green fluorescence from internalized DNO c) overlay of bright field and green 
fluorescence d) red fluorescence from CellTracker CM-Dil dye e) overlay of green and red 
fluorescence f) overlay of bright field, green and red fluorescence. 
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Figure S2.35: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor488 labeled DNO that were pre-incubated with clusterin. The incubated cells were 
treated with DNase.  
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APPENDIX B 
SUPPLEMENTAL INFORMATION FOR CHAPTER 3 
ENHANCING LOW SALT STABILITY OF DNA NANOSTRUCTURES USING  
FREE STABILIZING AGENTS 
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S3.1 Materials and Instruments 
L-arginine, L-lysine, poly-arginine, poly-lysine, spremine, netropsin, Hoechst dye 
and thiazole orange were purchased from Sigma-Aldrich and used without further 
purification. DAPI, YOYO, SYBR Green were purchased from Invitrogen. Glyoxyl-
derived lysine dimer trifluoroacetate salt was purchased from Iris Biotech GmbH. 30 nm 
AuNPs were purchased from Ted Pella, Inc. and used without any further treatment. 
M13mp18 single stranded DNA was purchased from New England Biolabs and was used 
without any further purification. All DNA strands except the m13 scaffold were purchased 
from Integrated DNA Technologies, Inc. (IDT, www.idtdna.com) in 96-well plate format, 
suspended in nanopure water (H2O, with resistivity up to 18.2 MΩ·cm) and used without 
further purification. All solutions were prepared with nanopure water as the solvent. 
Buffers: The buffers used in this study are described below – 
1. 1X 3D Buffer: 5mM Tris + 1mM EDTA (pH 7.9 at 20 C) + 16mM MgCl2 
2. Physiological buffer: 1.2 mM MgCl2 + 13.6 mM KCl + 136 mM NaCl 
Transmission electron microscopy was performed using Philips CM12 instrument. The 
melting points of DNs were measured using the PCR instrument from Qiagen. Prism 5 
software from Graphpad was used for plotting and analyzing the data. 
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S3.2 DN designs 
S3.2.1 DN1 
S3.2.1.1 Schematic for DN1 
 
Figure S3.1: DN1. a) Cartoon b) arrangement of double helices constituting DN1 c) TEM 
image (scale bar = 100 nm). 
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Figure S3.2: caDNAno schematic showing individual strands and scaffold for DN1. 
S3.2.1.2 Sequences for DN1 
Start End Sequence 
0[79] 2[72] TCGAGGTGTAGCCCGAGATAGGGTGAAAATCCTGTTTGAT 
33[80] 32[80] GAAACGCAAGTTTTGC 
35[104] 33[111] TAGAAAGACAAAAGGAATAGTAAG 
7[72] 10[64] TACATTTTCGTCTGAAATGGATTACGTGGCACTTTGAATG 
45[40] 43[39] TTAAAGCCGCATTGACAGGAGGTTCCACCGGA 
10[63] 12[64] GCTATTAGAGGAATTGAGGAAGGTATAATACA 
4[39] 19[39] AGTGTTTTTGTCCATCTCGCCTGATTGCTTTGTTATTCATTTCAATTA 
36[55] 40[48] AAGAACTGGGCGACATCATTACCACACTACGAGAACGAGG 
24[127] 47[140] ATATGCAATACAACGCTGAGAATAGAAAG 
23[64] 25[71] GTATCACCCATTTTCAAAAAAGCC 
42[87] 46[80] CTTTTTCATCAGAGCCACCGGAGTTGCAGACCCTCAGAGCGCTTTCGAAAAAAGGC 
44[119] 45[138] CCGATATAACCGATAGTTGCGCCGACAATGACAAC 
36[119] 42[120] GTAAATTGATTCAGTGAATAAGGCCGAGGGTA 
16[119] 5[111] CCGGTTGAGCCGGAGAGTTCTAGCTGATAAATGGTTTGCG 
28[95] 41[95] AAACCAATCTGGCTGATTGTGTCGATACACTA 
34[129] 54[109] AATGCAGATACATAACGCTTCATCAGAAATCAGGTCT 
32[95] 34[88] GCAAAAGAATAATAACGGAGAGGCATTACATACCCAAAAG 
35[72] 33[79] AAAACGAATGATTAAGAAACCGAG 
45[96] 44[104] TCTTAAACAGCTTGATTTCGGTCG 
10[95] 11[119] CCAGTCACAGGAGCACTAACGACAGTATCGGCCTCAGGAA 
2[71] 4[72] GGTGGTTCACAGGGCGCGTACTATAAGGGATT 
12[47] 10[48] TATTAGACCAAATCAACAGTTGAATCTTTAAT 
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6[39] 9[39] AAACTATCCGCCAGCCATTGCAACCACCAGTCACACGACCTAGAACCC 
5[48] 3[55] TAACCGTTGTAGCAATGAACGGTACGCCAGAACGCTTAAT 
9[120] 57[140] GAGGATCCCATAGCTGAGGCAAAGCGCCACAGCTGGC 
3[56] 0[64] GCGCCGCTCGAAATCGTTATAAATCAAAAGAACCGTAAAG 
47[48] 45[71] GGTTTTGCTCAGTATAGCAAGCCCGAGCCTTTAATCAGTCAAGCGTGTATCGGTTT 
42[55] 44[56] AAAATACGCCTCAGAGCCGCCACCACCAGAGC 
20[79] 17[79] AGCCTTTACTGAGTAATATACTTCAAGGCTAT 
61[16] 0[32] ATTAATTAACCTTGCTCGGCGAACGTGGCGAGAAAGGAAGGCCCCCGA 
12[63] 30[56] TTTGAGGATATCCGGTAGACGGGA 
52[31] 38[24] AGAGAGATCTAACGAGCGTCACCA 
54[34] 33[47] CCTAAGAAAAGTAAGCAGA 
33[48] 32[24] TAGCCGAACGACTTGCGGGAGGTTTTGAAGCCTTAAATCA 
37[40] 37[23] GACAAAAGGCTCATTATACATAAGTTTATTTTGTCACAATTTCATATG 
50[138] 41[135] GGATTTTGTAACAAGCGCG 
23[40] 22[40] ATATAAGTATCCAATC 
20[39] 29[39] AGAAGATGGCGGAACAAAGTACCGAATCCTAA 
45[72] 43[71] ATCAGCTTCGCCACCAGAACCACCCTCAGAAC 
24[63] 25[39] GGGACCAGGCGGATAAGTGCCGTCGAGAGCTTATAAGAAT 
59[24] 16[24] TGCAACAGTTGCACGT 
52[146] 13[138] AAGACTTCAAACAGACCGGTGAATCCCATG 
42[119] 50[107] GCAACGGCGGGATCGTAGTTTTGTCGTCT 
47[112] 24[104] GTACAAACCTAAAGTACGGCCACC 
1[96] 23[95] GTTCCAGTTCACCCAAATCAAGTTGTACCGCC 
43[104] 39[111] GCTTTTGCTACAGAGGATCTTTGAACCGTCACAAGAGTAA 
32[135] 36[120] TACCAGACGACGATAATATCATAATAAATCAATTGAGATTAACGAGTA 
11[80] 9[87] ATATCTTTGACGTTGTAAAATATTAGACAACGACGGCCAG 
55[109] 31[111] TTAATAGCGAGGGATAGCG 
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21[128] 27[135] AAGCCTCAATTTTTGCAATTGCTC 
4[103] 16[96] GGGAGCTAGGAGAGGCTAATGCCGAGTCTGGACAATATAA 
12[95] 30[88] CTAATAGAGTAAAATGGAGAGAAT 
7[56] 19[63] CGCTCATGTCACTTGCACAGTAACACATCGGGATTTTAAA 
37[104] 35[103] AAAGGTGAGGCTTGAGATGGTTTAATTACAGG 
5[112] 62[112] TATTGGGCGCCAGGGTTTCACCAGTCTACTAAAGGAGCTGAAAAGGTG 
31[112] 56[109] TCCAATACTCTGCCAGATGGGATAACCGCTTCTGG 
9[40] 7[55] TTCTGACCTGAAAGCGTAAGAATATTTACATTGGCAGATTAGGAAAAA 
0[47] 2[40] TAAAGGGAGGAAGAAAGCGATCCCGCAAAAAAGGAGCGGG 
58[146] 8[136] CTTCGCTATTAAGTGAGCTAATTCGTA 
7[24] 59[39] AATATTACGGCCTTGCGTAGATTTTCAGGTTTAAAATTATTGCCACGC 
36[138] 53[146] AGAAGGAAGCCCGA 
46[79] 24[80] TCCAAAAGAATAGGAACCCATGTATCAGAGCC 
17[48] 6[40] ATGAATATCTGAGTAGAAGAACTC 
42[138] 37[138] CAGCATCGGAATTGCCCTGACG 
24[103] 25[111] CTCAGAACAAATTCTTACCAGTAT 
31[48] 13[55] AGAAGGCTTTTAGAAGATTAAATG 
24[79] 22[72] ACCACCCTGTACTCAGGGTTATAT 
9[88] 7[87] TGCCAAGCCTCACAATTCCTCAATGACGCACA 
46[119] 47[111] ATAATAATTTTTTCACCGTCACCA 
2[39] 4[40] CGCTAGGGACCACCACACCCGCCGTCCTGAGA 
54[140] 34[130] GATTGCATCAAAACCCTCGTTTCAACT 
7[88] 19[95] CAACATACACCTGTCGTGCCTGAGGAGAGGGTTAAAGATT 
33[112] 30[112] AGCAACACAAACCAAACCCTGACTCAGATGAA 
32[79] 13[87] CAGGAGGCAACGCAGGGGGTAATATTAGAGCCTCTCCGTG 
56[34] 12[32] GAATCAGTTGGTTTACAAA 
43[40] 39[47] ACCGCCTCTAACCCCTATAGCTGCTTAGCAAGCAACTTTG 
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3[88] 1[95] TGACGAGCCAGCAGGCTGAGTGTT 
20[103] 29[103] ACCCTGTACAATTCATGCATGTAGATTTTTTG 
10[47] 13[31] GCGCGAACTGATAGCCCTAAAACAATATCTGGCCTCAAATACGCTGTA 
28[63] 41[63] CATTCCAACAGATGAACTTAGCCGAGGCACCA 
16[23] 3[23] AAAACAGAGAGGCGAAAATACCAAAAACAGTAGTGAGGCCGGTCACGC 
32[63] 34[56] GAACCTCCCAAAGTTACCAGAAGGACTCCTTATTACGCAG 
27[96] 38[96] AACAAGAACTGATAAACCTTCATCCGACTTGA 
8[103] 9[119] GTTATCCGTTGCATGCCTGCAGGTCGACTCTA 
44[55] 47[47] CGCCGCCAAGAATGGATCTGAATTTACCGTTCATTAGCGG 
34[55] 36[56] TATGTTAGTTGGGAAGAAAAATCTGCGATTTT 
44[103] 43[103] CTGAGGCTTAAAGGCC 
47[96] 45[95] CTGAGTTTGTTGAAAATCTCCAAAGGTGAATT 
2[103] 3[103] GTTTGCCCACGTATAA 
27[112] 60[107] TCCCAAGATACCAAAATTCGCAAACCTGTTTAGCTAT 
36[87] 40[80] TTTAATCAAAATATTGGGAATTAGGCAAAAGAAAATCCGC 
33[24] 35[47] CCCTTTTTGAATCTTAAAGACACCACGGACAGTCAGGACG 
34[87] 36[88] AACTGGCACTAACGGAACAACATTATTTCAAC 
18[47] 5[47] TAACGGATACGCAAAT 
0[63] 23[63] CACTAAATGAATAGGT 
23[96] 22[96] ACCCTCAGAACCGTGTTTAGTTTGACCTTTAA 
6[143] 58[115] AACTCACATTAATTGCGCCTAATGCGCTTCGCCATTCAGGCTGCG 
4[71] 16[64] TTAGACAGACTTCTTTTCTCTTTTAGTACACATGAATAAT 
23[128] 49[143] ATATAACATGTTTTAATGAATATACAGCGGAGGCGCTAAACAACTTTC 
5[24] 63[36] AAAGAGTCTATAATCACATAAATCAATAT 
37[72] 35[71] GGGAAGGTTTGTGAATTACCTTATACGTTAAT 
28[135] 55[140] TCCAACAGAAGCGAACTATCGCGTCAGAAGCAAAGCG 
12[31] 55[31] CAATTCGACCCAATAGAGTCAGAGTACAATTT 
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3[104] 2[104] CGTGCTTTCCTCGGACGGGCAACAAGTTGCAGCAAGCGGTCCACGCTG 
43[72] 39[79] CGCCACCCTGAGGAAGCGAAAGAGAGCCAGCAAGACCAGG 
5[88] 3[87] ACGCGCGGAACAGGAGGCCGATTAGGTTGCTT 
6[103] 7[119] GTCGGGAAGAGCCGGAAGCATAAAGTGTAAAG 
1[104] 1[140] TTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCC 
27[136] 15[138] CTTTTGATAAGCAAACAAT 
25[16] 22[11] ATAAATAAGAGAAAACTTTTT 
48[15] 26[5] ACTGGTAAACCGTGTGAGTACCGACAA 
37[24] 42[11] GTTTACCATTTGCCATCTTTTCATAATCA 
62[15] 62[5] TCTGTAAAACC 
27[16] 20[11] ATTCTGTCAACATCAAGAAAA 
3[24] 2[16] TGCGCGTACGCTGGCAAGTGTAGC 
50[31] 44[11] TTATTCTGCAGAGCCAGAGGCAGGTCAGACGATTGGC 
63[128] 19[135] TAGTAGTAAAAATTAATCACCATC 
46[140] 43[138] GAACAACTAAAGGTTTTCTGTCATCGCCCGCAGCGAAAGA 
37[11] 36[11] GAAAACAATA 
9[16] 58[24] TTCTGGCCAACAGAGAAGTAATAAATCACCTTAGCAGCAA 
12[138] 31[127] GGCGCATCGTAACCGTGCATGCGGAAT 
43[11] 48[16] AAATCACCGGAACCTTGAGTACCTATTTCACTAGTGT 
31[16] 12[11] TTACCGCGCAACTCGTATTAA 
2[143] 62[128] CGCCTGGCCCTGAGAGGCTGATTGAATCATAC 
7[120] 18[120] CCTGGGGTGTTGCGCTATGAACGGATTCAACC 
10[119] 8[104] AAGTTGGGCGGAAACCTTTCCTGTGTGAAATT 
57[3] 10[8] ATAAAACAGAGGTAAAAATAC 
27[5] 28[5] AAGGTAAAGTAGCAAGCCGTTT 
24[143] 23[138] GCTCAACAGTT 
51[0] 40[8] CAGTTAATGCCCCCTGACAGTGCCTTAACGGGAGCGTCAG 
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14[138] 59[146] ATTGGTGCGGGCCT 
61[0] 18[8] TTTGAATTTCGTCGCTACATTTAATTTAATGGGTTACAAA 
41[8] 38[3] ACTGTAGCATCGATAGCAGCA 
19[8] 16[13] ATCGCGCAAAT 
56[140] 11[135] GAAAGGGGCCAGCTCCAGGAT 
35[11] 54[3] TAAAAGAAACGCACCAATAAGAGCAAGAAACAAT 
17[13] 58[8] AAAGAGGCGGT 
4[132] 5[132] TTCTTGGTTT 
13[11] 56[3] ATCCTTTGCCCGAATCAAACCCCACCAGCAGAAG 
47[13] 24[5] GATACAGGCCTAATTTAATGGTTTGAAATA 
62[143] 3[143] ATCCAATACCCTTCAC 
55[3] 32[8] GAAATAGCTTTTGTGCTAAAT 
40[135] 39[140] AAACAAAGATATTCATTACCC 
48[143] 21[138] AACAGTTTATGCTGTAAAGAGGTCGAG 
18[135] 17[140] AATATGATTAATCGTAAAACT 
60[138] 63[143] AGCGCATTAAC 
49[5] 50[0] GTTCGTATAAA 
15[11] 14[11] TTTGAAAAAG 
38[140] 35[138] AAATCAACGTAACAGATTAAGAACACCAGTAGGAATACCA 
39[3] 52[8] CCGTAATCAGTAGAGAATTGA 
63[5] 60[0] TTTCAATTTCA 
23[11] 0[13] CAAATATATTTTATTGACGGGGAA 
38[95] 42[88] GCCATTTGACGGAAATACTAAAGA 
15[24] 49[36] ATCATTTTATGAAACACAGACGACTAATAAGAAAACATGAAAGTA 
38[23] 26[16] ATGAAACCGCGTTTTCTTGCCTTTGTCAGTGCGAATATAA 
38[63] 42[56] AGTAGCACTCAACCGAAAACGGGT 
19[40] 17[47] CCTGAAACACCATATCAACGTCAG 
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41[120] 44[120] GATTATACCGATCTAACACCCTCAACGCATAA 
22[95] 47[95] CCTCCGGCCGTTATACCGCCACCCCCGTAACA 
19[96] 17[111] CAAAAGGGTGAGAAAGTAATCAGAGCAAACAA 
16[95] 26[88] TCCTGATTGATGATGGATACTTTTAAGTCCTGAATTGAGA 
51[107] 48[112] TTCCAGACGTTAGTTCCACAG 
29[104] 15[119] TTTAACGTCAAAATTCATATTTTGAAAAACAG 
17[112] 6[104] GAGAATCGCACTGCCCGCTTTCCA 
21[56] 25[63] GTCAATAGGTAAATGCATTACTAG 
16[63] 26[56] GGAAGGGTGAGCGGAACAAGGATAATGCAGAAATGTAATT 
30[55] 14[48] GAATTAACTTACAAAACCATCAAA 
14[71] 32[64] TTAACCAATAACAACCAGCGCATTATTCTAAGGTTTTAGC 
40[31] 41[31] TAAGGAGTATCGGCAT 
13[56] 29[63] TGAGCGAGTAGGAACGTAAACAGC 
39[32] 53[39] GAACTGACGCCGGAAACGTCTTTC 
57[109] 10[96] TGCTAACGCCAGGGTTTTC 
25[112] 0[104] AAAGCAGCGAGTAGATCTGGAAGTGTCTATCAGTGAACCA 
18[79] 7[71] TTGAGAGAGATAATGAGCATTTAGTAATAACAGAAATACC 
26[55] 0[48] TAGGCAGAGAATCATATGATGCAAATAGCCCGCGGAACCC 
59[115] 27[127] CAACTGTTGGGAATATGTACCGAAGATTGATCGGTTGGTACCTTT 
39[80] 21[87] CGCATAGGCAATAATCCAATAGATGCGGGAGAATAGGTCT 
19[120] 25[127] CAGTCAAAGCAAATAATGGTCATACTGCGAACTTAATTGC 
13[88] 29[95] GGAACAAAATTTTTGTAAGAAACG 
29[40] 13[47] TTTGCCAGTGAACACCTCATCAAC 
39[48] 21[55] AAAGAGGAGAACGGGTTTCAGCTAAAAATTTTTGAGAAGA 
41[32] 37[39] TTTCGGTCTATTAGCGGCGCCAAA 
53[115] 38[120] ACGAGAATGACCAAAAGCTGC 
48[36] 51[31] TTAAGAGGCTGAGGGAACCTA 
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41[96] 37[103] AAACACTCCTTTGAGGTATTCATT 
15[80] 18[80] GATTATCAGTTTGGATTGTGTAGGAGCTATTT 
49[112] 20[104] ACAGCCCTTAGCAACGCTCAACAGAGATACATACATTATG 
58[39] 57[34] TGAGAGCCGCT 
39[112] 14[104] TCTTGACATAGTCCTAATTTACGAAAAGCCCCTTAAAATT 
40[79] 14[72] GACCTGCTTTTATCAAGGCTGTCTATATTCCTCTCATTTT 
13[32] 31[47] GCCAGCTTCTGAACAACAAGCAAATCAGATAT 
26[127] 46[120] GGATGGCTCATAGTTACTGTAGCATAAATGAAAATTGCGA 
60[31] 40[32] TTAGAATCTAGCGATAGCTTAGATCGAGCCAGGACAATAAGTCAATCA 
30[111] 12[96] AATAGCAGTGACCGTATTTGAGGGGACGACAA 
14[103] 32[96] CGCATTAACGGCGGATCCTTTACATTTAGACTAGGCTTTT 
40[47] 14[40] CGCAGACGACAACATGATTAAACCAAGAAACCAATAATTC 
13[128] 31[143] TGGTGTAGCCTCAAATCGTCATAAATATTCAT 
25[40] 20[40] AAACACCGGGCATTTTTAAGACGCTAGGCAAA 
41[64] 37[71] ACCTAAAATTTCCATTTTGAGGGA 
52[39] 55[34] CAGAGATCTAT 
62[36] 23[39] ATGTGAGTGAATAATTTTCCCTTTAGAGCGTTAATTTCATGGTTG 
29[16] 15[23] GTAGGAATTTAATTTTGTAACATT 
61[107] 23[127] ATTTTCATTTGGGGCGCGCAAGAAAAACCTTCATTCC 
21[88] 26[96] GAGAGACTACCTTATTTAGGGCTT 
22[71] 40[64] AACTATATTGAATTTAACGCCAACCGCGCCTGCCATGTTA 
30[127] 52[115] GCTTTAAAATTATAGTTTTAATTCAGAAA 
14[39] 39[31] GCGTCTGGCCTTCTTATGAGCGCTCACTCATCTCAGAACC 
19[64] 29[71] TGCAATGCTTTCAACGTTATCATCTTCCTTATCATATTAT 
38[119] 27[111] TCATTATCCCCCCAGCAGATTTGTATCATCGCAAATAATA 
26[87] 0[80] ATCGCCATATCATATGTTAGGTTGGAGGTTTATTTTGGGG 
29[72] 11[79] TTATCCCAAACAGGGACGTCGGATGTCAATAGTATCTAAA 
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15[48] 18[48] ACCAGAAGTAGAACCTCCTCATATAGAAACAA 
17[80] 5[87] CAGGTCATTGCCAGCTATCGGCCA 
30[87] 14[80] AACATAAAATCCAAATTAAATCAG 
25[72] 21[79] TGTTTAGTATTTAACATCAAAATC 
39[64] 38[64] CGGTGTACAAATCACC 
22[39] 47[31] GCAAGACAAAGAACGCGGCGTTAACTGACCTACAAGAGAA 
14[127] 40[120] AAACGTTAGAGCTTCAGTCAGGATAGAACCGGTACAACGG 
63[112] 4[104] GCATCAATTGATTAGAATCAGAGC 
0[140] 22[128] AACGTCAAAGGGCGGCAAAGATCCCAATT 
29[5] 29[15] TTATTTTCATC 
33[8] 30[16] AGCTATCTTACCGAAGAGATTAGTCACCCAGCGGTAATCA 
10[135] 13[127] GTGCTGCAAGGCGATTGATCGCACTTTCCGGCGGTCACGT 
21[11] 60[16] CAAAATTAAAACACTTGAATT 
53[8] 28[16] GTTAAGCCCAATAACGAACCCACACGACAGAAGAGAACAA 
16[140] 14[128] AGCATGTCAATCAGGGCGATCTAAATTGT 
11[8] 7[23] CGAACGAACTCAATCATCGCCATTTCTAAAGCAAGGGACATCCAGAAC 
45[11] 45[39] CTTGATATTCACAAACAAATAAATCCTCA 
59[8] 5[23] CAGTATTAACACCGCCATGAAAAAGAAATTGCTGGTAATAACCGAGTA 
20[138] 15[135] CATAAAGCTAATATAAGCA 
47[32] 46[13] GGATTAGGCAGTAAGCGTCATACATGGCTTTTGAT 
8[135] 9[143] ATCATGGTCCGGGTACCGAGCTCG 
34[47] 34[11] CAAACGTAGAAAATACATACATAAAGGTGGCAACATA 
4 spacer Ts were added to all the strand termini (5’ or 3’ or both) that end at the edges of 
DN1. 
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S3.2.2 DN2 
S3.2.2.1 Schematic for DN2  
 
 
Figure S3.3: DN2. a) Cartoon b) arrangement of double helices constituting DNO c) 
TEM image (scale bar = 50 nm). 
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Figure S3.4: caDNAno schematic showing individual strands and scaffold for DN2. 
S3.2.2.2 Sequences for DN2 
Start End Sequence 
16[111] 15[111] CATATGTATTTTAACC 
20[111] 11[111] TAAAAATTAGCGCCAT 
13[16] 1[23] AGAGATAGTAGAGCTTATCAAGTT 
38[39] 40[24] GACCGTGTTGTTTAGTAAAGCCAACGCTCAAC 
50[63] 61[79] GAGCGTCTGCAAGGCCGGAAACTCAGAGCCGC 
11[16] 3[23] ATTTTGACGCGCGTAAGAGAAAGG 
58[63] 52[48] TGCCTAACGCAAAGACGAGGGAGGCATAAAAA 
44[103] 53[103] AGCATCGGAAAATACGAACCCATGACCCTCAT 
50[79] 35[79] ATTTTCTGGCTTGCAGGCTACAGAGCTCATTA 
59[8] 58[8] TTACCAGCTAGAAAAT 
29[16] 17[23] TTACAAAAACCTCAAACCGCCTGC 
60[87] 49[87] CCTTGATACACCAGAAGTAAATGACAACAGTT 
3[88] 13[95] GGGTGGTTCACCGCCTGATTGACC 
29[8] 28[8] ATACCAAGTCGCCTGA 
35[64] 51[63] AAGAACTGGGCTTTGAGGACTTCCTTTACAGA 
60[79] 43[79] TTCACAAAGCCTGTAGTTCGTCACTGAGGAAG 
60[71] 61[55] CAAATAAATCCTCGGTAAATATTGTACCATTA 
28[71] 36[64] GAGCTTCAGTCAGGATTAATCATT 
62[111] 49[111] CAGAGCCGAGAAAGGA 
51[8] 52[8] AAATAAGAAACACCCT 
20[39] 25[39] ATCTTTAGAAGTATTACAAAATTATGGAAGGG 
48[103] 61[111] GAATAATAGTGAGAATCCACCCTCAGAGCCGCCGCCAGCA 
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15[80] 0[72] AAATTTTTAGTGTTGTTCCAGTTT 
2[71] 11[71] CAGCAAGCAGGCGGTTGACGACGACAGCTTTC 
53[8] 54[8] CAGAGGGTAAGCCCTT 
46[63] 63[63] ATATACACACGCTAACGCTCCAAAAGCGTTTG 
50[111] 45[111] GTTTTGTCATCGTCAC 
32[23] 32[8] ACCTTGCTTCTGTAAA 
33[40] 16[48] ATAGCGATAGCTTTACGAGAATGATAATGGAACAAATATT 
7[48] 6[56] CTGTCCATAGCTCGAAGCGGGAGC 
32[79] 17[79] ACCAAAATGAGGGGGTAATGCTTTAGCAAACA 
56[39] 57[23] CCCAAAAGAACTGGCATGATTAAGAAACGTAG 
22[23] 10[16] CGAACGTTACATTTGATGCAACAG 
42[47] 26[48] TAAAGTACACCTAAATTTAATTACCAACTAAA 
51[80] 34[80] CATTCCACTAGCAACGGGAGTTAAACAGGTAG 
19[80] 1[87] GACAGTCATCTGCCAGAAACGGCGGGCCCTGATTGATGGT 
3[24] 17[31] AAGGGAAGCCCCGATTAACCCTTCCAATATTTAACAGTGC 
55[24] 58[24] AACAAAGTAATAGCTAAAAATACAATTTTGTC 
42[39] 55[39] CGACAAAATTAGGCAGGAAATAGCTACCAGAA 
30[111] 17[111] AATCGTCAAAAACTAG 
41[64] 56[64] AGCGATTACAGAACCGTCAGTACCGGATTAGG 
36[103] 42[96] AAATTGGGCTTGCCCTTAAAACGA 
5[8] 6[8] CTTAATGCTACGCCAG 
19[56] 30[56] TTCAAAAGAGGCTATCCAAAAATCCAGAAAAC 
43[8] 42[8] ACAACATGCCAGACGA 
15[8] 14[8] GCGAACTGCTATTAGT 
62[23] 48[8] CAGAATCAGCGCGTTTGAGGTTTTGAAGCCTT 
30[103] 35[103] TAAATATTAAAGCGGAACGGAACAGGGAAGAA 
16[79] 2[72] CCAAAAACTTCGCATTGTAGCCAGAATCCTGTGAGAGTTG 
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22[103] 24[96] GCAAAGAATAGCATTAACATTTCG 
38[71] 40[56] ACAAGAACCATAAGGGCGGAACGAGGCGCAGA 
2[63] 31[63] 
GGTCCACGACCCGTCGAACATTAATTGCCTGATGTA 
TAAGAAAAGAAG 
18[47] 12[40] AAATCTAAAAGCGTAATTACATTG 
23[80] 6[80] ATTCTACTGCAGGTCGGTAACGCCAAAGTGTA 
27[32] 37[39] GAATATACATGCAAATATCTTCTG 
36[23] 28[16] AAGACAAACTTTTTAATAACGGAT 
36[31] 44[24] CCAATCGCATGCAGAACCTAATTT 
21[48] 4[40] AAACACGGGCTGGCGAAAGATCGCCAAAGGGCGCTGGCAA 
52[31] 60[24] ACGGGAGACAAAAGGGAAAGGTGA 
50[55] 32[48] TTCCAGAGTCTTACCATCATCGAGTAAGAACGACAGTACA 
31[8] 30[8] AATTAATTAAACATCA 
1[88] 15[95] GGTTCCGATAGGGTTGGTTAAATC 
55[8] 40[16] AGTAAGCAGATAGCCGAGTAGGGC 
51[32] 59[39] ACGTCAAATATTCATTCGACATTC 
35[48] 18[48] AACTATATCAGACCGGCCATAAATAGGATGAA 
36[87] 29[87] GGTTTAATTACCAGTCTATCGCGTTATTATAG 
50[47] 35[47] CCTAATTTGGTATTAAAAAAATAAGGTTATAT 
59[40] 53[47] AACCGATTACCACGGATAACCCAC 
5[96] 9[103] TAACTCACCAACTGTTCCCAGTCA 
41[16] 26[16] AACGCCAAAGGCGTTATATTTTAGTAAAACAG 
22[79] 7[79] ATAAAGCCTAAGTTGGACTCTAGACATGGTCA 
36[79] 21[79] TTCAACTTTAGAGAGTGTAGCTCAATGACCCT 
61[8] 60[8] ATTTGGGACGTCACCG 
18[39] 28[32] AGCATCACCAGTTGAAACATCGGG 
23[8] 5[23] GAGTAACATTATCATTTGATTAGTGAACTCAAAGGAA 
189 
 
CGGGCCGCTAC 
28[79] 10[72] TTTAATTCAGGCCGGATGCAATGCCGGCACCGGCGGGCCT 
5[24] 12[24] AGGGCGCGGTCACGCTGCTCAATCACCAGTCA 
8[55] 5[55] CACGCAAAAAGGGGGATAAACAGGACGAGCAC 
18[79] 4[72] TTTGAGAGGTGGGAACTTTGAGGGTGCGTATTTGCCAGCT 
24[47] 23[55] TCATATTCCCACCAGAAGGAGCGG 
57[40] 55[47] GGTGGCAAACGGAATAGGAAACCG 
53[88] 60[88] GAGCCACCTACCGTAATGAATTTAACGATTGG 
6[111] 8[96] ACACAACATACGAGCCGAAATTGTCCAAGCTT 
46[87] 32[80] ACAACCATATCAGCTTCGATAAAA 
15[96] 17[103] AGCTCATTCCCCGGTTGTAATCGT 
27[56] 34[56] TCCAACAGAAGCGAACGCGATTTTAGATTTAG 
3[40] 3[63] AGGAGCGGGCGCTCGCGCGGGGAG 
53[80] 43[87] CACCCTCAAAAGAATATTTCCATT 
20[71] 25[71] CTGAGTAAAAAACATTACATGTTTTTTCATTC 
7[24] 9[31] AGTGAGGCTTTTAGACACTATCGG 
47[32] 61[39] GGCTTATCACCTCCCGACAATTTTCCGTAATCTCACCAGT 
30[95] 47[103] CATTGAATAAGGAATTCCAGACGAGCTTTCGAGGTGAATT 
49[24] 63[39] ACCCAGCTACTTGCGGTCATCGGCATTTTCGG 
54[95] 58[88] CAGGAGGTTGCCCCCTAGTGTACT 
0[39] 13[39] TCCAACGTTCGAGGTGGGCACAGATGACCTGA 
55[56] 57[71] GGTTTTGCCCAATAATAGATGAGTAACAGTGC 
33[8] 34[8] TTAATTAACAAAATCA 
0[111] 1[103] AAAGAATAGCCCGAGAAATCGGCA 
7[80] 21[95] 
TAGCTGTTTCCTGTGTGGAAGCATAGGGTTTTGGGAAGG 
GTTTGCGGG 
44[111] 35[111] CGAAAGACAAATCTAC 
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27[16] 12[16] AGGTTTAAACAACTAATCAGTTGGCACGACCA 
41[72] 39[79] TACCAAGCTACTTAGCAACCGAAC 
6[79] 8[64] AAGCCTTAGAATCAGATTCGTAATGGATCCCC 
45[56] 51[71] CCGTTCGGTCGCTGAGTATGGGATACTACAAC 
51[48] 34[48] TAGCAGCCTGAACAAGACCAAGTAGAAAGATT 
37[64] 53[63] ACGTAACACACTCATCTTTGAATAAGTTAAGC 
14[95] 31[95] CGCGTCTGGATGAACGGATAATCAAATGTTTA 
58[87] 52[80] GGTAATAAGCAGTCTCCACTGAGT 
27[48] 12[48] AAGCAAACTAAGGTTAAGGAAAGAGCCTCAGG 
34[95] 49[95] ACATTATTAGGCCGCTCAATGACATCAGCGGA 
36[47] 21[47] AAATGCTGAGTAACAGTACCATATGACTTTAC 
54[23] 43[23] TCTTACCGAATTGAGCAATTCTGTTTCAGCTA 
9[56] 20[56] TGTGCTGCTTACGCCATTGTACCATGTGTAGG 
51[96] 59[103] CTCATAGTCAGGTCAGCCGTTCCA 
39[48] 22[48] CGTTATACAATTATCAGTACGGTGAATATTCG 
13[64] 19[71] GATTCTCCATCTACAAGGTGAGAA 
33[32] 50[32] TTGAAAACAGCCGTTTCAAGAACGGCCAGTTA 
60[111] 51[111] GGTTGAGGTAGCGTAA 
36[63] 43[71] GTGAATTAAAGAAAGACTTTTTCA 
22[39] 24[32] TATTAAATCAAAGAAACTGATTAT 
42[79] 23[79] 
CACTAAAAAAGCTGCTTAATCTTGCATATAAC 
TGTTTAGCTGGCATCA 
35[32] 52[32] TTAGGTTGTATCCCATCGCGCCTGCGCATTAG 
14[103] 18[96] AAATAATTGTAATGGGTTAATGCC 
12[95] 29[95] ACCGTGCAAATCACCAGGAGAGGGTCAGAAGC 
8[95] 26[88] GCATGCCTAATAGTAGTTAGCAAACCCAATTCTGCTGAAT 
10[31] 28[24] CCAGCCATGGATTTAGGAGCACTACGTCAGATAGAAACAA 
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24[95] 42[88] CAAATGGTTTTGAAAGTGACCTTCAAGTACAAAAGAGGCA 
15[48] 0[40] GTAAACGTATTAAAGAACGTGGAC 
24[71] 41[63] TATATTTTCATTTGGGCGGTCAATCGGATATTGTACCCCC 
29[32] 34[32] AGGCGAATGAGAAGAG 
37[88] 44[88] GAATAAGGCTTGAGATAAACGGGTAACGAGGG 
2[39] 11[39] AAGGGAGCAAAGCGAAGCAGATTCGTCTGAAA 
53[48] 36[48] AAGAATTGAGAGAATACAATAGATCCTTATGT 
4[39] 9[39] GTGTAGCGTACTATGGTATTACCGCCTTGCTG 
39[104] 39[111] TGAACGGT 
63[40] 49[47] TCATAGCCTAGCAGCAATCCTGAA 
54[47] 39[47] GAAACAATAGGCATTTACCAGTATATCATATG 
48[95] 63[111] ATTTTTTCCGGAACCAGAGCCACCACCGGAAC 
19[24] 30[24] CAAATCAACTTGCTGATCGCGCAGAAGAAGAT 
1[40] 15[63] CCGTAAAGCACTAGTTTGCCCCAGAGTCCACTTAATATTT 
13[48] 2[40] GAGTAACACTGAATCGGAACCCTA 
51[24] 62[24] TTTGTTTACAAAATAACAGCAAAAAGTAGCGA 
56[63] 54[48] ATTAGCGGCAATAATACATATAAAAAGAGCAA 
20[47] 6[40] TCTAAAATTGGATTATCAGAACAATTGCTTTGAGGCCGAT 
59[72] 54[72] TGGAAAGCGTTTTAACAGAACCGCGCCACCCT 
0[71] 14[64] GGAACAAGCAGGCGAACTTTCATC 
31[64] 46[64] TTTTGCCAAGCGAGAGACTAATGCCATAACCG 
20[95] 35[95] CCTCATATTTGCTCCTACTTCAAAAGGACGTT 
39[96] 55[95] AGGACAGACGAAATCCGCGACCTGTCGAGAGG 
19[96] 27[103] TCAATATGCCCGAAAGTTTGATAA 
41[96] 56[96] CGGAGATTACCGTACTGTTGATATAAGTATTA 
22[47] 7[47] ACAACTCGGTAATATCTTAACCGTAAAAGAGT 
33[24] 47[31] TAGAATCCAGTGAATAATATAGAA 
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51[88] 62[88] AGACAGCCAGACGTTACCACCACCAGAACCGC 
16[31] 32[32] CAGCAGAACAATTTCATTTGAATTTATATGTG 
25[24] 37[31] CTGAATAATTTGCACGTTAATTTC 
45[16] 30[16] TCTTTCCTGAATTTATTTTTCCCTGATGAAAC 
19[8] 20[8] ATATCTGGTAGATTAG 
36[111] 27[111] CGAGTAGTGAGGTCAT 
35[24] 46[24] CCTCCGGCTCAATAGTTATCATTCTTATTTTC 
47[64] 62[56] TTAATTGTAAAAAAAGTTTGCTAAACCCGTCACCAATGAA 
5[72] 11[95] TCGTGGGGTGCCTAATGAGTGAGCGTCGGGAAGCCGGAAA 
21[96] 38[96] AGAAGCCTAGCTTAATTGCGAACGAGGCTGGC 
16[47] 30[32] TAACCGAACGAACCACCACGCTGACTGAGCAA 
11[80] 3[87] CTTCTGGTACCTGTCGGGGCGCCA 
58[23] 44[16] ACAATCAAGCCAAAGAATTAACTGAACGATTTACGAGCAT 
56[95] 54[80] AGAGGCTGAGACTCCTACAGTTAATTAGTACC 
34[47] 19[47] AAGACGCTTATTCATTTACCTTTTAGGAATTG 
63[64] 49[79] CCATCTTTTCATAATCGAGCCACCACAACTTT 
33[56] 47[63] CACATTCAGCTTTTGCAGGAGCCT 
58[103] 57[111] GATACAGGGCCTATTTCGGAACCT 
62[87] 48[80] CACCCTCAAAAATCACACGTTGAA 
49[8] 50[8] TTAGTTGCATTATTTA 
38[87] 20[80] ATCAAGAGCATTCAGTATAATGCTACCTTTAAATTTTAAA 
33[80] 16[80] AACGCCAACCCCCTCAAATAGTAAGAAAAGCC 
61[40] 43[47] AGCACCATACGGAAATAATGAAAACAGGGAAGTTTATCAA 
14[111] 1[111] GCCATCAAAAATCCCT 
14[23] 0[8] TTGAATGGATAGCCCTGAAAAACCGTCTATCA 
31[16] 16[8] ACATTTAAGATAAAACAGAGGTGA 
5[56] 12[56] GTATAACGGAATCGGCACTCCAGCCAGTATCG 
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53[32] 57[39] CAGAGAGAATAAGTTTTACATAAA 
52[71] 58[64] CAGTACAACCACCCTCGGGGTCAG 
18[87] 14[80] TAGCTATTAGAGAATCGCCTTCCT 
52[63] 59[71] GAGAATAAGAAATTAAAGCCAGAA 
   
63[8] 62[8] AGACTGTAAGTTTGCC 
56[111] 55[111] AAACATGAAAGTATAG 
37[8] 38[8] TTCAAATAAATAAGAA 
48[111] 47[111] GGAATTGCTCTTAAAC 
57[8] 56[8] ATGTTAGCACTCCTTA 
10[111] 5[111] AGGCTGCGATTAATTG 
25[8] 24[8] TGTTTGGAATCAATAT 
32[111] 31[111] TCATAACCAGCGTCCA 
11[8] 10[8] ATACCTACGAAAAACG 
47[8] 46[8] ATAGCAAGAATCATTA 
1[8] 2[8] TCACCCAAGACGGGGA 
52[111] 43[111] CCAATAGGTAATGCCA 
4[71] 23[71] GCATTAATTGCTTTCCCTTCGCTAAAGGCGATTCAGAGCATGAAAAGG 
2[111] 20[96] ACAGCTGATTGCCCTTTTTCTTTTGCATCGTACCAGGCAATTTAGAAC 
57[72] 41[87] CCGTATAACAAGAGAAAGGCGGATAAGTGCCGCTCCATGTGCGAAACA 
42[111] 23[111] CACCAACCGACGAGAAAGGCGCATAGTAGATTCATTAGATACATCCAA 
39[80] 10[80] TGACCAACCAATAACCAGTTGATTATTAAGCAGTAATACTCGATCGGT 
48[79] 29[79] AATCTCCAATCGGTTTCGCCCACGAGATACATAAAGATTCACCCTGAC 
31[96] 50[96] GACTGGATCTCGTTTAACGAGGCATGCGCCGATTTGCGGGGTCTTTCC 
21[8] 7[23] TAGATAATATTAATTTGAGTAGAAAATAACATAAGTGTTTTTATAATC 
41[8] 25[23] TATTTAACTTAATTGAGAATCATAATTACTAGGGCAATTCTTATACTT 
60[23] 47[23] ATTATCACATTAGAGCACAGCCATTATTTTGCATCGTAGGCAAATCAG 
1[24] 14[40] TTTTGGGGCAAAGGGCAAAACATCGCCATTAAAAATAATTGAATACGT 
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4 spacer Ts were added to all the strand termini (5’ or 3’ or both) that end at the edges of 
DN2. 
S3.2.3 DN3  
S3.2.3.1 Schematic for DN3 
 
Figure S3.5: DN3. a) Cartoon b) arrangement of double helices constituting DN3 c) TEM 
image (scale bar = 50 nm). 
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Figure S3.6: caDNAno schematic showing individual strands and scaffold for DN3. 
S3.2.3.2 Sequences for DN3 
Start End Sequence 
56[78] 55[78] TTTTGTTAAGCCTTCCTG 
79[56] 12[56] ATAAGGGCCTGCTCAGTTTGAGACAACT 
10[74] 7[74] TTTTGCGGAACAATGGCAATAATCCTAAAATTATTTGC 
78[74] 79[74] CAACTCTGAC 
72[13] 72[2] TCAGTGAGGCCA 
78[69] 56[63] TTGAAAGCGTGGGATTCATCAGCGTCTGATCAGCT 
17[14] 15[20] GAACAAGTGTTTATAGACGAC 
22[55] 24[49] ATCGGAAAAGGCCGGGTCGCT 
64[34] 65[41] TTTTGCACCAATACTGCGGGC 
73[2] 31[13] CCGAGTAAAAGAAAGAGCAAGTCAGA 
93[5] 29[13] TTATAAATCACCCTGATAGCAGC 
92[34] 27[34] TGATGGTTGCCCCAAACGATTATTATTT 
15[2] 16[5] GTAATTCTGTCCCAACAATAG 
16[48] 83[48] AACAGTTCTAAAGCACAAAGTACGAAAG 
44[81] 43[81] AGTAAGCGTCATAGTGCCTTGAGT 
6[55] 54[49] AAATTGCGAACCTAATGTGAG 
66[48] 42[42] ATTTTAACTGTAATCCCATTA 
79[7] 12[14] TGCAAGGCGATTAACGTTGTATACCAGTGAGAATC 
65[2] 66[5] AGTAAAATGTTTCCCTCAAAT 
57[35] 4[42] AAGAACTGTAGTAAATGTTTAACGTCAGGCCTGAT 
4[41] 51[34] TGCTTCTGAGAGACGATGCAAATTGGGCCGAGAAAACCGCTTTTGGGAA 
22[74] 89[74] CTCAGCAGCGAACCAGTAATAAAA 
1[9] 0[9] CTTGCATAAC 
81[35] 15[34] GAGGAAATACAGTAATAAGAGAACAACA 
88[48] 22[35] ACCCTTCTGCCAACGCGCGGGGACGGGCAACAGTGAGAAGCA 
53[9] 55[27] CGCCAGCTCATCAAGAGTAATCAACGGCCCTGA 
65[21] 44[9] ATAGCGTAAAGAAGAGCCAGCGGCCGGAAACGTCACCAAT 
59[5] 62[5] GTTAATAAATTAGGAAAACTAATCATAACCCT 
49[9] 2[2] CAGAGCCACCACTGAGTGATTCTGTAGCTTAGATTAAGACGCTGA 
32[78] 31[78] AGCCCTCATATTTTCTGT 
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53[49] 9[41] CCCGTCGGGTGTAGATGGGCGCATCGGCCAAGAACGACCAGGTAATCAT 
15[21] 79[27] GACAATAAATATAAGCAGGTCGTCACGAGTTGGGT 
86[78] 21[78] TGAATGGCTAAACATCGC 
24[48] 28[49] GAGGCTTGATACCGTATTTACAACATTGCAACAGGGAAAATC 
20[27] 87[27] CGAGAACCATTACCGCTCACTAGCTGCA 
96[74] 97[74] CTAAAAAGCA 
1[42] 62[49] TTCCCTGATGAAACTTTTTTATACCCCGGTAAAACTGCCTGAAGATCTA 
35[14] 72[14] GAGGAAACGAACAAAACCAGAGATATAA 
12[13] 12[2] GCCATATTTAAC 
85[2] 84[2] TAAAGAAGTG 
75[9] 75[20] TGAGTGTTGTTC 
43[56] 61[62] GTTTTAAGCCGGAGCGTTCTATTTTGAGGAGTCTG 
34[48] 35[55] TCACCTTAACACCACCCTCAT 
41[9] 64[14] GATTGAGGGAGGCGACTTGGAATTAGTTTTGCC 
12[55] 16[49] CGTATTATTTGAGGATTAGAGAGGAAGGGCAAATC 
31[56] 31[55] ACGTTAGCAACTTTCAACAGTTTCAGAATATCGTCTTTCCAG 
58[20] 4[2] GGGAAGAGTGAATTTTAACCTCCGGCTTAGGTT 
71[2] 70[2] AGCTTATTCG 
65[63] 44[63] TAAAGATGAGAAAGCGGGGTCACATGGC 
19[2] 20[5] TCTTTCCTTATCCCGTTTTTA 
84[48] 85[34] ACCAACCTAACAATTCCACACGCTAACT 
72[74] 71[74] CAAATGGTCAATATTCTACTAATA 
8[55] 79[55] TGGATTACTGATTAATGAACGGTCAATC 
42[81] 67[78] AACAGTGCCCGTATTTCAACG 
54[48] 57[48] CGAGTGAACACGCCTAGGAGAGGTAAAC 
43[9] 42[9] TTTGGAGCCA 
84[62] 81[62] GCCACTAAGAATACATACCAAATCGCCT 
62[27] 45[27] AAGAGCAATAAAAAGTCAGACAGCAGCA 
90[34] 26[28] TGCCCTTCCTGAATCTAACGA 
82[78] 17[78] TTGACCCCCTATCAAACC 
94[34] 95[27] TAGCGGTCACGCTGGCCGCTA 
88[74] 88[65] GGGACATTCT 
40[62] 42[56] CAAGAGAACCTATTGTTAATG 
17[7] 18[2] AAGTCCTAATAATCGGCTG 
37[35] 69[41] GTGGCAAGAACTGGGACAAAG 
34[27] 38[9] AGATAGCCGCAATAAAGACTCATACATAAGACACCACGGAATAAGTT 
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61[21] 48[9] CATAACGTCATCAGTCGGTCATAATCAAAATCACCGGAAC 
33[35] 73[41] GAAGCCCCCACAAGACGAACG 
54[78] 53[81] TAGCCAGCTACAAACGGCGGA 
6[74] 5[74] ACGTAAAACAGAACAGTACCTTTT 
88[64] 86[56] GGCCAACAGATACGTGTTTAATG 
31[35] 92[35] AGAGAGAGCGCATTTAATAACTCCTGTT 
52[20] 52[9] TCTTCGCTATTA 
20[78] 87[78] CATTAAAAATACCGAAAGCCCTAATTAGTCGCACAGACAATATTTT 
21[35] 20[28] ATAGCCAAATACCGCACTCAT 
56[27] 49[27] TTGAGATCCTTATGGGACGTTAACGGAAATATATGCGGAACC 
38[81] 37[78] CGAGAGGGTTGAGCCACCCTC 
77[49] 32[49] TCATTTTTTAGCTATTAGTTTTCTAAAG 
71[42] 33[34] CGAGCTGATACAGGCAAGGAGCCCGAAACAAACTCAGTAAGCTCTTACC 
22[62] 19[74] AGACAGCAACTGATCGAACCAAGTATTAACACCGCCTGCA 
68[34] 71[41] AAATCAGTTAAGAGCATGATTATAACGGAATACCCTAAGAAACAGGGCG 
76[78] 75[81] GCTGAATATACTAAAGTACGG 
22[34] 89[48] AATCAGACCGACTTGCGGGAGGGAGTTACGAGGGTGCAGATT 
90[78] 26[70] CATTTTGACACAACCATTATCAG 
51[35] 50[42] GGTAACCGTGCATCGCCAGCT 
85[35] 19[34] CACATAGAAAATTTACGAGCATATTAAA 
96[34] 96[35] TTGCTTTAGGAGGCCGATTAAAGGGCGACCGATTTAGTATGG 
48[81] 47[81] AGAGCCGCCACCGACGATTGGCCT 
95[49] 77[48] GGGAAAGGGAGCCCAAAACCGACTGGACTCCAACGTAAGAGG 
7[21] 1[27] TTCATCTAGACAAAAAATGCTTACCTTTTATCAAAAGCGATAAATCGTC 
70[13] 33[13] CGTTTTACAAAGCGAGTTACCACAATGA 
55[49] 95[48] ATCAAAACACTCCATGCCAGTGCGCTAGGGCGCTGCTTGACG 
19[21] 84[21] GAACGGGTGTAGAATGAGTGAAACATAC 
14[74] 81[74] GAGCACTAACAAGATAAATTGTGT 
57[49] 6[56] GTTAATATTTTGTTCATTTTTTACAGTAAATAAAG 
38[62] 65[62] ATAGCCCCTCAGTACGGTTGTCGGGAGATAGAACCGTGTAGG 
11[2] 10[2] TATACTGCGT 
79[2] 78[2] TGTGCGGGGA 
4[74] 3[74] ACATCGGGAGAAGAGGCGAATTAT 
15[35] 80[42] TGTTCAAGGAATTGCCGTCAACGGAGATCTTAGCC 
48[41] 1[41] TTGCCATTCAGAGCCAGTACAATTAATT 
87[5] 26[5] GGAAACCTGGTATTGGGGTTTTTGAGAGAGTGCACCCCCTAATTTG 
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52[81] 52[70] TTGACCGTAATG 
13[2] 14[2] AACGCCAACATGACAAAAGGTAAA 
66[34] 41[27] TCATAAATATTCATAAAACGACCGTCACGAAGGTA 
14[62] 13[74] CTAATAGATTTAGAAGTATTAGACTT 
84[20] 13[20] GAGCCGGTTCCTGTAATTCGTCATGCCTAGTACCGTAATTTA 
61[63] 48[63] GAGCAAAGATGAACCAGGTCAAGAACCA 
83[49] 21[55] AGGCAAACGAAGGCCATGAGGCGGCTTTCAGAGCG 
5[2] 50[2] GGGTTATATAACTTTCAACAGTGAATCAGGCAAAGCGC 
77[5] 97[20] CTGAGAAGTGTTTTGTACGGTACAGCGGGA 
12[74] 11[74] TACAAACAATTCGTAACATTATCA 
69[42] 38[42] AATTAGCACATTATTTAGCGGGGTTTTGGGAATAGGTGTATA 
79[42] 53[48] GCAGACGGTGTACACGAACAA 
40[81] 39[81] TTAAGAGGCTGAGATAAGTGCCGT 
87[42] 90[49] CTGAAAGCGTAAGAAGATAGACACCAGTAATGGAT 
18[74] 85[74] ACAGTGCCACGCCATTAAACGGGT 
9[42] 8[28] CATATTCTACTTCTGAATAAATTTAATG 
41[28] 37[34] AATATTGCAAAGACGAAAATTAACGCAACATAAAG 
84[74] 84[63] AAAATACGTAAT 
51[2] 94[5] CATTCGCCATTCCCACCACAC 
2[34] 57[34] AAAACATATCATAGCCAGTCACGATTTT 
25[49] 27[48] ATAGTTGGAATTTCTTAAACATCAAAAA 
85[56] 15[74] AAGTTTCTGAGAGCTGCTGAATCAGTTGTTATCTAAAATATCTTTAG 
48[62] 2[56] CCACCAGCCGCCACAATTACCAAACATCCCTGAGC 
83[35] 16[28] CGCTCAAACTCCCCGGGTACCATATCCCATCCTATGAAGCTAATGCAGA 
64[74] 65[74] AGGGTTCAAA 
59[35] 2[35] ATTACAACATTATAGTTGAATACCAAGTGATTAGAATCCTTG 
10[55] 80[49] CACCAGATTTTAAACATGTTA 
8[74] 9[74] CAATATTCAT 
57[63] 49[81] AAAATTCGATTGTAATCAGAATCATTTGCCTCAGAGCCACCACCCTC 
32[48] 33[55] TTTTGACTTAGTACAAACTAC 
97[2] 96[2] CGTTATTCCT 
67[5] 35[13] GCTTTAAACTATTATAAAGCGGACGCAGTAGGAAACC 
24[62] 23[74] TATATTCCTTTTGCGGGATCGTCACC 
62[48] 60[35] CAAAGGCATATGATCCAATCAAGTTTGCCTTATTATCAGGTA 
7[2] 8[14] CAAATATATTTTAGTTAATATACCGA 
33[14] 74[9] AATAGCACAATAATGTCTGTCCCGAGATAGGGT 
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50[74] 50[63] ATCGGCCTCAGG 
89[14] 19[20] CTTTTCAGGCTTATTAGGAATAAGCAAGATTCCAA 
50[20] 54[5] CGGAAACAAGGCTTTAACAAAGCTGCTCAT 
92[78] 27[78] TTGCTGGTAAAATACCGAATAATATTGTATCG 
70[55] 34[49] ATAAATCAAAAGGTAGTTTCG 
23[2] 22[2] GAACGTCTAA 
92[13] 27[13] CAAAATCAGCAAGCAAAAATGAGTTACA 
50[62] 8[56] AAGATCGATAATTCACATTAACCATATCGATTGTT 
77[28] 31[34] ATTGCTCAGGTCAGCAAATTAAATTGAGTAATATC 
10[13] 82[7] TATCATAAAATTCTAAACGACAAGCTTGAATCATG 
8[13] 78[7] CCGTGTGCGTTAAAGCGAAAG 
6[41] 52[28] TTCAGCCAATCGCATCTGACCTACCCAAATCTTGAGATCGGT 
23[21] 88[21] GAACCTCTATAGAACCAGTGAGAGAGGC 
26[27] 29[27] GCGTCTTCAGCCATTTTTGTTGAGAGAA 
24[78] 90[63] GCCCACGCATAACCGAAATGACAGCTCAAT 
97[21] 51[20] GCTAAACGACGAGCACGTATATTAATGCCGCGTAAAGGCTGC 
63[14] 61[20] GACGACGACACTATGCAGATA 
52[27] 50[21] GCGGGCCGCAACTGCTGGTGC 
78[27] 10[14] GCTGGCTGACCTTGTAAGAATTGTTTAG 
81[2] 80[2] GTGCCGGCCA 
62[78] 45[81] CGGAGAGGGTAGCTATGCTGATAACAAATATCTCTGAATTTACCGTTCC 
9[28] 79[41] GGAATCACGCATAGAACGCCAGGGAGGC 
45[9] 59[20] GAAACCATCGATTGTAGCGGGCATTTTTGAGATACGAACT 
37[5] 70[14] TTAGCAAACGTAGAAACTTATTATTGCATCAATATCG 
26[69] 31[69] CTTGCTTGCCTTTAAATTTTTAACAACTTGCTAAATAAATGA 
75[63] 77[78] ATATGCAAATGCTGGGCTTAGAGCTTAATT 
42[41] 64[35] AAGGTGACCAGTAGATGAGGC 
89[2] 88[2] AGGGTGCGCC 
88[20] 18[14] GGTTTGCTCGTGCCGCCCGCTTGCCTAAACCAATC 
43[49] 68[49] GTAATAACCCCCTGACTTTTGACCAAAA 
2[74] 59[78] TCATTTCAATTAAAGAAAACAAAATTAACAATTAAGCCCCAA 
52[69] 51[74] GGATAGGGACGACGACAGT 
29[56] 89[62] AGAAAGGTCACGTTAAAAACGCGTCTGACACACGA 
47[56] 4[56] GTTGAGGGGTAATCGTTGATATAAGCAATCGCGCAACAATAA 
50[41] 6[42] TTCCGGCCACCAGATATTCATTAATGGAAGGGTTAGTAGATT 
47[9] 46[9] TCATCCGTTT 
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57[14] 6[2] TGAATTAGGTTTAATATATGTGAACGCGAGAAAACTTTTT 
74[27] 71[27] AATACGCCATCACGGATTAGACCGGAAG 
87[28] 21[34] TTAATGAATCGGACAATAATTGCGTTGCGCGCCCA 
76[34] 29[34] GATTTTAGAACAAGTTGTAGCTGATTAGAGACGGGTAACATA 
35[56] 97[69] TTTCAGGAACACTGGGCATCAAACCTGTTGCGGATTAGCTCATCTATCATGCCGTA 
29[14] 90[14] CTTTACATAACGTCGGTCCACTGGCCCT 
16[78] 83[78] CTCAATCAATATCTGGCCTCAAAAGCGATTACTAAAACACTCATCT 
12[34] 12[35] AGTAGGGGCATTTTCGAGCGATAATACAAATCCTTTGCCCAC 
34[78] 33[78] GGAACCCATTCCACAGAC 
83[5] 86[5] CATAGCTGTAAGCATACCTGGGGTTCCAGTCG 
68[74] 40[63] ATAAAGCTAAATCCAGGCGGACTCCT 
33[56] 75[62] AACGCCTGTAACGAGACCATTATATAACGTTTTAA 
9[2] 8[2] TAAGGATAAA 
32[69] 38[63] AGTTAGCGTAGCATGTACCGTGATAGCAACCCTCATAGTACCTATAAGT 
58[78] 57[78] AAACAGGAAGCATTAAAT 
39[9] 65[20] TATTTTGTCACACCCTGACAGTTCAGTGAATCCAGACTGG 
0[81] 1[81] CATTTAATTA 
60[74] 61[74] GAATCCAAGA 
63[35] 62[28] AGCGACATAACGAGGCATAGT 
37[49] 70[56] GTACTCAGGAGGTTGAACCGCAGCAATAACATCCA 
95[5] 76[5] CCGCCGCGCACGTGCTGAATCAGGCCAGAATC 
63[5] 64[2] CGTTTACCAAGAGGGGGTAAT 
70[27] 40[9] GACTTCAAAAAAGAGTCTTTAATCAATAAAAAGGGCGACATTCAACC 
4[55] 56[49] CGGATTCATGAATATAACCAA 
66[78] 41[81] CAAGGATAAAAATTTTAGCCTTTATAAACAATTCTGAAACATGAAAGTA 
30[27] 33[27] AGAATTATGAGCGCTTAAGCCATAGCTA 
27[35] 24[28] ATCCCAAGCCAACGCTTACTTGCAGGTTTTGAAGC 
24[27] 93[27] CTTAAATATTTTATCACCGCCGCTGGTTGGTTCCGTATTCTT 
92[55] 75[41] ATTACCGCCAGCAAATCACTTTCCCAATTCTGCCGAGTCCAC 
46[81] 63[78] TGATATTCACAAAATTAATGC 
20[48] 86[42] AAGATAAACGGCTAGAGGACT 
27[49] 25[62] AGGCTCCAAAAGGATCGAGGTCGCCGAC 
70[74] 69[74] GTAGTAGCATTAAAGCCTCAGAGC 
95[28] 94[35] CAGGGCGCGTACAGGCAAGTG 
2[55] 58[49] AAAAGAATACAAAAATATTTA 
49[42] 48[42] CGCCACCCTCAGAAAGCCGCCGCCAGGT 
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91[63] 73[74] CTCATGGATATCCAACTCAAATCATTCCAGATACATTTCG 
10[41] 81[34] GAATTATTACTAGACAACGCTTTTCCCAGACTCTA 
13[21] 8[21] GGCAGAGCTTAATTATAAAGCAAAAGCCAAACACCGTTTGAA 
28[48] 29[55] TCCAACAGGCGGAGTGAGAAT 
31[14] 92[14] GGGTAATACTGAACAAAAGAAAAATCGG 
27[14] 23[20] AAATAAATCCAGAGAGCTACACAAGATTTTTTAGC 
75[42] 92[56] TATTAAAGAACGATAGTTGATGCCTGAGTAGAAGAGAACAAT 
96[69] 95[62] TCGGAACCCTAAAGCCGGCGA 
81[49] 20[49] TTGTATCGCGCGAAATCACCTCAGCAGCGGCGGTCCCAGCAG 
3[2] 57[13] GAAGAGTCAATAAAAATCTATCATTG 
94[78] 95[78] AGGGAAGAAAGCGAAAACGTGGCGAGAAAGGA 
80[41] 10[42] GGAACGTCAGAACGTTATTAAAGGAGCG 
1[28] 61[41] GCTATTATAAATCACAACATTGAAAGATCCAAAAGGAATTTC 
45[28] 66[35] CCGTAATTTAGCAAAAAATCAATTATCAGAATGACCATAACCATAATCG 
74[81] 29[78] TGTCTGGAAGTTCTATCGGGGGATTTAAAGGAATT 
61[42] 47[48] AGGTCATTAGCATGGCCATTG 
69[49] 37[48] AAAATTACACCCTCAGAGCAACATCACC 
47[49] 66[49] ACAGGAGATTAAAGATTCAACACAGTCAGAGTAATCTCATAT 
16[27] 83[34] ACGCGCCAAAAATAGAGCTCGGTGAAATTGTTATC 
58[48] 0[42] AATTGCTTCATATGATGGAAA 
94[62] 10[56] GGAGCGGTTGAGGGTCACGTTGATTCTCAGGACAGTCAGATGAAGAAAC 
80[74] 79[69] CGAAATCCGCGAAACCGAA 
44[48] 44[49] GAGTGCCATTACCACAGTAGCGACAGAGAATGGAAGATACAG 
61[2] 60[2] CATTCTACCA 
73[42] 76[35] AGTAGATTATTTTCATTTGACCTTTTGATCAAAGG 
65[42] 43[48] AATGCCTAATCACCCATACTG 
21[7] 24[5] TTCATCGCCGGTATCGAGGCGAGTTGCTAT 
75[21] 77[27] CAGTTTGGACAGGAACCTTTA 
19[35] 85[48] CCAAGCAGAGGTGAAAATGAAACTTTTT 
49[28] 63[34] GCCTCCCCTTTTCATAGCCCCCTTTAGCCCAAAAT 
36[78] 35[78] AGAACCGCCAGCCCAATA 
44[62] 46[56] TTTTGATAGCGCAGAATCCTC 
69[2] 68[2] AAGCAGTCAG 
38[41] 68[35] TAAAAGACATATGGGAATCAA 
41[42] 41[41] TTATTTATTTCGGAAGGATTAGGATTTACCAGCGCACGGAAA 
29[35] 90[35] AAAACAGAATAAGAGCAGGCGATCTGAT 
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4 spacer Ts were added to all the strand termini (5’ or 3’ or both) that end at the edges of 
DN3. 
S3.3 Annealing DN1s and Characterization 
S3.3.1 Normal DNs 
By ‘normal’ DN we imply the DNs formed without any stabilizing agents except 
magnesium. All the structures were annealed in 5 nM concentration by mixing 5 nM m13 
scaffold and 10 fold excess of staples in 1X 3D buffer. The mixture was subjected to a 
thermal annealing program that heated the mixture initially at 95 C and gradually cooled 
down to 4 C over a period of 37 hours.  
S3.3.2 Stabilized DNs 
By ‘stabilized’ DNs we imply the DNs formed with at least one stabilizing agent in 
addition to magnesium. All the stabilizing agents used in this study are water soluble. 
While annealing the DN with stabilizing agents, each stabilizing agent was added to the 
mixture from an aqueous stock to achieve the desired concentration of the agent. 
S3.4 Characterization of DNs 
All the DNs used in these study have been characterized by TEM images from negatively 
stained samples. The detailed protocol for the TEM imaging is described below. 
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S3.4.1 Preparation of uranyl formate stain 
0.7 uranyl formate stain was prepared following the described procedure. 7.4 mg 
uranyl formate was weighed in a glass vial containing a stir bar. 1 mL of hot water was 
added to it and stirred for five minutes in dark. After that 10 uL of 2M aqueous sodium 
hydroxide was added and again stirred in the dark for another five minutes. The solution 
turned bright yellow. The resulting solution was filtered using a spinX column. The uranyl 
formate stain was prepared freshly before each imaging experiment.  
S3.4.2 Preparing TEM samples  
All the samples used in this study were negatively stained. 2 uL of each sample was 
deposited on a plasma-cleaned TEM grid (cleaned for 1 minute). The sample was soaked 
using a Whatman 2 filter paper after 2 minutes of deposition and the grid was washed twice 
with 10 uL water each time. Then 7 uL of freshly prepared uranyl formate stain was 
deposited on the grid, kept for 3 s, removed using filter paper and another drop of 7 uL 
uranyl formate stain was placed on the grid. It was removed using a piece of filter paper 
after 15 s. The sample was dried properly in open air for 30 minutes.  
S3.5 Time vs Stability Experiments 
Each DN was formed in 5 nM concentration using 1X 3D buffer that contained 16 
mM Mg2+. The control structures were formed without any stabilizing agents while the 
other structures were formed using the buffer containing the maximum amount of 
stabilizing agent (determined previously) that allowed the formation of DNs. Then the 
buffer of each DN was exchanged with the physiological buffer containing 1.2 mM Mg2+ 
205 
 
along with other cations. 100 kD molecular cut off filters were used for this purpose. 6 uL 
of each sample was taken out at each time point and three replicate samples were prepared 
for TEM following the protocol described in the previous section. 
S3.6 Counting of DNs 
S3.6.1 Internal standard for counting 
30 nM gold NPs were used as internal standards while counting the number of 
structures. The stock concentration as bought from the company contained 2.0 x 1011 
particles/mL that was concentrated ten times using 30 kD molecular cut-off filter and the 
resulting stock contained 2.0 x 1012 particles/mL. 
 
Figure S3.7: TEM image of concentrated gold NP solution (2.0 x 1012 particles/mL). 
(Scale bar = 100 nm) 
S3.6.2 Preparation of TEM samples for counting 
We used the concentrated AuNPs as internal standards for counting the structures. 
During the TEM grid preparation, there are several steps that can be broadly grouped in 
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the following sequence: a) deposition of sample b) washing the excess buffer c) staining. 
The addition of internal standard introduces another step and we had to optimize where 
this step could be introduced in the sequence. Following were the possibilities in hand: a) 
Deposit the AuNPs first before deositing the structures. We tried this, but when exposed to 
the physiological buffer the AuNPs got aggregated on the grid making their counting 
impossible. b) Deposit the AuNPs after the sample. When this was done, the AuNPs 
affected the staining of the particles and all the structures failed to produce properly 
recognizable contours when imaged. c) The AuNPs were deposited after staining, but when 
the excess AuNPs were removed using a piece of whatman filter paper, a part of the stain 
was also removed in the process and this made the structure positively stained that was not 
our requirement. So after all these trials, we depositied the AuNPs in between the two 
staining steps, that is after tha application of first aliquot of the stain, we placed 2 uL of the 
AuNP solution on the grid and let it deposit for 1 minute. After that the next aliquot of stain 
was applied and the step was completed as described in section S3.4.2. 
S3.6.3 Counting procedure 
We obeyed the following rules while counting: a) any structure that seemed to be 
deformed or did not match with the dimensions of the DN under study, were not taken into 
counting, b) any AuNP that aggregated beyond individual recognition were exempted from 
counting, c) any DN or AuNP that appeared partially on the image frame were not counted, 
d) there were frequent aggregates of DNs that might be due to the TEM sample making 
procedure or aggregation with time; for counting purposes we considered only the DNs 
that showed a proper contour and the full structure was recognizable. Otherwise, the whole 
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aggregate was left uncounted, e) the AuNPs bought from the company had some non-
spherical NPs (though negligible in percentage) mixed with the spherical NPs; those 
particles were also included while counting the standards, f) three replicates of each sample 
(each structure each time point with a particular stabilizing agent) were taken into 
consideration, and g) more than ten images were counted for each sample. 
S3.6.4 Illustration of the counting procedure 
The procedure for counting one structure (DN1) without any stabiliaing agent and 
with one stabilizing agent (1 mM arginine) is shown below. The exact protocol was 
followed for all counting experiments. One point has to be kept in mind that the numbers 
correcponding to the TEM images below are representative only. The actual numbers that 
were used to construct time vs stability plots came from thirty images for each time point. 
The images illustrate the various situations that were encoured during the process of 
counting like non-homogenous AuNPs, AuNP aggregates, Dn aggregates, deformed DNs, 
etc. The density of DNs probably decreases with time and hence gradually they lose the 
capability to provide good contrast in the images.  
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Figure S3.8: TEM counting of DN1 formed without any stabilizing agent subjected to 
physiological buffer. a) 0 min (19 DN1, 8 AuNP b) 20 min (17 DN1, 14 AuNP) c) 40 min 
(16 DN1, 26 AuNP), d) 60 min (7 DN1, 32 AuNP) e) 90 min (8 DN1, 10 AuNP) f) 120 
min (8 DN1, 4 AuNP) g) 180 min (0 DN1, 1 AuNP), and h) 240 min (0 DN1, 5 AuNP)  
(Scale bar = 100 nm) 
209 
 
 
Figure S3.9: TEM counting of DN1 formed with 1 mM free arginine subjected to 
physiological buffer. a) 0 min (19 DN1, 14 AuNP b) 20 min (12 DN1, 11 AuNP) c) 40 min 
(12 DN1, 29 AuNP), d) 60 min (9 DN1, 29 AuNP) e) 90 min (11 DN1, 36 AuNP) f) 120 
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min (6 DN1, 37 AuNP) g) 180 min (17 DN1, 5 AuNP), and h) 240 min (0 DN1, 7 AuNP)  
(Scale bar = 100 nm) 
S3.7 Determining half-lives of DNs 
S3.7.1 Procedure for calculation 
The AuNPs served as internal standards for counting and we calculated the number 
of intact DNs per 100 AuNPs and constructed the time vs number of each DN sample. 
Using Prism 5 software from Graphpad, the plots were fitted with one phase exponential 
decay (non-linear fitting) and the half-lives were obtained.  The half-lives thus obtained 
provided an indication of the efficiency of each stabilizing agent and their combinations.  
S3.7.2 Illustration of half-life calculation 
The construction of time vs stability plots for DN1 without any stabilizing agent 
and all the stabilizing agents separately and their combinations are shown below. 
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Figure S3.10: Time vs stability plots of DN1 formed with a) no stabilizing agent b) free 
arginine c) free lysine d) free bis-lysine, and e) hexamine cobalt.  
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Figure S3.11: Time vs stability plots of DN1 formed with a) free arginine + lysine b) free 
arginine + hexamine cobalt c) free lysine + hexamine cobalt, and d) free bis-lysine + 
hexamine cobalt.  
S3.8 Melting Temperature Study 
The melting points of DNs were determined using a time vs fluorescence method 
using a PCR instrument. 50 uL of each DN formed with or without stabilizing agents were 
mixed with SYBR green (the solution is made 2X with respect to SYBR green). The 
mixture was first heated from 25 C to 80 C and then cooled to 25 C, the complete thermal 
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program being of 19 hours. The plots were normalized and the melting points were 
obtained from the first derivative plot. Three sets of sample plots for DN1, DN2 and DN3 
controls are shown below.  
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Figure S3.12: Heating and cooling curves a) DN1 c) DN2 e) DN3. Derivative plots. b) 
DN1 d) DN2 f) DN3. 
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APPENDIX C 
SUPPLEMENTAL NFORMATION FOR CHAPTER 4 
BUILDING SERUM ALBUMIN-COATED DNA NANOSTRUCTURES FOR IN VIVO  
APPLICATIONS 
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S4.1 Materials and Instruments 
All DNA strands were purchased from Integrated DNA technologies. The strands 
for DNO were bought in 96 well plates and used without any further purification. Rest of 
the strands were purified using 10% denaturing polyacrylamide gels prior to annealing 
structures. DBCO-NHS ester was bought from Click Chemistry Tools. Anhydrous DMSO 
was purchased from Life Technologies. All the linear and branched PEG-azides were 
bought from Creative PEGWorks. DSPE-PEG (2000) Azide was bought from Avanti Polar 
Lipids. Propidium iodide and CellTracker CM-Dil dye were bought from ThermoFisher 
Scientific. RAW264.7 cells used in the cellular uptake study were bought from ATCC. 
FBS that was used to supplement DMEM cell culture medium was purchased from Gibco 
Life Technologies. Mouse serum was purchased from Sigma Aldrich. DNase I, Bovine 
Pancreas was purchased from Gold Biotechnology. Recombinant Human Clusterin alpha 
chain protein was purchased from Abcam. All the other chemicals that are not mentioned 
here were bought from Sigma-Aldrich. 
For the organic synthesis experiments, all solvents and reagents were obtained from 
Sigma–Aldrich, TCI America and Matrix Scientific and used without further purification. 
Analytical thin-layer chromatography (TLC) was performed on aluminum plates precoated 
with silica gel, also obtained from Sigma–Aldrich. Column chromatography was carried 
out on Merck 938S silica gel. Proton and carbon NMR spectra were recorded with a Varian 
400 MHz NMR spectrometer. Spectra were referenced to the residual solvent peak, and 
chemical shifts are expressed in ppm from the internal reference peak. All compounds 
described were of >95% purity. Purity was confirmed by analytical LC/MS recorded with 
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a Shimadzu system. Elution started with water (95%, +0.1% formic acid) and acetonitrile 
(5%, +0.1% formic acid) and ended with acetonitrile (95%, 0.1% formic acid) and water 
(5%, 0.1% formic acid) and used a linear gradient at a flow rate of 0.2 mL/min. The 
molecular ions [M]+, with intensities in parentheses, are given, followed by peaks 
corresponding to major fragment losses. Melting points were measured with a MEL-TEMP 
II melting point apparatus and are reported uncorrected. 
Live cell confocal microscopy was done using the Confocal laser scanning 
microscope Leica TCS SP8. Flow cytometry studies were conducted using the S1000EXi 
flow cytometer coupled with the CellCapTure software from Stratedigm. The cytometry 
data were analyzed using the Flowjo v10 software from Flowjo, LLC and plotted using the 
Prism 5 software from Graphpad. For the time vs stability experiments, the band intensities 
of gels were measured using the ImageJ software. 
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S4.2 Synthesis of AAM 
S4.2.1 Schematic of the organic synthesis 
 
Figure S4.1: Scheme showing the synthesis of AAM (SP141C). 
S4.2.2 Synthesis and characterization of the intermediate SP52D 
To a suspension of 10% palladium on carbon (25 mg) in THF (8 mL) was added a solution 
of 4,4-diphenyl-2-cyclohexen-1-one (500 mg, 2mmol) in THF (2 mL). The round-bottom 
flask was flushed with hydrogen gas, and the system was sealed under a hydrogen 
atmosphere (1 atm) and stirred vigorously for 24 h. The reaction mixture was filtered 
through Celite, and filter cake was washed with THF (2 x 5 mL). The filtrate was cooled 
down to 0 oC in an ice bath and was treated with sodium borohydride (20 mg, 0.52 mmol). 
Sodium borohydride was first dissolved in 0.1 M aqueous NaOH (2.5 mL) and cooled to 0 
oC, and then added dropwise to the reaction mixture. The reaction was warmed to room 
temperature and stirred overnight. The reaction was cooled again to 0 oC, and quenched 
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with 3 M aqueous HCl (~2 mL). The mixture was stirred for additional 1 hour in ice bath, 
and white precipitate formed. The precipitate was filtrated, filter cake was washed with 
ice-cold water and dried in lyophilizator. The crude was recrystallized in absolute ethanol, 
yielding intermediate SP52D as a white solid. 
4,4-diphenylcyclohexan-1-ol (SP52D) 
Yield 84%, 420 mg, white solid. 1H NMR (400 MHz, CDCl3): δ 7.31-7.11 (m, 10H), 3.79 
(m, 1H), 2.63 (d, J = 14 Hz, 2H), 2.09 (t, J = 11.2 Hz, 2H), 1.85 (s, 2H), 1.57-1.51 (m, 3H); 
13C NMR (100 MHz, CDCl3): δ 148.5, 146.9, 128.5, 128.3, 127.5, 126.7, 125.8, 125.7, 
69.7, 45.7, 33.8, 31.7.  
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Figure S4.2: 13C NMR for SP52D. 
 
Figure S4.3: 1H NMR for SP52D. 
S.4.2.3 Synthesis of albumin-attracting molecule SP141C  
Ethyl 6-hydroxyhexanoate (0.5 mL, 3.12 mmol) and diisopropylethylamine (1.03 mL, 6.25 
mmol) were dissolved in CH2Cl2 (10 mL) and stirred under argon atmosphere. Dropwise 
was added a solution of 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite (0.87 mL, 
3.9 mmol) in CH2Cl2 (2 mL), and the reaction was stirred overnight at room temperature. 
The reaction was washed with saturated aqueous sodium bicarbonate (25 mL), dried over 
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anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude 
material was purified by flash chromatography (9:1 hexane/EtOAc with 0.1% Et3N) to 
yield the product SP113C as a clear liquid. 
Ethyl 6-[(2-cyanoethyl)(N,N-diisopropylamino)phosphino]oxyhexanoate (SP113C)  
Yield 38%, 430 mg, clear liquid. 1H NMR (400 MHz, CDCl3): δ 4.12-4.06 (m, 4H), 3.82-
3.75 (m, 2H), 3.63-3.53 (m, 2H), 2.61 (t, J = 6.4 Hz, 2H), 2.30-2.25 (m, 4H), 1.67-1.58 (m, 
6H), 1.41-1.35 (m, 4H), 1.29 (d, J = 6.4 Hz, 4H), 1.25-1.19 (m, 12 H), 1.15 (t, J = 6.8 Hz, 
9H); 13C NMR (100 MHz, CDCl3): δ 173.7, 173.5, 117.7, 63.5, 63.4, 63.1, 60.3, 58.4, 58.2, 
46.2, 45.9, 43.1, 34.3, 34.1, 30.9, 30.5, 25.6, 24.7, 23.6, 22.4, 20.4, 14.3, 11.6. ESI-MS: 
[m/z+H]: 361. (REF 1) 
Ethyl 6-[(2-cyanoethyl)(N,N-diisopropylamino)phosphino]oxyhexanoate, SP113C (340 
mg, 0.94 mmol) and 4,4- diphenylcyclohexanol, SP52D (250 mg, 1 mmol) were dissolved 
in acetonitrile (10 mL). A solution of 1H-tetrazole in acetonitrile (70 mg, 1 mmol) in 
acetonitrile (2 mL) was added, and the reaction mixture was stirred at room temperature 
under argon atmosphere overnight. A 70% w/w aqueous solution of tert-
butylhydroperoxide (1.3 mL, 10 mmol) was added, and the reaction stirred for an additional 
2 h, then concentrated under reduced pressure. The resulting residue was concentrated, 
dissolved in ethyl acetate (25 mL), transferred to separatory funnel and washed with 10% 
solution of Na2S2O3 (2 x 25 mL), followed by washing with saturated aqueous NaHCO3 
(25 mL) and brine (25 mL), dried over anhydrous sodium sulfate, filtered and concentrated 
under reduced pressure. The crude material was purified by flash chromatography (1:1 
hexanes/EtOAc with 0.1% Et3N) to yield a colorless oil. This intermediate was treated with 
2 M ammonia in methanol (10 mL) and stirred at room temperature under argon 
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atmosphere overnight. The reaction was concentrated, and the resulting oil was dissolved 
in THF (10 mL) and cooled to 0 oC in an ice bath. A 2M aqueous solution of lithium 
hydroxide (5 mL) was added, and the reaction was warmed to room temperature and stirred 
overnight. The reaction was concentrated and the solution was acidified to pH=2 with 2M 
aqueous HCl, forming a white precipitate that was extracted with ethyl acetate (3 x 25 mL). 
The organic fractions were combined, dried over anhydrous sodium sulfate, filtered and 
concentrated to yield the product SP117C as a clear, colorless oil. (REF 2) 
7-((((4,4-diphenylcyclohexyl)oxy)(hydroxy)phosphoryl)oxy)heptanoic acid (SP117C) 
Yield 30%, 125 mg, clear, colorless oil. 1H NMR (400 MHz, CDCl3): δ 8.73 (s, 1H), 7.24-
7.20 (m, 8H), 7.13-7.10 (m, 2H), 4.44-4.43 (m, 1H), 3.96 (q, J = 6.8 Hz, 2H), 3.73 (t, J = 
6.8 Hz, 2H), 2.56-2.51 (m, 2H), 2.29 (t, J = 7.6 Hz, 2H), 2.20-2.14 (m, 2H), 1.89-1.78 (m, 
7H), 1.66-1.56 (m, 4H), 1.42-1.36 (m, 2H). 13C NMR (100 MHz, CDCl3): δ 178.8, 147.2, 
146.7, 128.5, 128.4, 127.0, 126.9, 125.8, 125.8, 68.0, 67.2, 67.2, 45.5, 33.9, 32.7, 29.9, 
29.8, 29.3, 25.6, 24.9, 24.2. ESI-MS: [m/z]: 446. 
Carboxylic acid SP117C (64 mg, 0.14 mmol) was refluxed 6 hours in neat SOCl2 (5 mL). 
Thionyl chloride was evaporated and acid chloride SP127C was used for the next step 
without further purification.  
Acid chloride SP127C (46 mg, 0.1 mmol) was dissolved in CH2Cl2 (5 mL) and Et3N (40 
μL, 0.3 mmol) was added, followed by addition of solution of O-(2-Aminoethyl)-O′-(2-
azidoethyl)heptaethylene glycol (44 mg, 0.1 mmol) in CH2Cl2 (2 mL). Reaction mixture 
was stirred at room temperature overnight under argon atmosphere. Reaction was 
concentrated under reduced pressure and resulting crude product loaded on column and 
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flash chromatography was performed in 0-5% methanol:dichloromethane solvent system. 
Final product SP141C was obtained as colorless thick oil. 
 1-azido-28-oxo-3,6,9,12,15,18,21,24-octaoxa-27-azatritriacontan-33-yl (4,4-
diphenylcyclohexyl) hydrogen phosphate (SP141C) 
Yield 38%, 33 mg, clear, colorless thick oil. 1H NMR (400 MHz, CDCl3): δ 7.23-7.19 (s, 
8H), 7.09 (s, 2H), 4.32 (s, 1H), 3.86 (s, 4H), 3.62-3.51 (m, 32H), 3.38-3.35 (m, 4H), 2.49 
(s, 2H), 2.13 (s, 3H), 1.81-1.57 (m, 6H), 1.33-1.23 (m, 2H). ESI-MS: [m/z+1]: 867. 
 
Figure S4.4: 13C NMR for SP113C. 
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Figure S4.5: 1H NMR for SP113C. 
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Figure S4.6: 13C NMR for SP117C. 
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Figure S4.7: 1H NMR for SP117C. 
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Figure S4.8: 1H NMR for SP141C. 
REF 1: S. Raddatz, J. Mueller-Ibeler, J. Kluge, L. Wab, G. Burdinski, J. R. Havens, T. J. 
Onofrey, D.Wang, M. Schweitzer, Nucleic Acids Res. 2002, 30, 4793. 
 
REF 2: ChemMedChem. 2014 Oct;9(10):2223-6. doi: 10.1002/cmdc.201402212. Epub 
2014 Jul 23. 
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S4.3 Details of Td and DNO structures 
S.4.3.1 Td 
S4.3.1.1 Strands for Td 
Strand 1: AGG CAC CAT CGT AGG TTT C TTG CCA GGC ACC ATC GTA GGT 
TTCT TGC CAG GCA CCA TCG TAG GTT T CTT GCC 
Strand 2: CAG AGG CGC TGC AAG CCT ACG ATG GAC ACG GTA ACG ACT 
Strand 3: AGC AAC CTG CCT GTT AGC GCC TCT GTT TTT TCG ATC ACG TAG 
CAC AGC AT 
Strand 4: /5Alex488N/TTA CCG TGT GGT TGC TAG TCG TT 
The complementary of the single stranded handle (labeled in red) with strand 3 was named 
strand 5 and it had an amine modification at the 5’ end.  
Strand 5: /5AmMC12/AT GCT GTG CTA CGT GAT CGA 
The Alexa fluor 488 dye was attached to strand 4 for flow cytometry studies. For all other 
experiments the unlabeled strand was used. 
S4.3.1.2 Schematic for Td 
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Figure S4.9: Schematic showing one unit of Td. 4 similar units assemble together through 
sticky end hybridization to build up the complete Td.  
231 
 
S.4.3.2 DNO 
S4.3.2.1 Schematic for DNO 
 
Figure S4.10: caDNAno image of DNO. a) DNO b) caDNAno image showing the 
arrangement of double helices constituting DNO. 
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Figure S4.11: caDNAno design of DNO. 
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S4.3.2.2 Sequences for DNO 
Start End Sequence 
16[111] 15[111] CATATGTATTTTAACC 
20[111] 11[111] TAAAAATTAGCGCCAT 
13[16] 1[23] AGAGATAGTAGAGCTTATCAAGTT 
38[39] 40[24] GACCGTGTTGTTTAGTAAAGCCAACGCTCAAC 
50[63] 61[79] GAGCGTCTGCAAGGCCGGAAACTCAGAGCCGC 
11[16] 3[23] ATTTTGACGCGCGTAAGAGAAAGG 
58[63] 52[48] TGCCTAACGCAAAGACGAGGGAGGCATAAAAA 
44[103] 53[103] AGCATCGGAAAATACGAACCCATGACCCTCAT 
50[79] 35[79] ATTTTCTGGCTTGCAGGCTACAGAGCTCATTA 
59[8] 58[8] TTACCAGCTAGAAAAT 
29[16] 17[23] TTACAAAAACCTCAAACCGCCTGC 
60[87] 49[87] CCTTGATACACCAGAAGTAAATGACAACAGTT 
3[88] 13[95] GGGTGGTTCACCGCCTGATTGACC 
29[8] 28[8] ATACCAAGTCGCCTGA 
35[64] 51[63] AAGAACTGGGCTTTGAGGACTTCCTTTACAGA 
60[79] 43[79] TTCACAAAGCCTGTAGTTCGTCACTGAGGAAG 
60[71] 61[55] CAAATAAATCCTCGGTAAATATTGTACCATTA 
28[71] 36[64] GAGCTTCAGTCAGGATTAATCATT 
62[111] 49[111] CAGAGCCGAGAAAGGA 
51[8] 52[8] AAATAAGAAACACCCT 
20[39] 25[39] ATCTTTAGAAGTATTACAAAATTATGGAAGGG 
48[103] 61[111] GAATAATAGTGAGAATCCACCCTCAGAGCCGCCGCCAGCA 
15[80] 0[72] AAATTTTTAGTGTTGTTCCAGTTT 
2[71] 11[71] CAGCAAGCAGGCGGTTGACGACGACAGCTTTC 
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53[8] 54[8] CAGAGGGTAAGCCCTT 
46[63] 63[63] ATATACACACGCTAACGCTCCAAAAGCGTTTG 
50[111] 45[111] GTTTTGTCATCGTCAC 
32[23] 32[8] ACCTTGCTTCTGTAAA 
33[40] 16[48] ATAGCGATAGCTTTACGAGAATGATAATGGAACAAATATT 
7[48] 6[56] CTGTCCATAGCTCGAAGCGGGAGC 
32[79] 17[79] ACCAAAATGAGGGGGTAATGCTTTAGCAAACA 
56[39] 57[23] CCCAAAAGAACTGGCATGATTAAGAAACGTAG 
22[23] 10[16] CGAACGTTACATTTGATGCAACAG 
42[47] 26[48] TAAAGTACACCTAAATTTAATTACCAACTAAA 
51[80] 34[80] CATTCCACTAGCAACGGGAGTTAAACAGGTAG 
19[80] 1[87] GACAGTCATCTGCCAGAAACGGCGGGCCCTGATTGATGGT 
3[24] 17[31] AAGGGAAGCCCCGATTAACCCTTCCAATATTTAACAGTGC 
55[24] 58[24] AACAAAGTAATAGCTAAAAATACAATTTTGTC 
42[39] 55[39] CGACAAAATTAGGCAGGAAATAGCTACCAGAA 
30[111] 17[111] AATCGTCAAAAACTAG 
41[64] 56[64] AGCGATTACAGAACCGTCAGTACCGGATTAGG 
36[103] 42[96] AAATTGGGCTTGCCCTTAAAACGA 
5[8] 6[8] CTTAATGCTACGCCAG 
19[56] 30[56] TTCAAAAGAGGCTATCCAAAAATCCAGAAAAC 
43[8] 42[8] ACAACATGCCAGACGA 
15[8] 14[8] GCGAACTGCTATTAGT 
62[23] 48[8] CAGAATCAGCGCGTTTGAGGTTTTGAAGCCTT 
30[103] 35[103] TAAATATTAAAGCGGAACGGAACAGGGAAGAA 
16[79] 2[72] CCAAAAACTTCGCATTGTAGCCAGAATCCTGTGAGAGTTG 
22[103] 24[96] GCAAAGAATAGCATTAACATTTCG 
38[71] 40[56] ACAAGAACCATAAGGGCGGAACGAGGCGCAGA 
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2[63] 31[63] GGTCCACGACCCGTCGAACATTAATTGCCTGATGTATAAGAAAAGAAG 
18[47] 12[40] AAATCTAAAAGCGTAATTACATTG 
23[80] 6[80] ATTCTACTGCAGGTCGGTAACGCCAAAGTGTA 
27[32] 37[39] GAATATACATGCAAATATCTTCTG 
36[23] 28[16] AAGACAAACTTTTTAATAACGGAT 
36[31] 44[24] CCAATCGCATGCAGAACCTAATTT 
21[48] 4[40] AAACACGGGCTGGCGAAAGATCGCCAAAGGGCGCTGGCAA 
52[31] 60[24] ACGGGAGACAAAAGGGAAAGGTGA 
50[55] 32[48] TTCCAGAGTCTTACCATCATCGAGTAAGAACGACAGTACA 
31[8] 30[8] AATTAATTAAACATCA 
1[88] 15[95] GGTTCCGATAGGGTTGGTTAAATC 
55[8] 40[16] AGTAAGCAGATAGCCGAGTAGGGC 
51[32] 59[39] ACGTCAAATATTCATTCGACATTC 
35[48] 18[48] AACTATATCAGACCGGCCATAAATAGGATGAA 
36[87] 29[87] GGTTTAATTACCAGTCTATCGCGTTATTATAG 
50[47] 35[47] CCTAATTTGGTATTAAAAAAATAAGGTTATAT 
59[40] 53[47] AACCGATTACCACGGATAACCCAC 
5[96] 9[103] TAACTCACCAACTGTTCCCAGTCA 
41[16] 26[16] AACGCCAAAGGCGTTATATTTTAGTAAAACAG 
22[79] 7[79] ATAAAGCCTAAGTTGGACTCTAGACATGGTCA 
36[79] 21[79] TTCAACTTTAGAGAGTGTAGCTCAATGACCCT 
61[8] 60[8] ATTTGGGACGTCACCG 
18[39] 28[32] AGCATCACCAGTTGAAACATCGGG 
23[8] 5[23] GAGTAACATTATCATTTGATTAGTGAACTCAAAGGAACGGGCCGCTAC 
28[79] 10[72] TTTAATTCAGGCCGGATGCAATGCCGGCACCGGCGGGCCT 
5[24] 12[24] AGGGCGCGGTCACGCTGCTCAATCACCAGTCA 
8[55] 5[55] CACGCAAAAAGGGGGATAAACAGGACGAGCAC 
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18[79] 4[72] TTTGAGAGGTGGGAACTTTGAGGGTGCGTATTTGCCAGCT 
24[47] 23[55] TCATATTCCCACCAGAAGGAGCGG 
57[40] 55[47] GGTGGCAAACGGAATAGGAAACCG 
53[88] 60[88] GAGCCACCTACCGTAATGAATTTAACGATTGG 
6[111] 8[96] ACACAACATACGAGCCGAAATTGTCCAAGCTT 
46[87] 32[80] ACAACCATATCAGCTTCGATAAAA 
15[96] 17[103] AGCTCATTCCCCGGTTGTAATCGT 
27[56] 34[56] TCCAACAGAAGCGAACGCGATTTTAGATTTAG 
3[40] 3[63] AGGAGCGGGCGCTCGCGCGGGGAG 
53[80] 43[87] CACCCTCAAAAGAATATTTCCATT 
20[71] 25[71] CTGAGTAAAAAACATTACATGTTTTTTCATTC 
7[24] 9[31] AGTGAGGCTTTTAGACACTATCGG 
47[32] 61[39] GGCTTATCACCTCCCGACAATTTTCCGTAATCTCACCAGT 
30[95] 47[103] CATTGAATAAGGAATTCCAGACGAGCTTTCGAGGTGAATT 
49[24] 63[39] ACCCAGCTACTTGCGGTCATCGGCATTTTCGG 
54[95] 58[88] CAGGAGGTTGCCCCCTAGTGTACT 
0[39] 13[39] TCCAACGTTCGAGGTGGGCACAGATGACCTGA 
55[56] 57[71] GGTTTTGCCCAATAATAGATGAGTAACAGTGC 
33[8] 34[8] TTAATTAACAAAATCA 
0[111] 1[103] AAAGAATAGCCCGAGAAATCGGCA 
7[80] 21[95] TAGCTGTTTCCTGTGTGGAAGCATAGGGTTTTGGGAAGGGTTTGCGGG 
44[111] 35[111] CGAAAGACAAATCTAC 
27[16] 12[16] AGGTTTAAACAACTAATCAGTTGGCACGACCA 
41[72] 39[79] TACCAAGCTACTTAGCAACCGAAC 
6[79] 8[64] AAGCCTTAGAATCAGATTCGTAATGGATCCCC 
45[56] 51[71] CCGTTCGGTCGCTGAGTATGGGATACTACAAC 
51[48] 34[48] TAGCAGCCTGAACAAGACCAAGTAGAAAGATT 
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37[64] 53[63] ACGTAACACACTCATCTTTGAATAAGTTAAGC 
14[95] 31[95] CGCGTCTGGATGAACGGATAATCAAATGTTTA 
58[87] 52[80] GGTAATAAGCAGTCTCCACTGAGT 
27[48] 12[48] AAGCAAACTAAGGTTAAGGAAAGAGCCTCAGG 
34[95] 49[95] ACATTATTAGGCCGCTCAATGACATCAGCGGA 
36[47] 21[47] AAATGCTGAGTAACAGTACCATATGACTTTAC 
54[23] 43[23] TCTTACCGAATTGAGCAATTCTGTTTCAGCTA 
9[56] 20[56] TGTGCTGCTTACGCCATTGTACCATGTGTAGG 
51[96] 59[103] CTCATAGTCAGGTCAGCCGTTCCA 
39[48] 22[48] CGTTATACAATTATCAGTACGGTGAATATTCG 
13[64] 19[71] GATTCTCCATCTACAAGGTGAGAA 
33[32] 50[32] TTGAAAACAGCCGTTTCAAGAACGGCCAGTTA 
60[111] 51[111] GGTTGAGGTAGCGTAA 
36[63] 43[71] GTGAATTAAAGAAAGACTTTTTCA 
22[39] 24[32] TATTAAATCAAAGAAACTGATTAT 
42[79] 23[79] CACTAAAAAAGCTGCTTAATCTTGCATATAACTGTTTAGCTGGCATCA 
35[32] 52[32] TTAGGTTGTATCCCATCGCGCCTGCGCATTAG 
14[103] 18[96] AAATAATTGTAATGGGTTAATGCC 
12[95] 29[95] ACCGTGCAAATCACCAGGAGAGGGTCAGAAGC 
8[95] 26[88] GCATGCCTAATAGTAGTTAGCAAACCCAATTCTGCTGAAT 
10[31] 28[24] CCAGCCATGGATTTAGGAGCACTACGTCAGATAGAAACAA 
24[95] 42[88] CAAATGGTTTTGAAAGTGACCTTCAAGTACAAAAGAGGCA 
15[48] 0[40] GTAAACGTATTAAAGAACGTGGAC 
24[71] 41[63] TATATTTTCATTTGGGCGGTCAATCGGATATTGTACCCCC 
29[32] 34[32] AGGCGAATGAGAAGAG 
37[88] 44[88] GAATAAGGCTTGAGATAAACGGGTAACGAGGG 
2[39] 11[39] AAGGGAGCAAAGCGAAGCAGATTCGTCTGAAA 
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53[48] 36[48] AAGAATTGAGAGAATACAATAGATCCTTATGT 
4[39] 9[39] GTGTAGCGTACTATGGTATTACCGCCTTGCTG 
39[104] 39[111] TGAACGGT 
63[40] 49[47] TCATAGCCTAGCAGCAATCCTGAA 
54[47] 39[47] GAAACAATAGGCATTTACCAGTATATCATATG 
48[95] 63[111] ATTTTTTCCGGAACCAGAGCCACCACCGGAAC 
19[24] 30[24] CAAATCAACTTGCTGATCGCGCAGAAGAAGAT 
1[40] 15[63] CCGTAAAGCACTAGTTTGCCCCAGAGTCCACTTAATATTT 
13[48] 2[40] GAGTAACACTGAATCGGAACCCTA 
51[24] 62[24] TTTGTTTACAAAATAACAGCAAAAAGTAGCGA 
56[63] 54[48] ATTAGCGGCAATAATACATATAAAAAGAGCAA 
20[47] 6[40] TCTAAAATTGGATTATCAGAACAATTGCTTTGAGGCCGAT 
59[72] 54[72] TGGAAAGCGTTTTAACAGAACCGCGCCACCCT 
0[71] 14[64] GGAACAAGCAGGCGAACTTTCATC 
31[64] 46[64] TTTTGCCAAGCGAGAGACTAATGCCATAACCG 
20[95] 35[95] CCTCATATTTGCTCCTACTTCAAAAGGACGTT 
39[96] 55[95] AGGACAGACGAAATCCGCGACCTGTCGAGAGG 
19[96] 27[103] TCAATATGCCCGAAAGTTTGATAA 
41[96] 56[96] CGGAGATTACCGTACTGTTGATATAAGTATTA 
22[47] 7[47] ACAACTCGGTAATATCTTAACCGTAAAAGAGT 
33[24] 47[31] TAGAATCCAGTGAATAATATAGAA 
51[88] 62[88] AGACAGCCAGACGTTACCACCACCAGAACCGC 
16[31] 32[32] CAGCAGAACAATTTCATTTGAATTTATATGTG 
25[24] 37[31] CTGAATAATTTGCACGTTAATTTC 
45[16] 30[16] TCTTTCCTGAATTTATTTTTCCCTGATGAAAC 
19[8] 20[8] ATATCTGGTAGATTAG 
36[111] 27[111] CGAGTAGTGAGGTCAT 
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35[24] 46[24] CCTCCGGCTCAATAGTTATCATTCTTATTTTC 
47[64] 62[56] TTAATTGTAAAAAAAGTTTGCTAAACCCGTCACCAATGAA 
5[72] 11[95] TCGTGGGGTGCCTAATGAGTGAGCGTCGGGAAGCCGGAAA 
21[96] 38[96] AGAAGCCTAGCTTAATTGCGAACGAGGCTGGC 
16[47] 30[32] TAACCGAACGAACCACCACGCTGACTGAGCAA 
11[80] 3[87] CTTCTGGTACCTGTCGGGGCGCCA 
58[23] 44[16] ACAATCAAGCCAAAGAATTAACTGAACGATTTACGAGCAT 
56[95] 54[80] AGAGGCTGAGACTCCTACAGTTAATTAGTACC 
34[47] 19[47] AAGACGCTTATTCATTTACCTTTTAGGAATTG 
63[64] 49[79] CCATCTTTTCATAATCGAGCCACCACAACTTT 
33[56] 47[63] CACATTCAGCTTTTGCAGGAGCCT 
58[103] 57[111] GATACAGGGCCTATTTCGGAACCT 
62[87] 48[80] CACCCTCAAAAATCACACGTTGAA 
49[8] 50[8] TTAGTTGCATTATTTA 
38[87] 20[80] ATCAAGAGCATTCAGTATAATGCTACCTTTAAATTTTAAA 
33[80] 16[80] AACGCCAACCCCCTCAAATAGTAAGAAAAGCC 
61[40] 43[47] AGCACCATACGGAAATAATGAAAACAGGGAAGTTTATCAA 
14[111] 1[111] GCCATCAAAAATCCCT 
14[23] 0[8] TTGAATGGATAGCCCTGAAAAACCGTCTATCA 
31[16] 16[8] ACATTTAAGATAAAACAGAGGTGA 
5[56] 12[56] GTATAACGGAATCGGCACTCCAGCCAGTATCG 
53[32] 57[39] CAGAGAGAATAAGTTTTACATAAA 
52[71] 58[64] CAGTACAACCACCCTCGGGGTCAG 
18[87] 14[80] TAGCTATTAGAGAATCGCCTTCCT 
52[63] 59[71] GAGAATAAGAAATTAAAGCCAGAA 
   
63[8] 62[8] AGACTGTAAGTTTGCC 
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56[111] 55[111] AAACATGAAAGTATAG 
37[8] 38[8] TTCAAATAAATAAGAA 
48[111] 47[111] GGAATTGCTCTTAAAC 
57[8] 56[8] ATGTTAGCACTCCTTA 
10[111] 5[111] AGGCTGCGATTAATTG 
25[8] 24[8] TGTTTGGAATCAATAT 
32[111] 31[111] TCATAACCAGCGTCCA 
11[8] 10[8] ATACCTACGAAAAACG 
47[8] 46[8] ATAGCAAGAATCATTA 
1[8] 2[8] TCACCCAAGACGGGGA 
52[111] 43[111] CCAATAGGTAATGCCA 
4[71] 23[71] GCATTAATTGCTTTCCCTTCGCTAAAGGCGATTCAGAGCATGAAAAGG 
2[111] 20[96] ACAGCTGATTGCCCTTTTTCTTTTGCATCGTACCAGGCAATTTAGAAC 
57[72] 41[87] CCGTATAACAAGAGAAAGGCGGATAAGTGCCGCTCCATGTGCGAAACA 
42[111] 23[111] CACCAACCGACGAGAAAGGCGCATAGTAGATTCATTAGATACATCCAA 
39[80] 10[80] TGACCAACCAATAACCAGTTGATTATTAAGCAGTAATACTCGATCGGT 
48[79] 29[79] AATCTCCAATCGGTTTCGCCCACGAGATACATAAAGATTCACCCTGAC 
31[96] 50[96] GACTGGATCTCGTTTAACGAGGCATGCGCCGATTTGCGGGGTCTTTCC 
21[8] 7[23] TAGATAATATTAATTTGAGTAGAAAATAACATAAGTGTTTTTATAATC 
41[8] 25[23] TATTTAACTTAATTGAGAATCATAATTACTAGGGCAATTCTTATACTT 
60[23] 47[23] ATTATCACATTAGAGCACAGCCATTATTTTGCATCGTAGGCAAATCAG 
1[24] 14[40] TTTTGGGGCAAAGGGCAAAACATCGCCATTAAAAATAATTGAATACGT 
The green strands are modified with a handle at their five prime end for hybridization 
with a strand containing alexafluor488 dye at its 5’ end. The modified sequences are: 
Start End Sequence 
63[8] 62[8] AAT GGC ACA CCA ACG ATC AGC AAAGACTGTAAGTTTGCC 
56[111] 55[111] AAT GGC ACA CCA ACG ATC AGC AAAAACATGAAAGTATAG 
37[8] 38[8] AAT GGC ACA CCA ACG ATC AGC AATTCAAATAAATAAGAA 
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48[111] 47[111] AAT GGC ACA CCA ACG ATC AGC AAGGAATTGCTCTTAAAC 
57[8] 56[8] AAT GGC ACA CCA ACG ATC AGC AAATGTTAGCACTCCTTA 
10[111] 5[111] AAT GGC ACA CCA ACG ATC AGC AAAGGCTGCGATTAATTG 
25[8] 24[8] AAT GGC ACA CCA ACG ATC AGC AATGTTTGGAATCAATAT 
32[111] 31[111] AAT GGC ACA CCA ACG ATC AGC AATCATAACCAGCGTCCA 
11[8] 10[8] AAT GGC ACA CCA ACG ATC AGC AAATACCTACGAAAAACG 
47[8] 46[8] AAT GGC ACA CCA ACG ATC AGC AAATAGCAAGAATCATTA 
1[8] 2[8] AAT GGC ACA CCA ACG ATC AGC AATCACCCAAGACGGGGA 
52[111] 43[111] AAT GGC ACA CCA ACG ATC AGC AACCAATAGGTAATGCCA 
The pink strands are modified with a handle at their five prime end for further attachment 
of PEGs and DSPE-PEG. The modified sequences are: 
Start End Sequence 
4[71] 23[71] TCG ATC ACG TAG CAC AGC 
ATGCATTAATTGCTTTCCCTTCGCTAAAGGCGATTCAGAGC 
ATGAAAAGG 
2[111] 20[96] TCG ATC ACG TAG CAC AGC 
ATACAGCTGATTGCCCTTTTTCTTTTGCATCGTACCAGGCAATTTAGAAC 
57[72] 41[87] TCG ATC ACG TAG CAC AGC 
ATCCGTATAACAAGAGAAAGGCGGATAAGTGCCG 
CTCCATGTGCGAAACA 
42[111] 23[111] TCG ATC ACG TAG CAC AGC 
ATCACCAACCGACGAGAAAGGCGCATAGTAGATTCATTAGATACATCCAA 
39[80] 10[80] TCG ATC ACG TAG CAC AGC 
ATTGACCAACCAATAACCAGTTGATTATTAAGCAGTAATACTCGATCGGT 
48[79] 29[79] TCG ATC ACG TAG CAC AGC 
ATAATCTCCAATCGGTTTCGCCCACGAGATACATAAAG 
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ATTCACCCTGAC 
31[96] 50[96] TCG ATC ACG TAG CAC AGC 
ATGACTGGATCTCGTTTAACGAGGCATGCGCCGATTTGCGGGGTCTTTCC 
21[8] 7[23] TCG ATC ACG TAG CAC AGC 
ATTAGATAATATTAATTTGAGTAGAAAATAACATAAGTGTTTTTATAATC 
41[8] 25[23] TCG ATC ACG TAG CAC AGC 
ATTATTTAACTTAATTGAGAATCATAATTACTAGGGCAATTCTTATACTT 
60[23] 47[23] TCG ATC ACG TAG CAC AGC 
ATATTATCACATTAGAGCACAGCCATTATTTTGCA 
TCGTAGGCAAATCAG 
1[24] 14[40] TCG ATC ACG TAG CAC AGC 
ATTTTTGGGGCAAAGGGCAAAACATCGCCATTAAAAA 
TAATTGAATACGT 
55[48] 25[47] TCG ATC ACG TAG CAC AGC 
ATAGGAAACGAAATTCTTTCGAGCCACATGGTTTGAAATACC 
TTAGAACC 
59[104] 40[104] TCG ATC ACG TAG CAC AGC 
ATGTAAGCGTCTTTTGATTTTCAGGGGGTGTATCTGTATCATAATTGTGT 
46[111] 19[111] TCG ATC ACG TAG CAC AGC 
ATCCGATAGTTAGTAAGAACGAACTATTGCATCAAGAGGA 
AGATATTCAA 
26[111] 7[111] TCG ATC ACG TAG CAC AGC 
ATTGGCTTAGTTATTTCACAGGCAAGCGACGTTGGGCCAG 
TGTATCCGCT 
18[111] 4[96] TCG ATC ACG TAG CAC AGC 
ATCTGATAAAATAGGTCAAGATGGGCCACCAGTGCACTGCCCG 
CTTTCCA 
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17[8] 4[8] TCG ATC ACG TAG CAC AGC 
ATTATTAACATATCAAACTGGCCAACGTAATAAAAAC 
GTGGCCCACCACA 
62[55] 46[40] TCG ATC ACG TAG CAC AGC 
ATACCATCGACCCTTATTCGAGGCGTTTTAGCGACGGT 
ATTCAACAAGCA 
45[8] 26[8] TCG ATC ACG TAG CAC AGC 
ATATCGGCTGGTAGAAACGAGACTACGAACGCGA 
AGATTTTCAAATAAAG 
8[63] 37[63] TCG ATC ACG TAG CAC AGC 
ATGGGTACCGGCGCGAGCTAAAGCTATCTGGAAGTAAAT 
ATGCCAAATCA 
24[31] 53[31] TCG ATC ACG TAG CAC AGC 
ATCAGATGATAAAAAGCCGATAAATACATGTAATGGTAAAGT 
GCTAATAT 
15[64] 34[64] TCG ATC ACG TAG CAC AGC 
ATTGTTAAAAAGGAAGATGAGTCTGGAAACAGTTAG 
GTCTTTATCAGTTG 
6[39] 22[24] TCG ATC ACG TAG CAC AGC 
ATTAAAGGGACACCGAGTTGTAGCAATACTTCTTTTG 
CGGAACCTTTGCC 
32[47] 14[48] TCG ATC ACG TAG CAC AGC 
ATTAAATCAAACCTTTTTTCAATTACGAGCCAGCAGC 
AATCAATGTGAGC 
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S4.4 Annealing the DNs 
S.4.3.1 Td 
          Strand 5 was reacted with DBCO-NHS ester separately and converted to DNA-
DBCO. The five strands (1:2:3:4:5) were mixed in the molar ratio of 1:3:3:3:3 in 1X TAE 
buffer (containing 12.5 mM Mg2+) and was subjected to a 12 hour thermal annealing 
program starting from 80C and ending at 4C with a regular decrease in the temperature 
by 1C. The structure was characterized and purified using 1% agarose gel electrophoresis.  
S.4.4.2 DNO 
DNO was annealed in 5 nM concentration by mixing 5 nM m13 scaffold and 10X 
staples in 1X 3D buffer. The annealing program used heated the mixture of strands to 95C 
and cooled them to 4C over a period of 37 hours. 
S4.5 Conjugation of DBCO to S5-amine 
S4.5.1 Procedure 
100 mM stock solution of DBCO-NHS ester was prepared in anhydrous DMSO. 
20 uL of DBSO-NHS stock was diluted using the same solvent and reacted with 100 uM 
aqueous solution of S5-amine in 50 mM phosphate buffer (pH = 8.5). The volume ratio of 
S5-amine: DBSO-NHS (diluted with anhydrous DMSO): phosphate buffer was 1:8:3. The 
reaction mixture was stirred at room temperature for 30 minutes and then lyophilized 
overnight. The lyophilized powder was dissolved in water and purified using HPLC to 
obtain pure S5-DBCO. The product was characterized by mass spectroscopy. 
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S4.5.2 Mass spectroscopic characterization 
The conjugation of DBCO to S5-amine was confirmed by MALDI. The mass shifted from 
~6407 D to ~6727 D that corresponds to the attachment of DBCO to the DNA-amine. 
a) 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
6407.44 
6727.92 
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Figure S4.12: MALDI spectrum. a) S5-amine b) S5-DBCO. 
S4.6 Conjugation of AAM to S5-DBCO 
S4.6.1 Procedure 
20 uL 100 uM S5-DBCO was reacted with 1, 2.5 and 5 equivalents of AAM in 0.1 
M phosphate buffer (pH = 7.5) at room temperature for six hours. MALDI spectrum of the 
reaction mixtures showed that S5-DBCO: AAM = 1:2.5 led to the formation of S5-AAM. 
Control reaction mixtures containing S5-amine instead of S5-DBCO showed no shift in the 
peak from the characteristic S5-amine peak. The product was purified using HPLC.  
S4.6.2 Mass spectroscopic characterization 
a) 
 
 
 
 
 
 
 
7667.28 
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b) 
 
 
 
 
 
 
 
 
c) 
 
 
 
 
 
 
Figure S4.13: MALDI spectrum of S5-DBCO + AAM with S5-DBCO: AAM molar ratio 
of a) 1:1 b) 1:2.5, and c) 1:5. 
7757.84 
7776.82 
248 
 
a) 
 
 
 
 
 
 
b)  
 
 
 
 
 
 
 
 
 
 
6562.29 
6604.68 
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c)  
 
 
 
 
 
 
 
Figure S4.14: MALDI spectrum of S5-amine + AAM with S5-amine: AAM molar ratio 
of a) 1:1 b) 1:2.5, and c) 1:5. 
S4.7 HSA Binding of S5-AAM 
S4.7.1 Reaction 
S5-AAM was mixed with 1, 2.5, 5, 7.5 and 10 equivalents of HSA in 1X 
TAE/Mg2+. The reaction mixtures were left at room temperature for 4 h without shaking. 
The reaction mixtures were kept protected from light.  
S4.7.2 Characterization 
10 uL of each reaction mixture was run on 12% native polyacrylamide gel prepared 
in 1X TBE buffer at 45C 30 mins under 200V for 30 minutes and then under 500V for 1 
6622.
9 
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h. These conditions were used by Lacroix and coworkers to characterize HAS binding to 
their alkyl conjugated DNA. The gel was stained with ethidium bromide for band 
visualization. From the bands it was found that that showed a 1:5 ratio of S5-AAM: HSA 
led to decent conversion to S5-HSA. 
S4.8 Time vs Stability Studies 
For the time vs stability studies the Td and DNO samples were concentrated 20 fold 
and then diluted to DMEM + 10% FBS medium, the final concentrations being 1 uM and 
10 nM for Td and DNO respectively. The Td samples were studied for 48 hours while the 
DNO samples were studied for 5 hours. 30 uL aliquots were taken out from each sample 
at different time points and were run on three separate gels (triplicate). The Td samples 
were run on 1.5 % agarose gel and the DNO samples on 1% agarose gel, both in 1X 3D 
buffer, at 4C. After the completion of run, the gels were stained with SYBR green for 
band visualization.  
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Figure S4.15: Time vs stability plots for a) bare Td, b) HSA coated Td, c) bare DNO, and 
d) HSA coated DNO. 
S4.9 Confocal Microscopy 
The confocal microscopy was performed on living cells in 1X PBS buffer. Cells 
were seeded at 3000 cells/well and grown for 24 h in a special 8 well transparent bottomed 
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in DMEM + 10% FBS medium. Then each well was incubated with 2 uL of the sample 
(dye labeled DNA or structure, their concentrations modified in a way that alexa fluor 488 
concentration in each sample was always 120 nM). Incubation procedure similar to the one 
followed during flow cytometry studies was followed. After incubation for 1h, the cells 
were washed once with 1X PBS and 1 uM solution of the CellTracker CM-Dil dye in 1X 
PBS was added. The cells were incubated at 37C for 5 minutes and then at 4C for 15 
more minutes. The medium was again replaced with fresh 1X PBS. In addition to imaging 
cells directly after incubation, we also studied batches treated with DNase after incubation, 
such that any DNA or DN sticking to the surface was degraded by the nuclease. 
Conditions similar to cell growth were maintained during imaging. We used a 40X 
immersion objective and a white light laser for imaging.  
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Figure 4.16: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled S5. The cell membranes were stained with CellTracker CM-Dil dye. A) Bright field 
image b) green fluorescence from internalized S5 c) overlay of bright field and green 
fluorescence d) red fluorescence from CellTracker CM-Dil dye e) overlay of green and red 
fluorescence f) overlay of bright field, green and red fluorescence. 
 
Figure 4.17: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor488 labeled S5. The crosshairs indicate orthogonal sectioning. The bottom and right 
panels show the sectioned planes and confirm that fluorescent particles (green) are located 
inside the cells and not merely attached to the cell membrane. 
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Figure S4.18: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled S5 followed by DNase treatment. The cell membranes were stained with 
CellTracker CM-Dil dye. a) Bright field image b) green fluorescence from internalized S5 
c) overlay of bright field and green fluorescence d) red fluorescence from CellTracker CM-
Dil dye e) overlay of green and red fluorescence f) overlay of bright field, green and red 
fluorescence. 
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Figure S4.19: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled S5 and then treated with DNase.  
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Figure S4.20: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled DNO. The cell membranes were stained with CellTracker CM-Dil dye. a) Bright 
field image b) green fluorescence from internalized DNO c) overlay of bright field and 
green fluorescence d) red fluorescence from CellTracker CM-Dil dye e) overlay of green 
and red fluorescence f) overlay of bright field, green and red fluorescence. 
 
Figure S4.21: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled DNO.  
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Figure S4.22: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled DNO followed by DNase treatment. The cell membranes were stained with 
CellTracker CM-Dil dye. a) Bright field image b) green fluorescence from internalized 
DNO c) overlay of bright field and green fluorescence d) red fluorescence from 
CellTracker CM-Dil dye e) overlay of green and red fluorescence f) overlay of bright field, 
green and red fluorescence. 
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Figure S4.23: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled DNO and then treated with DNase.  
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Figure S4.24: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled DNO. The cell membranes were stained with CellTracker CM-Dil dye. a) Bright 
field image b) green fluorescence from internalized coated DNO c) overlay of bright field 
and green fluorescence d) red fluorescence from CellTracker CM-Dil dye e) overlay of 
green and red fluorescence f) overlay of bright field, green and red fluorescence. 
 
Figure S4.25: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled HSA coated DNO.  
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Figure S4.26: Confocal microscopy images of RAW cells incubated with Alexa fluor 488 
labeled DNO followed by DNase treatment. The cell membranes were stained with 
CellTracker CM-Dil dye. a) Bright field image b) green fluorescence from internalized 
coated DNO c) overlay of bright field and green fluorescence d) red fluorescence from 
CellTracker CM-Dil dye e) overlay of green and red fluorescence f) overlay of bright field, 
green and red fluorescence. 
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Figure S4.27: Z-stacked confocal microscopy images of RAW cells incubated with Alexa 
fluor 488 labeled HSA coated DNO and then treated with DNase.  
S4.10 Flow Cytometry 
S.4.10.1 Incubation with DNs 
Before incubation the existing medium was replaced with fresh medium. The cells 
in each well were incubated with 10 uL of each sample (S5-dye or DN), the concentration 
of the sample was such adjusted that the concentration of Alexa fluor 488 was always 120 
nM. Td was annealed in 250 nM concentration and as each Td contained 12 fluorophores, 
hence the concentration of the fluorophore became 3 uM. The sample was diluted 25 fold 
and 10 uL of the diluted sample was added to each well when required. DNO was annealed 
in 5 nM and then concentrated to 10 nM. As each structure contained 12 fluorophores, 
hence concentration of fluorophore became 120 nM.  
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An issue that we had to face during incubation of the cells with DNs was the 
instability of the structures in cell culture medium. Our previous experiments showed that 
Td had a half-life of about 5 h in DMEM + 10% FBS medium whereas the same was only 
~39 minutes for DNO. So, if we incubate the cells with only one aliquot of the structure, 
there was obvious chances of the macrophages internalizing free dye labeled DNA that 
resulted from the degradation of DNs. Hence, we replaced the medium every 30 minutes 
for Td incubation and added fresh aliquot of Td (10 nM, 10 uL) and for incubation with 
DNO the process was repeated every 10 minutes. This minimized the chance of dye labeled 
DNA internalization. 
S.4.10.2 Dead cell staining 
Propidium iodide stock was prepared by dissolving solid propidium iodide in 
deionized water and the stock concentration was 1 mg/mL. While staining the cells, the 
stock was diluted to 3 uM by using 1X PBS buffer. 1 mL of the 3 uM dye was added to 
each well.  
S.4.10.3 DNase treatment 
DNase powder was dissolved at a concentration of 1 mg/mL in 50% Glycerol with 
20 mM Tris-HCl, pH 7.5, and 1 mM MgCl2. After the cells have been incubated with the 
DN, we replaced the medium and added 10 uL of the DNase stock per mL of the medium, 
incubated at 37C for 10 minutes and again changed the medium with 1X PBS in case of 
confocal microscopy or with 3 uM propidium iodide solution (in 1X PBS) in case of flow 
cytometry studies.  
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S.4.10.4 Analysis of FACS data 
The RFI value from RAW cells incubated 10 uL of the blank was collected each 
time the experiment was done and this value was subtracted from the RFI values of 
samples. 40,000 events were collected for each sample and each sample was studied in 
triplicates. A separate sample was prepared for dead cells and they were incubated with 
propidium iodide (PI) for 15 minutes prior to the flow cytometry experiment. RFI value 
from this control sample show that most of the dead cells has an RFI (form PI) higher than 
102. This value for PI RFI was used as a gating. All the samples were incubated with PI 
solution prior to flow analysis and the gating was applied so that while analysis we could 
collect the RFI values only from living cells. This minimized the chance of false positives 
as dead cells have a much higher permeability in comparison to the living ones. 
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APPENDIX D 
SUPPLEMENTAL NFORMATION FOR CHAPTER 5 
PROXIMITY LIGATION ASSAY TO ESTIMATE THE STABILITY OF DNA  
NANOSTRUCTURES 
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S5.1 Methods and Instruments 
All DNA strands were purchased from Integrated DNA technologies. The strands 
for DNC were bought in 96 well plates and used without any further purification. Rest of 
the strands were purified using 10% denaturing polyacrylamide gels prior to annealing 
structures. FBS that was used to supplement DMEM cell culture medium was purchased 
from Gibco Life Technologies. Human serum was purchased from Sigma Aldrich. All the 
other chemicals that are not mentioned here were bought from Sigma-Aldrich.  
Real time PCR instrument from Qiagen was used for the PCR experiments. The 
time vs stability results were plotted using the Prism 5 software from Graphpad. For the 
time vs stability experiments, the band intensities of gels were measured using the ImageJ 
software. 
S5.2 DNA nanostructure designs 
S5.2.1 Wireframe Tetrahedron (Td) 
S5.2.1.1 Sequences for TdP0: 
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Strand 1: 
ACA TTC CTA AGT CTG AAA CAT TAC AGC TTG CTA CAC GAG AAG AGC 
CGC CAT AGT A 
Strand 2: 
TAT CAC CAG GCA GTT GAC AGT GTA GCA AGC TGT AAT AGA TGC GAG 
GGT CCA ATA C 
Strand 3: 
TCA ACT GCC TGG TGA TAA AAC GAC ACT ACG TGG GAA TCT ACT ATG 
GCG GCT CTT C  
Strand 4: 
TTC AGA CTT AGG AAT GTG CTT CCC ACG TAG TGT CGT TTG TAT TGG ACC 
CTC GCA T 
S5.2.1.2 Sequences for the antennae pair (A1 and A2) 
A1: TGTG GTC TAT GTC GTC GTT CG CTA GTA GTT CCT GGG CTG CAC 
A2: TCG AGG CGT AGA ATT CCC CCG ATG CGC GCT GTT CTT ACT CA 
S5.2.1.3 Sequences for TdP2 
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The two strands 1 and 4 were replaced with PN1 and PN2.  
PN1 (Added antennae to 3’ end of Strand 1): 
ACA TTC CTA AGT CTG AAA CAT TAC AGC TTG CTA CAC GAG AAG AGC CGC 
CAT AGT A TGTG GTC TAT GTC GTC GTT CG CTA GTA GTT CCT GGG CTG 
CAC 
PN2 (Added antennae to 5’ end of Strand 4): 
TCG AGG CGT AGA ATT CCC CCG ATG CGC GCT GTT CTT ACT CA TTC AGA 
CTT AGG AAT GTG CTT CCC ACG TAG TGT CGT TTG TAT TGG ACC CTC GCA 
T 
S5.2.1.4 Sequences for TdS2 
 
The two strands 1 and 4 were replaced with PN1S and PN2S. ‘*’ indicates 
phosphorothioation of the DNA backbone. 
PN1S (Added antennae to 3’ end of Strand 1): 
A*C*A* T*T*C* C*T*A* A*G*T* C*T*G* A*A*A* C*A*T* TA*C* A*G*C* T*TG* 
C*T*A C*A*C* G*A*G* A*A*G* A*G*C* C*G*C* C*A*T* A*G*T* A* TGTG GTC 
TAT GTC GTC GTT CG CTA GTA GTT CCT GGG CTG CAC 
PN2S (Added antennae to 5’ end of Strand 4): 
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TCG AGG CGT AGA ATT CCC CCG ATG CGC GCT GTT CTT ACT CA T*T*C* 
A*G*A* C*T*T* A*G*G* A*A*T* G*T*G* C*T*T* C*C*C* A*C*G* T*A*G* 
T*G*T* C*G*T* T*T*G* T*A*T* T*G*G* A*C*C* C*T*C* G*C*A* T* 
S5.2.2 Larger Tetrahedron (TD) 
S5.2.2.1 Sequences for TDP0: 
Strand 1: AGG CAC CAT CGT AGG TTT C TTG CCA GGC ACC ATC GTA GGT 
TTCT TGC CAG GCA CCA TCG TAG GTT T CTT GCC 
Strand 2: CAG AGG CGC TGC AAG CCT ACG ATG GAC ACG GTA ACG ACT 
Strand 3: AGC AAC CTG CCT GTT AGC GCC TCT  
Strand 4: TTA CCG TGT GGT TGC TAG TCG TT 
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Figure S5.1: Schematic of TDP0 
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S5.2.2.2 Sequences for TDP24 
 
 
Figure 5.2: Schematic of TDP24 
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Antennae + Strands: 
XA1 = strand 3 + 5T linker + A1: 
AGC AAC CTG CCT GTT AGC GCC TCT G TTTTT TGTG GTC TAT GTC GTC 
GTT CG CTA GTA GTT CCT GGG CTG CAC 
XA2 = A2 + 5T linker + strand 4  
TCG AGG CGT AGA ATT CCC CCG ATG CGC GCT GTT CTT ACT CA TTTT TTA 
CCG TGT GGT TGC TAG TCG TT 
While annealing TDP24, the strands 3 and 4 were replaced with XA1 and XA2 
respectively. 
S5.2.3 DNA Origami 
S5.2.3.1 caDNAno schematic for DNCP0 
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Figure 5.3: caDNAno schematic for DNCP0 
S5.2.3.2 Strand sequences for DNCP0 
Start End Sequence 
0[79] 2[72] TCGAGGTGTAGCCCGAGATAGGGTGAAAATCCTGTTTGAT 
33[80] 32[80] GAAACGCAAGTTTTGC 
35[104] 33[111] TAGAAAGACAAAAGGAATAGTAAG 
7[72] 10[64] TACATTTTCGTCTGAAATGGATTACGTGGCACTTTGAATG 
45[40] 43[39] TTAAAGCCGCATTGACAGGAGGTTCCACCGGA 
10[63] 12[64] GCTATTAGAGGAATTGAGGAAGGTATAATACA 
4[39] 19[39] AGTGTTTTTGTCCATCTCGCCTGATTGCTTTGTTATTCATTTCAATTA 
36[55] 40[48] AAGAACTGGGCGACATCATTACCACACTACGAGAACGAGG 
24[127] 47[140] ATATGCAATACAACGCTGAGAATAGAAAG 
23[64] 25[71] GTATCACCCATTTTCAAAAAAGCC 
42[87] 46[80] CTTTTTCATCAGAGCCACCGGAGTTGCAGACCCTCAGAGCGCT 
TTCGAAAAAAGGC 
44[119] 45[138] CCGATATAACCGATAGTTGCGCCGACAATGACAAC 
36[119] 42[120] GTAAATTGATTCAGTGAATAAGGCCGAGGGTA 
16[119] 5[111] CCGGTTGAGCCGGAGAGTTCTAGCTGATAAATGGTTTGCG 
28[95] 41[95] AAACCAATCTGGCTGATTGTGTCGATACACTA 
34[129] 54[109] AATGCAGATACATAACGCTTCATCAGAAATCAGGTCT 
32[95] 34[88] GCAAAAGAATAATAACGGAGAGGCATTACATACCCAAAAG 
35[72] 33[79] AAAACGAATGATTAAGAAACCGAG 
45[96] 44[104] TCTTAAACAGCTTGATTTCGGTCG 
10[95] 11[119] CCAGTCACAGGAGCACTAACGACAGTATCGGCCTCAGGAA 
2[71] 4[72] GGTGGTTCACAGGGCGCGTACTATAAGGGATT 
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12[47] 10[48] TATTAGACCAAATCAACAGTTGAATCTTTAAT 
6[39] 9[39] AAACTATCCGCCAGCCATTGCAACCACCAGTCACACGACCTAGAACCC 
5[48] 3[55] TAACCGTTGTAGCAATGAACGGTACGCCAGAACGCTTAAT 
9[120] 57[140] GAGGATCCCATAGCTGAGGCAAAGCGCCACAGCTGGC 
3[56] 0[64] GCGCCGCTCGAAATCGTTATAAATCAAAAGAACCGTAAAG 
47[48] 45[71] GGTTTTGCTCAGTATAGCAAGCCCGAGCCTTTAATCAGTCAAG 
CGTGTATCGGTTT 
42[55] 44[56] AAAATACGCCTCAGAGCCGCCACCACCAGAGC 
20[79] 17[79] AGCCTTTACTGAGTAATATACTTCAAGGCTAT 
61[16] 0[32] ATTAATTAACCTTGCTCGGCGAACGTGGCGAGAAAGGA 
AGGCCCCCGA 
12[63] 30[56] TTTGAGGATATCCGGTAGACGGGA 
52[31] 38[24] AGAGAGATCTAACGAGCGTCACCA 
54[34] 33[47] CCTAAGAAAAGTAAGCAGA 
33[48] 32[24] TAGCCGAACGACTTGCGGGAGGTTTTGAAGCCTTAAATCA 
37[40] 37[23] GACAAAAGGCTCATTATACATAAGTTTATTTTGTCACAATT 
TCATATG 
50[138] 41[135] GGATTTTGTAACAAGCGCG 
23[40] 22[40] ATATAAGTATCCAATC 
20[39] 29[39] AGAAGATGGCGGAACAAAGTACCGAATCCTAA 
45[72] 43[71] ATCAGCTTCGCCACCAGAACCACCCTCAGAAC 
24[63] 25[39] GGGACCAGGCGGATAAGTGCCGTCGAGAGCTTATAAGAAT 
59[24] 16[24] TGCAACAGTTGCACGT 
52[146] 13[138] AAGACTTCAAACAGACCGGTGAATCCCATG 
42[119] 50[107] GCAACGGCGGGATCGTAGTTTTGTCGTCT 
47[112] 24[104] GTACAAACCTAAAGTACGGCCACC 
1[96] 23[95] GTTCCAGTTCACCCAAATCAAGTTGTACCGCC 
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43[104] 39[111] GCTTTTGCTACAGAGGATCTTTGAACCGTCACAAGAGTAA 
32[135] 36[120] TACCAGACGACGATAATATCATAATAAATCAATTGAGAT 
TAACGAGTA 
11[80] 9[87] ATATCTTTGACGTTGTAAAATATTAGACAACGACGGCCAG 
55[109] 31[111] TTAATAGCGAGGGATAGCG 
21[128] 27[135] AAGCCTCAATTTTTGCAATTGCTC 
4[103] 16[96] GGGAGCTAGGAGAGGCTAATGCCGAGTCTGGACAATATAA 
12[95] 30[88] CTAATAGAGTAAAATGGAGAGAAT 
7[56] 19[63] CGCTCATGTCACTTGCACAGTAACACATCGGGATTTTAAA 
37[104] 35[103] AAAGGTGAGGCTTGAGATGGTTTAATTACAGG 
5[112] 62[112] TATTGGGCGCCAGGGTTTCACCAGTCTACTAAAGGAG 
CTGAAAAGGTG 
31[112] 56[109] TCCAATACTCTGCCAGATGGGATAACCGCTTCTGG 
9[40] 7[55] TTCTGACCTGAAAGCGTAAGAATATTTACATTGGCAGATTA 
GGAAAAA 
0[47] 2[40] TAAAGGGAGGAAGAAAGCGATCCCGCAAAAAAGGAGCGGG 
58[146] 8[136] CTTCGCTATTAAGTGAGCTAATTCGTA 
7[24] 59[39] AATATTACGGCCTTGCGTAGATTTTCAGGTTTAAAATTATTGCCACGC 
36[138] 53[146] AGAAGGAAGCCCGA 
46[79] 24[80] TCCAAAAGAATAGGAACCCATGTATCAGAGCC 
17[48] 6[40] ATGAATATCTGAGTAGAAGAACTC 
42[138] 37[138] CAGCATCGGAATTGCCCTGACG 
24[103] 25[111] CTCAGAACAAATTCTTACCAGTAT 
31[48] 13[55] AGAAGGCTTTTAGAAGATTAAATG 
24[79] 22[72] ACCACCCTGTACTCAGGGTTATAT 
9[88] 7[87] TGCCAAGCCTCACAATTCCTCAATGACGCACA 
46[119] 47[111] ATAATAATTTTTTCACCGTCACCA 
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2[39] 4[40] CGCTAGGGACCACCACACCCGCCGTCCTGAGA 
54[140] 34[130] GATTGCATCAAAACCCTCGTTTCAACT 
7[88] 19[95] CAACATACACCTGTCGTGCCTGAGGAGAGGGTTAAAGATT 
33[112] 30[112] AGCAACACAAACCAAACCCTGACTCAGATGAA 
32[79] 13[87] CAGGAGGCAACGCAGGGGGTAATATTAGAGCCTCTCCGTG 
56[34] 12[32] GAATCAGTTGGTTTACAAA 
43[40] 39[47] ACCGCCTCTAACCCCTATAGCTGCTTAGCAAGCAACTTTG 
3[88] 1[95] TGACGAGCCAGCAGGCTGAGTGTT 
20[103] 29[103] ACCCTGTACAATTCATG 
CATGTAGATTTTTTG 
10[47] 13[31] GCGCGAACTGATAGCCCTAAAACAATATCTGGCCTCA 
 
AATACGCTGTA 
28[63] 41[63] CATTCCAACAGATGAACTTAGCCGAGGCACCA 
16[23] 3[23] AAAACAGAGAGGCGAAAATACCAAAAACAGTAGTGAG 
GCCGGTCACGC 
32[63] 34[56] GAACCTCCCAAAGTTACCAGAAGGACTCCTTATTACGCAG 
27[96] 38[96] AACAAGAACTGATAAACCTTCATCCGACTTGA 
8[103] 9[119] GTTATCCGTTGCATGCCTGCAGGTCGACTCTA 
44[55] 47[47] CGCCGCCAAGAATGGATCTGAATTTACCGTTCATTAGCGG 
34[55] 36[56] TATGTTAGTTGGGAAGAAAAATCTGCGATTTT 
44[103] 43[103] CTGAGGCTTAAAGGCC 
47[96] 45[95] CTGAGTTTGTTGAAAATCTCCAAAGGTGAATT 
2[103] 3[103] GTTTGCCCACGTATAA 
27[112] 60[107] TCCCAAGATACCAAAATTCGCAAACCTGTTTAGCTAT 
36[87] 40[80] TTTAATCAAAATATTGGGAATTAGGCAAAAGAAAATCCGC 
33[24] 35[47] CCCTTTTTGAATCTTAAAGACACCACGGACAGTCAGGACG 
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34[87] 36[88] AACTGGCACTAACGGAACAACATTATTTCAAC 
18[47] 5[47] TAACGGATACGCAAAT 
0[63] 23[63] CACTAAATGAATAGGT 
23[96] 22[96] ACCCTCAGAACCGTGTTTAGTTTGACCTTTAA 
6[143] 58[115] AACTCACATTAATTGCGCCTAATGCGCTTCGCCATTCAGGCTGCG 
4[71] 16[64] TTAGACAGACTTCTTTTCTCTTTTAGTACACATGAATAAT 
23[128] 49[143] ATATAACATGTTTTAATGAATATACAGCGGAGGCGC 
TAAACAACTTTC 
5[24] 63[36] AAAGAGTCTATAATCACATAAATCAATAT 
37[72] 35[71] GGGAAGGTTTGTGAATTACCTTATACGTTAAT 
28[135] 55[140] TCCAACAGAAGCGAACTATCGCGTCAGAAGCAAAGCG 
12[31] 55[31] CAATTCGACCCAATAGAGTCAGAGTACAATTT 
3[104] 2[104] CGTGCTTTCCTCGGACGGGCAACAAGTTGCAGCAAGCG 
GTCCACGCTG 
43[72] 39[79] CGCCACCCTGAGGAAGCGAAAGAGAGCCAGCAAGACCAGG 
5[88] 3[87] ACGCGCGGAACAGGAGGCCGATTAGGTTGCTT 
6[103] 7[119] GTCGGGAAGAGCCGGAAGCATAAAGTGTAAAG 
1[104] 1[140] TTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCC 
27[136] 15[138] CTTTTGATAAGCAAACAAT 
25[16] 22[11] ATAAATAAGAGAAAACTTTTT 
48[15] 26[5] ACTGGTAAACCGTGTGAGTACCGACAA 
37[24] 42[11] GTTTACCATTTGCCATCTTTTCATAATCA 
62[15] 62[5] TCTGTAAAACC 
27[16] 20[11] ATTCTGTCAACATCAAGAAAA 
3[24] 2[16] TGCGCGTACGCTGGCAAGTGTAGC 
50[31] 44[11] TTATTCTGCAGAGCCAGAGGCAGGTCAGACGATTGGC 
63[128] 19[135] TAGTAGTAAAAATTAATCACCATC 
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46[140] 43[138] GAACAACTAAAGGTTTTCTGTCATCGCCCGCAGCGAAAGA 
37[11] 36[11] GAAAACAATA 
9[16] 58[24] TTCTGGCCAACAGAGAAGTAATAAATCACCTTAGCAGCAA 
12[138] 31[127] GGCGCATCGTAACCGTGCATGCGGAAT 
43[11] 48[16] AAATCACCGGAACCTTGAGTACCTATTTCACTAGTGT 
31[16] 12[11] TTACCGCGCAACTCGTATTAA 
2[143] 62[128] CGCCTGGCCCTGAGAGGCTGATTGAATCATAC 
7[120] 18[120] CCTGGGGTGTTGCGCTATGAACGGATTCAACC 
10[119] 8[104] AAGTTGGGCGGAAACCTTTCCTGTGTGAAATT 
57[3] 10[8] ATAAAACAGAGGTAAAAATAC 
27[5] 28[5] AAGGTAAAGTAGCAAGCCGTTT 
24[143] 23[138] GCTCAACAGTT 
51[0] 40[8] CAGTTAATGCCCCCTGACAGTGCCTTAACGGGAGCGTCAG 
14[138] 59[146] ATTGGTGCGGGCCT 
61[0] 18[8] TTTGAATTTCGTCGCTACATTTAATTTAATGGGTTACAAA 
41[8] 38[3] ACTGTAGCATCGATAGCAGCA 
19[8] 16[13] ATCGCGCAAAT 
56[140] 11[135] GAAAGGGGCCAGCTCCAGGAT 
35[11] 54[3] TAAAAGAAACGCACCAATAAGAGCAAGAAACAAT 
17[13] 58[8] AAAGAGGCGGT 
4[132] 5[132] TTCTTGGTTT 
13[11] 56[3] ATCCTTTGCCCGAATCAAACCCCACCAGCAGAAG 
47[13] 24[5] GATACAGGCCTAATTTAATGGTTTGAAATA 
62[143] 3[143] ATCCAATACCCTTCAC 
55[3] 32[8] GAAATAGCTTTTGTGCTAAAT 
40[135] 39[140] AAACAAAGATATTCATTACCC 
48[143] 21[138] AACAGTTTATGCTGTAAAGAGGTCGAG 
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18[135] 17[140] AATATGATTAATCGTAAAACT 
60[138] 63[143] AGCGCATTAAC 
49[5] 50[0] GTTCGTATAAA 
15[11] 14[11] TTTGAAAAAG 
38[140] 35[138] AAATCAACGTAACAGATTAAGAACACCAGTAGGAATACCA 
39[3] 52[8] CCGTAATCAGTAGAGAATTGA 
63[5] 60[0] TTTCAATTTCA 
23[11] 0[13] CAAATATATTTTATTGACGGGGAA 
38[95] 42[88] GCCATTTGACGGAAATACTAAAGA 
15[24] 49[36] ATCATTTTATGAAACACAGACGACTAATAAGAAAACATGAAAGTA 
38[23] 26[16] ATGAAACCGCGTTTTCTTGCCTTTGTCAGTGCGAATATAA 
38[63] 42[56] AGTAGCACTCAACCGAAAACGGGT 
19[40] 17[47] CCTGAAACACCATATCAACGTCAG 
41[120] 44[120] GATTATACCGATCTAACACCCTCAACGCATAA 
22[95] 47[95] CCTCCGGCCGTTATACCGCCACCCCCGTAACA 
19[96] 17[111] CAAAAGGGTGAGAAAGTAATCAGAGCAAACAA 
16[95] 26[88] TCCTGATTGATGATGGATACTTTTAAGTCCTGAATTGAGA 
51[107] 48[112] TTCCAGACGTTAGTTCCACAG 
29[104] 15[119] TTTAACGTCAAAATTCATATTTTGAAAAACAG 
17[112] 6[104] GAGAATCGCACTGCCCGCTTTCCA 
21[56] 25[63] GTCAATAGGTAAATGCATTACTAG 
16[63] 26[56] GGAAGGGTGAGCGGAACAAGGATAATGCAGAAATGTAATT 
30[55] 14[48] GAATTAACTTACAAAACCATCAAA 
14[71] 32[64] TTAACCAATAACAACCAGCGCATTATTCTAAGGTTTTAGC 
40[31] 41[31] TAAGGAGTATCGGCAT 
13[56] 29[63] TGAGCGAGTAGGAACGTAAACAGC 
39[32] 53[39] GAACTGACGCCGGAAACGTCTTTC 
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57[109] 10[96] TGCTAACGCCAGGGTTTTC 
25[112] 0[104] AAAGCAGCGAGTAGATCTGGAAGTGTCTATCAGTGAACCA 
18[79] 7[71] TTGAGAGAGATAATGAGCATTTAGTAATAACAGAAATACC 
26[55] 0[48] TAGGCAGAGAATCATATGATGCAAATAGCCCGCGGAACCC 
59[115] 27[127] CAACTGTTGGGAATATGTACCGAAGATTGATCGGTTGGTACCTTT 
39[80] 21[87] CGCATAGGCAATAATCCAATAGATGCGGGAGAATAGGTCT 
19[120] 25[127] CAGTCAAAGCAAATAATGGTCATACTGCGAACTTAATTGC 
13[88] 29[95] GGAACAAAATTTTTGTAAGAAACG 
29[40] 13[47] TTTGCCAGTGAACACCTCATCAAC 
39[48] 21[55] AAAGAGGAGAACGGGTTTCAGCTAAAAATTTTTGAGAAGA 
41[32] 37[39] TTTCGGTCTATTAGCGGCGCCAAA 
53[115] 38[120] ACGAGAATGACCAAAAGCTGC 
48[36] 51[31] TTAAGAGGCTGAGGGAACCTA 
41[96] 37[103] AAACACTCCTTTGAGGTATTCATT 
15[80] 18[80] GATTATCAGTTTGGATTGTGTAGGAGCTATTT 
49[112] 20[104] ACAGCCCTTAGCAACGCTCAACAGAGATACATACATTATG 
58[39] 57[34] TGAGAGCCGCT 
39[112] 14[104] TCTTGACATAGTCCTAATTTACGAAAAGCCCCTTAAAATT 
40[79] 14[72] GACCTGCTTTTATCAAGGCTGTCTATATTCCTCTCATTTT 
13[32] 31[47] GCCAGCTTCTGAACAACAAGCAAATCAGATAT 
26[127] 46[120] GGATGGCTCATAGTTACTGTAGCATAAATGAAAATTGCGA 
60[31] 40[32] TTAGAATCTAGCGATAGCTTAGATCGAGCCAGGACAAT 
AAGTCAATCA 
30[111] 12[96] AATAGCAGTGACCGTATTTGAGGGGACGACAA 
14[103] 32[96] CGCATTAACGGCGGATCCTTTACATTTAGACTAGGCTTTT 
40[47] 14[40] CGCAGACGACAACATGATTAAACCAAGAAACCAATAATTC 
13[128] 31[143] TGGTGTAGCCTCAAATCGTCATAAATATTCAT 
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25[40] 20[40] AAACACCGGGCATTTTTAAGACGCTAGGCAAA 
41[64] 37[71] ACCTAAAATTTCCATTTTGAGGGA 
52[39] 55[34] CAGAGATCTAT 
62[36] 23[39] ATGTGAGTGAATAATTTTCCCTTTAGAGCGTTAATTTCATGGTTG 
29[16] 15[23] GTAGGAATTTAATTTTGTAACATT 
61[107] 23[127] ATTTTCATTTGGGGCGCGCAAGAAAAACCTTCATTCC 
21[88] 26[96] GAGAGACTACCTTATTTAGGGCTT 
22[71] 40[64] AACTATATTGAATTTAACGCCAACCGCGCCTGCCATGTTA 
30[127] 52[115] GCTTTAAAATTATAGTTTTAATTCAGAAA 
14[39] 39[31] GCGTCTGGCCTTCTTATGAGCGCTCACTCATCTCAGAACC 
19[64] 29[71] TGCAATGCTTTCAACGTTATCATCTTCCTTATCATATTAT 
38[119] 27[111] TCATTATCCCCCCAGCAGATTTGTATCATCGCAAATAATA 
26[87] 0[80] ATCGCCATATCATATGTTAGGTTGGAGGTTTATTTTGGGG 
29[72] 11[79] TTATCCCAAACAGGGACGTCGGATGTCAATAGTATCTAAA 
15[48] 18[48] ACCAGAAGTAGAACCTCCTCATATAGAAACAA 
17[80] 5[87] CAGGTCATTGCCAGCTATCGGCCA 
30[87] 14[80] AACATAAAATCCAAATTAAATCAG 
25[72] 21[79] TGTTTAGTATTTAACATCAAAATC 
39[64] 38[64] CGGTGTACAAATCACC 
22[39] 47[31] GCAAGACAAAGAACGCGGCGTTAACTGACCTACAAGAGAA 
14[127] 40[120] AAACGTTAGAGCTTCAGTCAGGATAGAACCGGTACAACGG 
63[112] 4[104] GCATCAATTGATTAGAATCAGAGC 
0[140] 22[128] AACGTCAAAGGGCGGCAAAGATCCCAATT 
29[5] 29[15] TTATTTTCATC 
33[8] 30[16] AGCTATCTTACCGAAGAGATTAGTCACCCAGCGGTAATCA 
10[135] 13[127] GTGCTGCAAGGCGATTGATCGCACTTTCCGGCGGTCACGT 
21[11] 60[16] CAAAATTAAAACACTTGAATT 
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53[8] 28[16] GTTAAGCCCAATAACGAACCCACACGACAGAAGAGAACAA 
16[140] 14[128] AGCATGTCAATCAGGGCGATCTAAATTGT 
11[8] 7[23] CGAACGAACTCAATCATCGCCATTTCTAAAGCAAGGG 
ACATCCAGAAC 
45[11] 45[39] CTTGATATTCACAAACAAATAAATCCTCA 
59[8] 5[23] CAGTATTAACACCGCCATGAAAAAGAAATTGCTGGTAA 
TAACCGAGTA 
20[138] 15[135] CATAAAGCTAATATAAGCA 
47[32] 46[13] GGATTAGGCAGTAAGCGTCATACATGGCTTTTGAT 
8[135] 9[143] ATCATGGTCCGGGTACCGAGCTCG 
34[47] 34[11] CAAACGTAGAAAATACATACATAAAGGTGGCAACATA 
S5.2.3.2 Strand sequences for DNCP2 
For making DNCP2 (5 nm) the two red strands were replaced by DA1 and DA2.  
DA1 = 10[119] + A1: 
AAGTTGGGCGGAAACCTTTCCTGTGTGAAATT TGTG GTC TAT GTC GTC 
GTT CG CTA GTA GTT CCT GGG CTG CAC 
DA2 = A2 + 7[120]: 
TCG AGG CGT AGA ATT CCC CCG ATG CGC GCT GTT CTT ACT CA 
CCTGGGGTGTTGCGCTATGAACGGATTCAACC  
For all other structures, DA2 was always used instead of the normal strand (without 
antenna). For making DNCP2 (21 nm), DA2 was used. To provide the other antenna, the 
blue strand was replaced by DA3. 
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DA3 = 9[40] + A1: 
TTCTGACCTGAAAGCGTAAGAATATTTACATTGGCAGATTAGGAAAAATGTG
GTC TAT GTC GTC GTT CG CTA GTA GTT CCT GGG CTG CAC 
For making DNCP2 (33 nm), DA4 was used instead of DA3 (the normal green strand was 
replaced). 
DA4 = 16[23] + A1: 
AAAACAGAGAGGCGAAAATACCAAAAACAGTAGTGAGGCCGGTCACGCTGT
G GTC TAT GTC GTC GTT CG CTA GTA GTT CCT GGG CTG CAC 
For making DNCP2 (41 nm), DA5 was used instead of DA4 (the normal purple strand was 
replaced).  
AAACACTCCTTTGAGGTATTCATT TGTG GTC TAT GTC GTC GTT CG CTA 
GTA GTT CCT GGG CTG CAC 
S5.3 Annealing the DNs 
S5.3.1 Td  
All the wireframe tetrahedron structures (TdP0, TdP1, TdP2, TdP3, TdP4, TdS1, TdS2) 
used in this project were annealed in 1 uM concentration mixing the four constituent 
strands in 1:1:1:1 molar ratio in 1X TAE/Mg2+ buffer  following a flash-freeze protocol (2 
min heating at 80C, immediately cooling down to 4C).  
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S5.3.2 TD 
All the larger tetrahedral (TDP0, TDP12, TDP24) were annealed in 250 nM concentration 
mixing the strands 1,2,3 and 4 in the molar ratio 1:3:3:3 in 1X 3D buffer following an 
annealing program that heated the strands to 80C and cooled them to 4C over a period of 
12 hours. 
S5.3.3 DNC 
All the DNC structures were annealed in 5 nM concentration by mixing 5 nM m13 scaffold 
and 10X staples in 1X 3D buffer. The annealing program used heated the mixture of strands 
to 95C and cooled them to 4C over a period of 37 hours. 
S5.4 Characterization of annealed DNs 
S.5.4.1.Td 
The annealed structures were characterized via a 3% mini agarose gel run in 5 mM borax 
buffer for 8 min at room temperature under 300V. 5 uL of 1 uM structures mixed with 1 
uL 6X loading dye was loaded on each well. After completion of run, the gel was stained 
with ethidium bromide solution for 5 minutes for band visualization. 
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Figure 5.4: Agarose gel for characterization of TdP structures. 
S.5.4.2 TD 
The annealed structures were characterized via a 1.5% agarose gel run in 1X 3D buffer for 
30 min at 4C under 100V. 5 uL of 1 uM structures mixed with 1 uL 6X loading dye was 
loaded on each well. After completion of run, the gel was stained in ethidium bromide 
solution for 5 minutes for band visualization. After completion of run, the gel was stained 
with ethidium bromide solution for 5 minutes for band visualization. 
 
Figure 5.5: Agarose gel for characterization of TDP structures. 
S.5.4.3 DNC 
The annealed structures were characterized via a 1% agarose gel run in 1X 3D buffer for 1 
h at 4C under 100V. 10 uL of 5 nM DNC mixed with 2 uL 6X loading dye was loaded on 
each well. After completion of run, the gel was stained with ethidium bromide solution for 
5 minutes for band visualization. 
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Figure 5.6: Agarose gel for characterization of DNC structures. 
S5.5 Proximity Ligation 
The ligation mixture contained 11.2 uL (7 uM) of the connector strand, 200 uL of 10X T4 
ligase buffer, 2 uL (40U/uL) of T4 ligase, 768 uL water, thus resulting to a total volume of 
1000 uL. We mixed this solution with each sample as and when required in 1:1 volume 
ratio and incubated for 10 minutes at room temperature prior to RTPCR.  
S5.6 RTPCR 
S5.6.1 Primers used during RTPCR: 
P1 forward:  5'ATG TGG TCT ATG TCG TCG TTC G 
P2 reverse:  5' TGA GTA AGA ACA GCG CGC AT 
S5.6.2 RTPCR Protocol 
We optimized the PCR conditions and obtained the finalized protocol as:  
Stage 1: 95 C 120 s Optics off 
Stage 2 (Repeat 37 times): 95 C 15 s optics off, 58 C 20 s optics on, 75 C 15 s optics off 
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Stage 3 (Melting curve): Start 57 C end 95 C optics Ch1, 0.2 C/sec 
S5.7 Calibration Curve 
S5.7.1 PLA product for the antennae pair  
A1 & A2 = A1+A2: 
TGT GGT CTA TGT CGT CGT TCG CTA GTA GTT CCT GGG CTG CAC TCG AGG 
CGT AGA ATT CCC CCG ATG CGC GCT GTT CTT ACT CA  
S5.7.2 Construction of the calibration curve  
We used serially diluted concentrations of the ligated product (A1 + A2) of the 
antennae pair to construct the calibration curve. Log of copy number per unit volume was 
plotted against the threshold cycle (Ct) values. This curve was used in further experiments 
to fit the threshold cycle (Ct) values obtained from RTPCR experiments and obtain the 
particles per unit volume.  
 
Figure 5.7: Calibration curve for PLA 
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S5.8 Data Analysis 
All the Td, TD and SQ samples were annealed at 1 M, 250 nM and 5 nM 
concentrations (of structures and not antennae) respectively. The Td samples were 
annealed in 1X TAE/Mg2+ buffer while the other two in 1X 3D buffer. Four serial dilutions 
(each 10 fold) were made for each sample and triplicate of each dilution was studied. The 
values presented here are the average values from a particular triplicate of the third dilution, 
which is 103 fold dilution. Hence, for Td, TD and SQ, we reported the values from 1 nM, 
0.25 nM and 0.05 nM samples. 
S5.9 PLA in Different In Vitro Conditions  
We incubated TdP2 and TdS2 in four different media for 48 hours and collected 12 uL 
aliquots at different time intervals. Those aliquots were used for PLA and gel 
electrophoresis experiments. The gel electrophoresis was done using 1% agarose gel, in 
1X 3D buffer under 90 volts and 4C. 
a)                                                          b) 
  
c)                                                           d)                                  
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Figure 5.8: In vitro time vs stability plots for TdP2 in a) 1X 3D buffer b) DMEM c) DMEM 
+ 10% FBS, and d) human serum. 
S5.10 PLA in In Vivo Conditions  
S5.10.1 Injection 
100 uL, 1 uM of each of TdP2 and TdS2 in 1X PBS buffer were injected separately 
in Wister rats. A small cut was made at the tail-end of each animal and 5 uL of blood was 
collected at different time points for each sample. 
S5.10.2 Separation of samples from blood 
a) Add 3 uL of blood in 200 uL of 5% suspension of Chelex 100 in water. 
b) Vortex immediately for 10 sec 
c) Incubate for 30 min on 56C 
d) Vortex for 10 sec 
e) 8 min in boiling water 
f) Centrifugation 3 min 10000g 
g) Separate supernatant for RT PCR 
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Then I add 1 uL of sample to 24 uL of RT PCR master mix and run it on the previously 
mentioned RTPCR program. 
